ANNUAL REPORT

FY 2023 — Annual report

FY 2023PDF · 86 pages9.0 MB
2 0 2 3 A N N U A L R E P O R T

-- 1 of 86 --

TABLE OF CONTENTS
1 	Letter to Shareholders
5 	Abbott 2023
6 	From Data to Decisions
8 	Laboratory Diagnostics
10 	Rapid Diagnostics
12 	Vascular
14 	Electrophysiology
16 	From Insight to Innovation
18 	Structural Heart
20 	Neuromodulation
22 	Heart Failure Management
24 	Cardiac Rhythm Management
26 	From Engagement to Empowerment
28 	Medicines
30 	Nutrition
32 	Diabetes Care
34 	The Future in Fast Forward
36 	Financial Report
Throughout our long history, we
have continually reinvented Abbott to
meet the needs of every age and stage of
a person’s life, innovating to create
leading-edge technologies that empower
individuals to take ever-increasing
control over their own health.
We believe the best medical products
are those that help the most people.
With a focus on maximizing broad access
and affordability across our businesses —
nutrition, medicines, medical devices,
and diagnostics — we’re working to help
more people in more places meet their
most urgent healthcare needs.
In a constantly evolving environment
that requires visionary leadership,
we are well-positioned to continue
delivering long-term, sustainable growth
and shareholder returns.
Front Cover:
ZULEYMA SANTOS
LOS ANGELES, CALIFORNIA, USA
HEARTMATE 3
Zuleyma relies on Abbott’s
HeartMate 3 Left Ventricular
Assist Device, a mini heart
pump for patients in advanced-
stage heart failure.

-- 2 of 86 --

DEAR FELLOW SHAREHOLDER:
2023 was the year we’ve been working toward.
With all four of our major businesses again delivering
consistently strong performance, Abbott accelerated
its base-business growth and its momentum. In our
135th anniversary year, Abbott again demonstrated the
resilience, the creativity, and the commitment needed
to meet the challenges of the present and the vast
potential of the future of healthcare.
ROBERT FORD
Chairman of the Board and
Chief Executive Officer

-- 3 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
2
$40.1B
WORLDWIDE
SALES
Our diversified
business mix
delivered another
strong year
ADJUSTED
DILUTED EPS
11.6%
*
$4.44 **
BASE-BUSINESS
ORGANIC
SALES GROWTH
RESILIENCE
The key to Abbott’s successful 2023
was balance. With supply chains and
the volume of hospital procedures
largely returned to normal after the
disruptions of COVID-19, our base-
business growth accelerated from its
pre-pandemic rate.
The year clearly demonstrated the
value of our diversified business
strategy. Our broad range of
therapeutic areas, products,
and technologies gives Abbott a
unique and differentiated view
of healthcare, providing us more
insights, access, and opportunities.
It allows us to see interconnectivity
across the spectrum of healthcare,
which gives us greater ability to
see around corners and anticipate
developing trends and needs. And
the breadth and depth of our product
portfolio gives Abbott both defensive
strength with the ability to balance
challenges in one business with
overperformance in another, and
offensive strength with more ways
to win.
At the root of Abbott’s resilience is
our culture, which is every bit as
real an asset as the more tangible
ones. Over its generations of
success, Abbott has thrived through
all manner of challenges from
our business environment. That
experience has tempered us as an
organization. We know how to meet
such situations because we’ve done
so time and again, and we’ve built
the company accordingly for long-
term durability.
Financial Performance
Investments made at the peak
of COVID-19 testing sales have
positioned us for sustainable growth,
making us stronger today than at the
beginning of the pandemic.
Our balanced success in 2023 led
to excellent financial results for the
year, with both sales and earnings
exceeding the expectations we
shared at the beginning of the year.
Sales were $40.1 billion, which
reflects an increase of 11.6% on an
organic basis for the base business.*
Adjusted diluted earnings per share
were $4.44**, above the midpoint of
our original guidance range.
In December we announced a
dividend increase of 7.8 percent
for 2024. Abbott recently paid
its 400th consecutive quarterly
dividend, completing a full century
of uninterrupted returns to
shareholders. And our dividends
have risen in each of the last 52 years,
earning Abbott membership in the
exclusive ranks of Dividend Kings.
We’re focused on returning our gross
margin to historic levels to allow us
to increase investment in our new-
product pipeline, in building our
market presence, and in the broad
range of opportunities before us.
CREATIVITY
Resilience requires the ability to
adapt, adjust, and evolve at speed
— in other words, creativity. Abbott
people bring creative problem
solving to every aspect of our
operations; but our creative energy
is most focused and systematized in
our innovation of new products and
technologies. The results here have
been outstanding.
Base-business
growth continued
in 2023
* On a GAAP basis, full-year 2023 Abbott sales decreased 8.1%
** Full-year 2023 GAAP diluted EPS was $3.26
For full financial data and reconciliation of non-GAAP measures, please
see Abbott’s 2023 earnings releases at www.abbottinvestor.com

-- 4 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
3
Pipeline Productivity
In 2023, we continued to introduce
a robust stream of important new
healthcare products. These included:
• Alinity TBI, a laboratory test for
concussion
• Alinity h, an integrated hematology
system for advanced testing of
complete blood counts
• Alinity m high risk HPV, a new test for
HPV detection and for use in routine
cervical cancer screening
• Assert-IQ, a Bluetooth®-enabled
insertable cardiac monitor that
provides industry-leading accuracy
for the long-term monitoring of
heart rhythms
• Aveir DR, the world’s first dual
chamber, leadless pacemaker, a
breakthrough in pacing technology
• The cardiovascular medicines RefSav
in India and Omacor in China
• Eterna SCS, the smallest implantable,
rechargeable spinal cord stimulator
on the market
• GLP systems Track, our innovative
total laboratory automation solution,
which was launched in the U.S.
• Lingo, our new consumer
biowearable device
• The expansion of our position in
biosimilar medicines through the
launch of Rytuzeq in Colombia and
Central America for treatment of
cancers of the white blood system
• Navitor, our next-generation
transcatheter aortic valve
implantation (TAVI) system to
treat aortic stenosis
• PediaSure 10+, Abbott’s first nutrition
shake developed specifically for
children aged 10-15 years
• PROTALITY, a nutritional designed
to help the growing number of
adults interested in maintaining
muscle mass
• TactiFlex, our new ablation catheter to
help treat abnormal heart rhythms
Putting AI to Work
2023 was, of course, the year that
generative artificial intelligence
exploded into the public
consciousness with the arrival of
compelling, popular language and
visual tools. Forms of AI and machine
learning have been employed in
healthcare for some time; but 2023
marked the crossing of an important
threshold in the sophistication and
perception of the technology as well
as the scope of its consumer potential.
Abbott is already well versed in
AI and employs it in multiple
applications. For instance, Ultreon,
our newest OCT (optical coherence
tomography) imaging system, uses AI
to automatically analyze key patient
metrics to help optimize procedures.
And we’ve used our vast body of
clinical trial data on our XIENCE
drug-eluting stents to create machine-
learning models for individual
risk prediction.
As generative AI tools rapidly evolve
in capability, we’re forming teams
across our businesses to understand
the ways in which they can make a
positive difference in our work. We’ve
identified three major categories of
use for artificial intelligence that we
believe will have meaningful impact
on healthcare; Abbott has expertise
and existing positions in all three:
• In diagnosis, generative AI will
allow us to identify conditions faster,
earlier, and more accurately. The
analysis of healthcare’s huge data sets
can guide truly personalized care —
moving from reporting on populations
to giving physicians actionable
insights for individuals. We’ll see
AI-based systems helping to review
and analyze medical histories and
patient records. And the data sets they
generate will be processed to identify
patterns that help predict and reduce
serious health issues, particularly
through earlier intervention.
PIPELINE
HIGHLIGHTS
Navitor
Transcatheter Aortic Valve
Replacement
TriClip
Transcatheter
Tricuspid Valve Repair
PROTALITY
Nutrition Shake for
Muscle Mass
i-STAT TBI
Handheld Test
for Concussion
Aveir DR
Dual-Chamber Leadless
Pacemaker
Lingo
Consumer Biowearable

-- 5 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
4
A B B O T T 2 0 2 3 A N N U A L R E P O R T
4
• In treatment, it will have the same
kind of impact on the discovery of
new therapeutics — from med-tech
to pharma to nutrition — making
the process vastly more efficient.
Generative AI can more rapidly
explore hypotheses, examine
alternatives, and play out scenarios,
resulting in more and better products,
faster and more effectively. It can
help us build models to predict which
patients may have better outcomes
with one therapy versus another, or
tailor treatment to a patient’s personal
anatomy, disease, and characteristics.
And it will continue to advance how
we conduct clinical studies — from
pre-trial planning, to participant
identification and management,
to trial surveillance — helping us
increase diversity in clinical trials,
which will improve outcomes and
increase health equity.
• And it will help us to significantly
improve consumer empowerment.
AI will not only allow us to engage
more deeply with the people who use
our products, but it will also let them
do so with their caregivers. This can
improve their adherence to treatment,
resulting in better outcomes. And,
most importantly, it can provide
consumers greater power in an area
where they’ve traditionally had too
little, allowing users to personalize
and manage their health and care.
We expect generative AI to help
us accelerate our work to digitize,
decentralize, and democratize
healthcare, enabling our customers
to receive the care they need,
when and where they need it, and
allowing Abbott to help more people
than ever before.
COMMITMENT
The reason Abbott has been so
successful for so long is clear: our
purpose as a company inspires
extraordinary commitment from our
colleagues around the world. Abbott
people care that their work means so
much to those we serve. Our products
help people live fuller lives. That
matters to us, deeply.
Our driving ambition today is to help
three billion people with Abbott
products and services every year by
2030. It’s an ambitious goal — the
kind that inspires people to achieve
more than they thought they could.
Reaching one-third of the people on
the planet starts with the way
we create our products. We aim
to expand access to healthcare by
making it easier to use, more available,
and more affordable. And this
customer-centric perspective extends
to every part of the company. We’ve
adopted design principles to build
this thinking into every stage of the
product process, from invention, to
supply chain, to production.
And people driven by a noble
purpose — supported and propelled
by a culture of achievement — can
accomplish great things. Healthcare
not only inspires that kind of
greatness, it demands it. At Abbott,
we know that our products aren’t just
products, and our work is not just
a job. For 135 years, we’ve had the
privilege of purpose. That’s a legacy
we mean to preserve, a standard we
intend to meet, and a commitment you
can count on.
Abbott Proud,
ROBERT B. FORD
Chairman of the Board
and Chief Executive Officer
March 4, 2024
Consistently
strong
shareholder
returns
allowing Abbott to help more people
Abbott Proud,
ROBERT B. FORD
100
CONSECUTIVE
YEARS OF
DIVIDENDS PAID
50+
CONSECUTIVE
YEARS OF RISING
DIVIDENDS
~80%
DIVIDEND
INCREASE
SINCE 2018

-- 6 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
5
Abbott 2023
With strong organic growth across our company’s
base businesses, Abbott’s performance is proof
of the power of our broadly diversified business.
With visibility to the entire spectrum of
healthcare, we see trends early, then focus on
investing and innovating to position our company
for leadership and impact over the long term.

-- 7 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
From data
to decisions
T H E F U T U R E O F H E A LT H C A R E
Abbott technologies give
physicians data and insights
to enable faster and
more accurate diagnosis.
We’re exploring how we can
combine artificial intelligence
with Abbott diagnostics
and technology leadership
to transform our impact on
human health.
INSIGHTS IN REAL TIME
Using AI and machine learning to build and
analyze massive data sets, Abbott can help
physicians quickly identify and implement
the optimal approach to care, streamlining
treatment and improving outcomes.
PREDICTIVE POTENTIAL
We envision a future in which smaller, smarter
devices will generate data that can be used
to identify patterns, helping to predict and
reduce serious health issues through earlier
interventions.
TRANSFORMATIVE IMPACT
The integration of multiple data streams —
to both patients and providers — will give
them the opportunity to benefit from the data
they produce from their devices, and will help
Abbott understand how that information can
be used to improve care.
6

-- 8 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
7
Ultreon, Abbott’s first-of-its-kind imaging
software, merges optical coherence tomography
(OCT) — an imaging technology that provides
a comprehensive view inside an artery or blood
vessel — with the power of AI to enhance the
precision of physicians’ decision-making during
coronary stenting procedures.

-- 9 of 86 --

8
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Abbott offers customized,
scalable solutions to
help laboratories improve
throughput, accuracy,
and productivity
in diagnostic labs.
Abbott is a market leader in diagnostic tests,
instruments, and informatics systems. Our products
deliver crucial information to help guide decision
making for hundreds of health conditions — from
heart attacks to blood disorders to infectious diseases
and cancers.
Our Alinity portfolio of harmonized diagnostic systems
includes the Alinity ci series, which integrates clinical
chemistry and immunoassay testing to help maximize
its operational efficiency. In 2023, the Alinity i test
menu had a notable expansion with U.S. clearance for
the first commercially available lab-based blood
test to help evaluate concussion. We also launched
the Alinity h series, for advanced testing of patients’
complete blood counts.
AlinIQ, Abbott’s suite of digital health solutions, helps
labs uncover intelligent insights from the data they
generate and discover greater operational productivity
with existing resources.
And Abbott remains the global leader in systems
and tests used to screen donated blood. Following a
pandemic-influenced slowdown, our blood-screening
business delivered solid growth in 2023. Today, Abbott
systems and tests screen more than 50% of the world’s
blood and plasma supply.
Alinity s, which was purpose-built for blood and
plasma screening, allows laboratory staff to process
more samples with less effort, greater consistency, and
increased control, leading to a more productive blood-
and plasma-screening process.
ALINITY S
Purpose-built for
blood and plasma
screening, this
transformational
innovation helps
labs achieve
greater operational
efficiency.
Laboratory
Diagnostics

-- 10 of 86 --

9
A B B O T T 2 0 2 3 A N N U A L R E P O R T
ABBOTT
IS A MARKET
LEADER IN
DIAGNOSTIC
TESTS,
INSTRUMENTS,
AND
INFORMATICS
SYSTEMS.
SIES HEALTH
BOGOTÁ, COLOMBIA
Abbott	Abbott Alinity	Alinity systems have been	systems have been
key to the efficient expansion of core	key to the efficient expansion of core
laboratory diagnostics services at	laboratory diagnostics services at
SIES Salud Health System, a leading	SIES Salud Health System, a leading
healthcare provider in Colombia.	healthcare provider in Colombia.

-- 11 of 86 --

10
A B B O T T 2 0 2 3 A N N U A L R E P O R T
MARKET-LEADING
TESTS FOR HIV
AND RESPIRATORY
ILLNESS
LEADING GLOBAL
PROVIDER OF
RAPID, POINT-OF-
CARE TESTS
Abbott is an industry leader in at-home and point-
of-care testing solutions for both consumers and
healthcare providers.
Abbott’s BinaxNOW and Panbio COVID-19 tests
have been used almost 3 billion times around the world
since their development in 2020. Another rapid test, our
Panbio HIV Self Test, empowers people to proactively
know their HIV status and live fuller lives through
earlier diagnosis and treatment.
Our i-STAT TBI plasma test, the first rapid handheld
traumatic brain injury blood test, will help clinicians
assess individuals with suspected mild TBIs, including
concussions. Test results are available within 15 minutes
after plasma is placed in the test cartridge.*
In our point-of-care testing portfolio, the installed
base of our ID NOW benchtop analyzer has increased
more than fivefold since 2019, accelerating Abbott’s
strategy to decentralize testing. We are working
to expand the test menu for this system to increase
utilization beyond COVID-19 and flu testing.
This portfolio also includes Piccolo Express, the only
portable diagnostic analyzer to offer a full complement
of CLIA-waived blood chemistry tests at the point of
care; Afinion 2, a compact, rapid, multi-assay analyzer;
and the Cholestech LDX analyzer, which empowers
healthcare professionals and patients with a lab-
accurate complete lipid profile and glucose level in
just five minutes per test cassette.
Abbott is working to
ensure diagnostic testing is
available wherever people
need care.
Rapid
Diagnostics
* i-STAT TBI plasma test is not intended for use as a point-of-care device.

-- 12 of 86 --

11
PANBIO HIV
SELF TEST
Simple-to-use
home test lets
people know their
HIV status in just
15 minutes.
LUCAS RANIEL
SÃO PAULO, BRAZIL
PANBIO HIV
Lucas, an influencer and
activist, works to help
others better understand
what it’s like to live a full
life while HIV-positive.
In his outreach work, he
recommends that people
regularly check their
HIV status with Abbott’s
Panbio HIV.
ID NOW
Our benchtop
molecular analyzer
offers reliable,
rapid results,
giving healthcare
professionals
information they need
to make faster, more
effective treatment
decisions.

-- 13 of 86 --

12
In addition to our broad portfolio of market-leading
stents, Abbott provides diagnostic and imaging devices,
cutting-edge thrombectomy and atherectomy systems,
and a full line of vessel-closure devices.
Our OPTIS Imaging Systems use optical coherence
tomography to deliver hundreds of micron-level
resolution images of the artery. These images are then
analyzed by our AI-powered Ultreon 2.0 imaging and
physiology software, which provides insights to help
doctors better assess arterial blockages and optimize
treatment decisions.
Our XIENCE family of stents includes our next-
generation XIENCE Skypoint, which allows physicians
to treat larger blood vessels and longer lesions.
Abbott is working to expand this portfolio with the
Esprit BTK (below the knee) everolimus eluting
resorbable scaffold system, which is currently being
evaluated by the FDA as a treatment for people with
chronic limb-threatening ischemia.
Our JETi hydrodynamic thrombectomy system uses
a uniquely positioned high-pressure saline jet to
fragment clots within the safety of the catheter tip
while reducing catheter clogs.
In April 2023, Abbott completed our acquisition of
Cardiovascular Systems, Inc., adding CSI’s leading
atherectomy system, Diamondback 360, which prepares
vessels for angioplasty or stenting to restore blood flow.
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Vascular
Expanding our
comprehensive portfolio
of devices to optimize
vascular interventions.
EUNICE GIVENS
FORT WORTH, TEXAS, USA
ESPRIT BTK
Eunice participated in a clinical trial
for Abbott’s investigational Esprit BTK
bioresorbable scaffold system, which is
currently being evaluated by the U.S.
FDA as a treatment for people with
chronic limb-threatening ischemia.*
*CAUTION: Investigational device. Limited by Federal (U.S.) law to investigational use only.

-- 14 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
13
ULTREON
VASCULAR
IMAGING
SYSTEM
Ultreon Software is
our new-generation
intravascular imaging
and coronary
physiology software
to guide percutaneous
coronary intervention.
ESPRIT BTK
Abbott’s investigational drug-
eluting Esprit BTK resorbable
scaffold is made of dissolving
material that is designed to
disappear over time after it has
opened a clogged artery.
DIAMONDBACK 360
Atherectomy system to prepare vessels
for stenting or angioplasty

-- 15 of 86 --

14
A growing portfolio of cutting-edge
technologies for the precision treatment
of atrial fibrillation.
Electrophysiology
A B B O T T 2 0 2 3 A N N U A L R E P O R T

-- 16 of 86 --

DR. KENT NILSSON
AND DR. DANIEL
HAITHCOCK
ATHENS, GEORGIA, USA
Dr. Nilsson (left) and
Dr. Haithcock (right) rely on
Abbott’s EnSite X mapping
system to guide them in
delivering cardiac ablation
therapy to their patients.
15
A B B O T T 2 0 2 3 A N N U A L R E P O R T
ENSITE X SYSTEM
Next-generation 3D
mapping platform
TACTIFLEX ABLATION
CATHETER
First-of-its-kind catheter with
unique flexible tip
Abbott has helped fuel the strong growth of our Electrophysiology
business with innovative additions to our portfolio of devices that
analyze and treat abnormal heart rhythms.
Atrial fibrillation (AFib) is the most common type of arrhythmia,
or irregular heartbeat, impacting more than 37 million people, a
number that is expected to grow to more than 60 million by 2050.
Abbott devices, from implantable monitors to sophisticated
mapping systems, generate complex data sets that help doctors
more effectively treat this condition. Our Advisor HD Mapping
Catheter uses a first-of-its-kind electrode configuration to
create more-highly detailed maps of the heart. Our best-in-class
cardiac-mapping system, EnSite X, allows doctors to diagnose
a wide range of arrhythmias. EnSite X features a screen that
displays 3D images of the heart and its activity in real time,
helping a doctor find the specific tissue that’s causing the heart
to beat irregularly.
Our TactiFlex ablation catheter, Sensor Enabled, is the world’s first
ablation catheter designed with a unique flexible electrode tip and
contact-force sensing.

-- 17 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
T H E F U T U R E O F H E A LT H C A R E
Abbott uses leading-edge
tools to streamline and
accelerate clinical research
and product development,
helping us expand our
broad portfolio of new,
life-changing solutions.
BROADER BUSINESS, DEEPER INSIGHTS
As one of the most diverse companies in
healthcare, Abbott has a unique perspective
that gives us insights into the health challenges
people face at every stage of life. This cross-
disciplinary knowledge informs our development
process, helping us create products to transform
the standard of care.
ACCELERATING THE ABBOTT PIPELINE
Abbott’s global presence and extensive
experience conducting clinical trials let us
collect vast amounts of data, then use that
information to both improve existing products
and create entirely new solutions.
EFFECTIVE PRODUCT LAUNCHES
Abbott’s demonstrated commitment to
outstanding commercial execution helps
ensure that the benefits of our innovations
are available more quickly, to more people,
in more places.
16
From insight
to innovation

-- 18 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
17
NeuroSphere Virtual	NeuroSphere Virtual
Clinic	Clinic connects doctors	connects doctors
remotely with their	remotely with their
patients to interact	patients to interact
and make real-time	and make real-time
adjustments to	adjustments to
Abbott devices that	Abbott devices that
treat chronic pain or	treat chronic pain or
movement disorders.	movement disorders.

-- 19 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
Structural Heart
Improving outcomes with a broad portfolio
of innovative, minimally invasive devices.
18
TRICLIP G4 SYSTEM
Next-generation
transcatheter edge-to-
edge repair system for
leaky tricuspid valves.
NAVITOR TAVI SYSTEM
Transcatheter aortic valve
implantation system delivers
precise, stable deployment and
excellent procedural outcomes,
and is designed for lifetime
patient management.
AMPLATZER AMULET
Left-atrial-appendage
occluder is designed to
reduce the risk of ischemic
stroke caused by atrial
fibrillation.

-- 20 of 86 --

19
JAVIER VILLARROYA
BOADILLA DEL MONTE, SPAIN
TRICLIP TEER
To treat his mitral valve disease, Javier had an
Abbott Masters mitral valve implanted at a young
age. When his doctors told him that his tricuspid
valve needed repairing, he told them he would
prefer they use an Abbott product. His heart team
was already in agreement on his treatment and
they implanted Abbott’s TriClip.
Abbott has the most comprehensive Structural Heart
treatment portfolio in the industry. Our broad array of
minimally invasive treatment options is supported by
data showing that our devices are safe, effective, durable,
and deliver the best clinical outcomes for patients.
TriClip, approved in more than 50 countries,* is a first-
of-its-kind minimally invasive transcatheter edge-to-
edge repair (TEER) device specifically designed to treat
tricuspid regurgitation, or a leaky tricuspid valve.
Our MitraClip is the world’s first minimally invasive
TEER therapy for both primary and secondary mitral
regurgitation.
Our transcatheter aortic valve implantation (TAVI)
and surgical valve portfolios are designed to maximize
key clinical outcomes and the possibilities for patient
lifetime management of their heart-valve disease.
Navitor, Abbott’s latest-generation TAVI system, was
approved by the FDA in January 2023. It features
advancements to reduce the risk of blood leakage
around the implant.
The Epic Max aortic stented tissue valve is designed
to help patients with more complex cases of aortic
regurgitation or stenosis who cannot take blood-
thinning medications.
A B B O T T 2 0 2 3 A N N U A L R E P O R T
* Investigational device in the U.S.

-- 21 of 86 --

20
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Neuromodulation
Advanced technologies for improving care
for movement disorders and chronic pain.
JILL SOBULE
NEW YORK, NEW YORK, USA
INFINITY DBS
Jill, a successful singer-
songwriter, had lived with
essential tremor for years.
Then, in 2020, she noticed
that what she had described
in a song as her “shaky
hands” were getting worse,
impeding her ability to play
the guitar. A consultation
with her neurologist resulted
in Jill receiving Abbott’s
Infinity DBS (deep brain
stimulation) system, calming
her tremor and restoring
her ability to play.
ETERNA SCS SYSTEM
With Xtend energy
technology and BurstDR
stimulation
INFINITY DBS SYSTEM
Deep brain stimulation system
for people with Parkinson’s or
essential tremor.

-- 22 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
21
Abbott is a global leader in the development of chronic-
pain therapy solutions. Our unique portfolio includes
radiofrequency ablation, spinal cord stimulation (SCS)
technologies, including BurstDR stimulation, and dorsal
root ganglion (DRG) stimulation for the treatment of
chronic pain.
In 2023, Abbott expanded its Pain Management
portfolio with the launch of Eterna, the world’s smallest
implantable, rechargeable SCS system. Eterna is
designed to optimize the charging experience, requiring
as few as five recharges per year under standard use
from a wireless charger.
For movement disorders, such as Parkinson’s disease
and essential tremor, Abbott’s Infinity DBS system
employs a directional lead that’s capable of sending
energy toward all major therapeutic targets for both
conditions while reducing stimulation to areas that may
create side effects.
Our first-of-its-kind NeuroSphere Virtual Clinic lets
doctors remotely reprogram a patient’s implant via
a secure video chat integrated into our NeuroSphere
digital health ecosystem.
For our pain-management devices, Abbott’s
NeuroSphere myPath connected-care app stores
data that helps people objectively evaluate SCS or
DRG therapy as they’re trying a new device. With
myPath, doctors have better visibility to patients’
collected outcomes, helping them have better informed
discussions as they craft treatment plans.

-- 23 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
22
Heart Failure
Management
Solutions for every stage
of heart failure, from the earliest
to the most advanced.

-- 24 of 86 --

CARDIOMEMS
HF SYSTEM
Abbott’s paper-
clip-sized device
can alert doctors
to worsening heart
failure before
symptoms arise.
23
HEARTMATE 3
ZULEYMA SANTOS
LOS ANGELES, CALIFORNIA, USA
HEARTMATE 3
Because of a naturally high antibody count, there’s
a higher risk that Zuleyma’s body would reject a
transplanted heart. That’s why her doctors chose
to implant Abbott’s HeartMate 3 LVAD. Thanks to
its constant assistance, Zuleyma can get back to
her daily activities and be the mom she wants to
be for her kids.
Abbott’s industry-leading portfolio of solutions includes
diagnostics, devices, data, and analytics that can help
physicians and hospitals manage heart failure more
holistically for the nearly 26 million people around the
world who suffer from it.
Our CardioMEMS HF System is a pulmonary artery
pressure monitoring system that provides early
detection of worsening heart failure. By continuously
generating data that can be shared with the patient’s
care team, CardioMEMS can help prevent worsening
heart failure, which lowers mortality rates and
improves quality of life.
Our cardiac resynchronization therapy is a proven
clinical treatment for heart failure management.
These devices can communicate with Abbott’s
Merlin@home system to facilitate efficient remote care
management of patients, complementing or replacing
in-clinic visits with remote patient transmissions.
Our HeartMate 3 is a left-ventricular assist device
(LVAD) — a mini heart pump for patients in advanced-
stage heart failure. HeartMate 3 uses Full MagLev
flow technology, which suspends the pump rotor with
magnetic force, reducing trauma to the blood as it
passes through the pump.
Our CentriMag circulatory support system was a life-
saving option for thousands of patients who required
respiratory and circulatory support during the
COVID-19 pandemic. In 2023, CentriMag was approved
by the FDA for longer-term life support.
CENTRIMAG CIRCULATORY
SUPPORT SYSTEM
Blood-pumping system
used to support
patients with acute heart
and lung failure.

-- 25 of 86 --

24
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Cardiac Rhythm
Management
Building on our leadership
with innovative new solutions
for managing abnormal
heart rhythms.
AVEIR DR
World’s first
dual-chamber
leadless
pacemaker.

-- 26 of 86 --

FOR POSITION ONLY
25
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Abbott’s Cardiac Rhythm Management business
is well positioned for accelerated growth, thanks
to the introduction of our AVEIR DR — the world’s
first dual-chamber, leadless pacemaker system. The
system consists of two pacers, each smaller than
a AAA battery, that are implanted via a minimally
invasive procedure, using the devices’ unique mapping
capability to assess their correct positioning prior to
placement. The devices communicate with each other
through our proprietary i2i system. AVEIR is also
designed to be easily retrievable, should the patient’s
therapy needs change.
Our implantable cardioverter defibrillators (ICD)
are designed to continuously monitor patients’ heart
rhythms and detect irregular heartbeats, delivering
electrical signals and controlled shocks to restore a
normal heart rhythm when necessary. These devices
are setting the standard for patient care through
new algorithms and technology intended to improve
patient safety and therapy assurance. This portfolio
includes the Ellipse ICD, which offers non-invasive
programming options and wireless remote monitoring
with our Merlin@home transmitter; and Gallant ICD,
which combines built-in smartphone connectivity
with intuitive programming to help doctors meet
patients’ changing needs.
SARA WYKURZ
LIBERTYVILLE, ILLINOIS, USA
AVEIR DR
Sara received her AVEIR DR leadless pacemaker
after learning she had neurocardiogenic
syncope, a type of fainting — or brief loss of
consciousness — due to a sudden drop of heart
rate and blood pressure.

-- 27 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
From engagement
to empowerment
T H E F U T U R E O F H E A LT H C A R E
At Abbott, it’s always been
about empowering people
to live their fullest lives.
Abbott’s portfolio is filled
with products and solutions
that let people engage more
fully with their care, taking
an active role in maintaining
their health.
ACCELERATING THE PERSONALIZATION
OF HEALTHCARE
Abbott is revolutionizing health with the most
personal technologies and empowering people
with the data and knowledge they need to help
them live longer and better.
PUTTING CONSUMERS IN CONTROL
With continuous data, people can understand
how choices impact their health, helping them
take better control of their conditions.
HELPING HEALTHY PEOPLE STAY THAT WAY
Our connected-care and digital-health tools,
along with our portfolio of targeted nutrition
products and medicines, are helping people
make better, faster, and more complete decisions
about their health in ways that fit easily into
their lives.
26

-- 28 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
27
Christos Gkipatas
Munich, Germany
JETi Thrombectomy
System
After his doctors
used Abbott’s JETi
thrombectomy system
to remove blood clots
in his legs, Chris was
able to walk without
pain for the first time
in months.

-- 29 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
28
Medicines
A growing array of medicines and therapies
to transform the quality of healthcare
in emerging markets worldwide.
Every day, more than 62 million people around the world
use Abbott medicines. Our targeted product portfolios
span multiple therapeutic areas, with key offerings in
gastroenterology, women’s health, cardiometabolic, pain
management/central nervous system, and respiratory.
By focusing our medicines business solely in
emerging markets, Abbott is able to develop a detailed
understanding of the unique health challenges and
needs of local communities. We build on that knowledge,
bringing our broad and deep scientific expertise to
improve trusted medicines, differentiating ourselves
from pure generic competitors through our exacting
quality standards, reliable supply chain, broad product
range, deep understanding of our customers’ needs, and
patient-centered innovation.
In 2023, we made great progress in broadening access
to health in emerging markets by expanding our
collaboration with biotech leader mAbxience Holdings
to commercialize several biosimilar molecules, with the
goal of bringing these newer therapies — for oncology,
women’s health, and respiratory diseases — to more
people, in more places.
We also offer services that help people better manage
their health. For example, our a:care initiative offers
digital solutions, developed with behavioral science and
AI at its core, to build healthy habits, giving patients and
healthcare providers tools, tips, and resources. These
tools can help redefine how people manage their health,
improving interactions between patients and healthcare
professionals, and helping reduce healthcare costs.
A representative sample of our broad portfolio
of leading medicines in emerging markets.

-- 30 of 86 --

29
A B B O T T 2 0 2 3 A N N U A L R E P O R T
WANNAPAPORN
APIVATMONGKOL
BANGKOK, THAILAND
DUPHASTON
Duphaston has helped more than
113 million women worldwide, with
an estimated 20 million pregnancies,
in the past 60 years. Wannapaporn,
shown here with her family, became
pregnant through in vitro fertilization
with the help of Duphaston.	MABXIENCE
BIOSIMILARS
PARTNERSHIP
Expanded partnership
brings the benefits
of biologic medicines
to a wider pool
of patients.

-- 31 of 86 --

30
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Nutrition
Setting the standard for science-based
nutrition to support the growth, health, and
wellness of people at every stage of life.
For almost 100 years, Abbott has been a leader in
complete and supplemental nutrition.
Our adult nutritional products fill nutrition gaps —
nourishing patients who are not able to eat adequately,
or supporting active adults in leading an overall
healthy lifestyle. We helped create this category in
1973, with the launch of Ensure. Today, Ensure
is the No. 1 doctor-recommended brand of nutritional
shake, encompassing a full line that includes pre-
and post-surgery shakes specifically formulated to
support recovery. We’re expanding our portfolio
with PROTALITY, which is designed to support the
growing number of adults interested in pursuing
weight loss while maintaining muscle mass.
Our specialty nutrition brands include Glucerna
products, made with Carbsteady, a unique blend of
slow-release carbohydrates, that helps minimize
blood sugar spikes for people with diabetes; Nepro,
formulated to help replace protein lost during dialysis
treatments; and Juven, which is formulated to support
wound healing.
The foundation of our pediatric nutrition portfolio
is our market-leading Similac line of infant formulas.
Similac 360 Total Care contains an exclusive prebiotic
blend that makes these formulas closer than ever to
breast milk. We’ve also developed a variety of amino-
acid-based formulas for children who suffer from food
allergies, gastrointestinal disorders, and inborn errors
of metabolism.
ADULT AND PEDIATRIC NUTRITION
Broad-based offering for every age and stage of life.

-- 32 of 86 --

A B B O T T 2 0 2 3 A N N U A L R E P O R T
PediaSure provides complete, balanced nutrition,
including all macro- and micronutrients
needed to help children achieve optimal rates
of growth and development.
Pedialyte, the No. 1 doctor-recommended
brand, helps people of all ages replace fluids
and electrolytes they’ve lost due to mild-to-
moderate dehydration.
GLUCERNA
Nutritional shake
designed to help
manage blood sugar.
VICKY RAO
SEREMBAN, MALAYSIA
GLUCERNA
When Vicky was diagnosed with
type 2 diabetes, he knew he had
to make some changes in his
life. Today he stays healthy by
exercising regularly, eating right,
and supplementing his diet
with Glucerna.
31

-- 33 of 86 --

32
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Diabetes Care
Making diabetes management
easier and more accessible.
Our commitment to continuous innovation has
made Abbott the global leader in continuous glucose
monitoring. 1 We designed our FreeStyle Libre portfolio
with access and affordability in mind from Day One, and
today it’s the world’s most affordable and widely used
continuous glucose monitoring system, 2 with more than
5 million regular users across more than 60 countries. 3
Our flagship product, the FreeStyle Libre 3 system,
features the world’s smallest, thinnest, and most
discreet sensor.4 Real-world and clinical data show that
this technology helps people with diabetes improve
their glucose control, lower their HbA1Cs (a measure
of glucose levels over time), decrease diabetes-related
hospital admissions, and improve their quality of life. 5
We’re working to develop and launch the first
automated insulin delivery (AID) system powered by
the FreeStyle Libre 3 sensor.
We are integrating data from connected insulin pens
with FreeStyle LibreLink6 and LibreView,7 letting
patients, caregivers, and healthcare professionals view
glucose and insulin data together to help them make
better-informed treatment decisions.
And in 2023, we acquired Bigfoot Biomedical, adding
the Unity diabetes management system to our diabetes
care offering. Unity features smart caps for disposable
insulin-injector pens that integrate with our FreeStyle
technology to provide dose recommendations for people
with diabetes who use multiple daily injections of insulin.

-- 34 of 86 --

33
A B B O T T 2 0 2 3 A N N U A L R E P O R T
DOUG MASIUK
BRECKENRIDGE, COLORADO, USA
FREESTYLE LIBRE 3
An outdoor sports enthusiast and
an avid runner, Doug was the
first person with type 1 diabetes
to run all the way across the
United States.
FREESTYLE
LIBRE 3
CONTINUOUS
GLUCOSE
MONITORING
SYSTEM
More than 5 million people
in 60 countries rely on
our FreeStyle Libre portfolio
to help them manage
their diabetes.
>	>5	5million users

-- 35 of 86 --

34
A B B O T T 2 0 2 3 A N N U A L R E P O R T
World-class marathoner
Eliud Kipchoge has relied
on Abbott’s glucose sport
biosensors to give him
continuous insights into his
body’s fuel levels as he trains.

-- 36 of 86 --

35
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Abbott is leveraging
decades of leadership
in glucose monitoring,
moving beyond diabetes
to create the future of
biowearables with Lingo,
its new device that helps
users understand the
unique languages of
their bodies.
The future
in fast forward
Emerging technologies promise rapid,
dramatic change across every aspect
of life, with transformative potential
for healthcare. At Abbott, our broad-based
model and focus on innovation put us
in a strong position to lead the way.

-- 37 of 86 --

36
2023 FINANCIAL
REPORT
37 	Consolidated Statement of Earnings
38 Consolidated Statement of
Comprehensive Income
39 	Consolidated Statement of Cash Flows
40 Consolidated Balance Sheet
42 Consolidated Statement of
Shareholders’ Investment
43 Notes to Consolidated
Financial Statements
62 	Management Report on Internal
Control Over Financial Reporting
62 	Report of Independent Registered
Public Accounting Firm
64 Report of Independent Registered
Public Accounting Firm
65 	Financial Instruments and
Risk Management
66 Financial Review
79 	Performance Graph
80 Summary of Selected Financial Data
81 	Directors and Corporate Officers
82 	Shareholder and Corporate
Information
A B B O T T 2 0 2 3 A N N U A L R E P O R T

-- 38 of 86 --

37
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Year Ended December 31 	2023 	2022 	2021
Net Sales 	$40,109 	$43,653 	$43,075
Cost of products sold, excluding amortization of intangible assets 	17,975 	19,142 	18,537
Amortization of intangible assets 	1,966 	2,013 	2,047
Research and development 	2,741 	2,888 	2,742
Selling, general and administrative 	10,949 	11,248 	11,324
Total Operating Cost and Expenses 	33,631 	35,291 	34,650
Operating Earnings 	6,478 	8,362 	8,425
Interest expense 	637 	558 	533
Interest income 	(385) 	(183) 	(43)
Net foreign exchange (gain) loss 	41 	2 	1
Other (income) expense, net 	(479) 	(321) 	(277)
Earnings before Taxes 	6,664 	8,306 	8,211
Taxes on Earnings 	941 	1,373 	1,140
Net Earnings 	$÷5,723 	$÷6,933 	$÷7,071
Basic Earnings Per Common Share 	$÷÷3.28 	$÷÷3.94 	$÷÷3.97
Diluted Earnings Per Common Share 	$÷÷3.26 	$÷÷3.91 	$÷÷3.94
Average Number of Common Shares Outstanding Used for
Basic Earnings Per Common Share 	1,740 	1,753 	1,775
Dilutive Common Stock Options 	9 	11 	14
Average Number of Common Shares Outstanding Plus
Dilutive Common Stock Options 	1,749 	1,764 	1,789
Outstanding Common Stock Options Having No Dilutive Effect 	5 	3 	—
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F E A R N I N G S
(in millions except per share data)

-- 39 of 86 --

38
A B B O T T 2 0 2 3 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C O M P R E H E N S I V E I N C O M E
(in millions)
Year Ended December 31 	2023 	2022 	2021
Net Earnings 	$«5,723 	$«6,933 	$«7,071
Foreign currency translation gain (loss) adjustments 	229 	(894) 	(980)
Net actuarial gains (losses) and prior service cost and credits and amortization
of net actuarial losses and prior service cost and credits, net of taxes of $31 in
2023, $330 in 2022 and $340 in 2021 	117 	1,177 	1,201
Net gains (losses) on derivative instruments designated
as cash flow hedges, net of taxes of $(66) in 2023, $11 in 2022 and $63 in 2021 	(134) 	40 	351
Other Comprehensive Income (Loss) 	212 	323 	572
Comprehensive Income 	$«5,935 	$«7,256 	$«7,643
Supplemental Accumulated Other Comprehensive Income (Loss) Information,
net of tax as of December 31:
Cumulative foreign currency translation (loss) adjustments 	$(6,504) 	$(6,733) 	$(5,839)
Net actuarial (losses) and prior service (cost) and credits 	(1,376) 	(1,493) 	(2,670)
Cumulative gains (losses) on derivative instruments designated
as cash flow hedges 	41 	175 	135
Accumulated other comprehensive income (loss) 	$(7,839) 	$(8,051) 	$(8,374)
The accompanying notes to consolidated financial statements are an integral part of this statement.

-- 40 of 86 --

39
A B B O T T 2 0 2 3 A N N U A L R E P O R T
C O N S O L I D AT E D S TAT E M E N T O F C A S H F L O W S
(in millions)
Year Ended December 31 	2023 	2022 	2021
Cash Flow From (Used in) Operating Activities:
Net earnings 	$«5,723 	$«6,933 	$÷7,071
Adjustments to reconcile earnings to net cash from operating activities —
Depreciation 	1,277 	1,254 	1,491
Amortization of intangible assets 	1,966 	2,013 	2,047
Share-based compensation 	644 	685 	640
Investing and financing losses, net 	126 	215 	55
Trade receivables 	(356) 	(68) 	(383)
Inventories 	(232) 	(1,413) 	(456)
Prepaid expenses and other assets 	(542) 	(75) 	(312)
Trade accounts payable and other liabilities 	(760) 	420 	1,288
Income taxes 	(585) 	(383) 	(908)
Net Cash From Operating Activities 	7,261 	9,581 	10,533
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment 	(2,202) 	(1,777) 	(1,885)
Acquisitions of businesses and technologies, net of cash acquired 	(877) 	— 	(187)
Proceeds from business dispositions 	40 	48 	134
Purchases of investment securities 	(159) 	(185) 	(173)
Proceeds from sales of investment securities 	43 	152 	77
Other 	22 	22 	26
Net Cash From (Used in) Investing Activities 	(3,133) 	(1,740) 	(2,008)
Cash Flow From (Used in) Financing Activities:
Proceeds from issuance of (repayments of ) short-term debt, net and other 	21 	47 	(204)
Proceeds from issuance of long-term debt and debt with maturities over 3 months 	2 	7 	4
Repayments of long-term debt and debt with maturities over 3 months 	(2,498) 	(753) 	(48)
Purchases of common shares 	(1,227) 	(3,795) 	(2,299)
Proceeds from stock options exercised 	167 	167 	255
Dividends paid 	(3,556) 	(3,309) 	(3,202)
Net Cash From (Used in) Financing Activities 	(7,091) 	(7,636) 	(5,494)
Effect of exchange rate changes on cash and cash equivalents 	(23) 	(122) 	(70)
Net Increase (Decrease) in Cash and Cash Equivalents 	(2,986) 	83 	2,961
Cash and Cash Equivalents, Beginning of Year 	9,882 	9,799 	6,838
Cash and Cash Equivalents, End of Year 	$«6,896 	$«9,882 	$÷9,799
Supplemental Cash Flow Information:
Income taxes paid 	$«1,475 	$«1,864 	$÷1,941
Interest paid 	662 	563 	544
The accompanying notes to consolidated financial statements are an integral part of this statement

-- 41 of 86 --

40
A B B O T T 2 0 2 3 A N N U A L R E P O R T
December 31 	2023 	2022
Assets
Current assets:
Cash and cash equivalents 	$÷6,896 	$÷9,882
Investments, primarily bank time deposits and U.S. treasury bills 	383 	288
Trade receivables, less allowances of — 2023: $444; 2022: $500 	6,565 	6,218
Inventories:
Finished products 	3,946 	3,805
Work in process 	807 	680
Materials 	1,817 	1,688
Total inventories 	6,570 	6,173
Other prepaid expenses and receivables 	2,256 	2,663
Total current assets 	22,670 	25,224
Investments 	799 	766
Property and equipment, at cost:
Land 	529 	511
Buildings 	4,161 	4,053
Equipment 	15,179 	14,164
Construction in progress 	2,064 	1,484
21,933 	20,212
Less: accumulated depreciation and amortization 	11,779 	11,050
Net property and equipment 	10,154 	9,162
Intangible assets, net of amortization 	8,815 	10,454
Goodwill 	23,679 	22,799
Deferred income taxes and other assets 	7,097 	6,033
$73,214 	$74,438
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 42 of 86 --

41
A B B O T T 2 0 2 3 A N N U A L R E P O R T
December 31 	2023 	2022
Liabilities and Shareholders’ Investment
Current liabilities:
Trade accounts payable 	$÷«4,295 	$÷«4,607
Salaries, wages and commissions 	1,597 	1,556
Other accrued liabilities 	5,422 	5,845
Dividends payable 	955 	887
Income taxes payable 	492 	343
Current portion of long-term debt 	1,080 	2,251
Total current liabilities 	13,841 	15,489
Long-term debt 	13,599 	14,522
Post-employment obligations and other long-term liabilities 	6,947 	7,522
Commitments and contingencies
Shareholders’ investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued 	— 	—
Common shares, without par value Authorized — 2,400,000,000 shares
Issued at stated capital amount — Shares: 2023: 1,987,883,852; 2022: 1,986,519,278 	24,869 	24,709
Common shares held in treasury, at cost — Shares: 2023: 253,807,494; 2022: 248,724,257 	(15,981) 	(15,229)
Earnings employed in the business 	37,554 	35,257
Accumulated other comprehensive income (loss) 	(7,839) 	(8,051)
Total Abbott Shareholders’ Investment 	38,603 	36,686
Noncontrolling interests in subsidiaries 	224 	219
Total Shareholders’ Investment 	38,827 	36,905
$«73,214 	$«74,438
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D B A L A N C E S H E E T
(dollars in millions)

-- 43 of 86 --

42
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Year Ended December 31 	2023 	2022 	2021
Common Shares:
Beginning of Year
Shares: 2023: 1,986,519,278; 2022: 1,985,273,421; 2021: 1,981,156,896 	$«24,709 	$«24,470 	$«24,145
Issued under incentive stock programs
Shares: 2023: 1,364,574; 2022: 1,245,857; 2021: 4,116,525 	66 	72 	173
Share-based compensation 	646 	687 	642
Issuance of restricted stock awards 	(552) 	(520) 	(490)
End of Year
Shares: 2023: 1,987,883,852; 2022: 1,986,519,278; 2021: 1,985,273,421 	$«24,869 	$«24,709 	$«24,470
Common Shares Held in Treasury:
Beginning of Year
Shares: 2023: 248,724,257; 2022: 221,191,228; 2021: 209,926,622 	$(15,229) 	$(11,822) 	$(10,042)
Issued under incentive stock programs
Shares: 2023: 4,881,031; 2022: 4,980,202; 2021: 5,650,168 	297 	269 	271
Purchased
Shares: 2023: 9,964,268; 2022: 32,513,231; 2021: 16,914,774 	(1,049) 	(3,676) 	(2,051)
End of Year
Shares: 2023: 253,807,494; 2022: 248,724,257; 2021: 221,191,228 	$(15,981) 	$(15,229) 	$(11,822)
Earnings Employed in the Business:
Beginning of Year 	$«35,257 	$«31,528 	$«27,627
Net earnings 	5,723 	6,933 	7,071
Cash dividends declared on common shares
(per share — 2023: $2.08; 2022: $1.92; 2021: $1.82) 	(3,625) 	(3,365) 	(3,235)
Effect of common and treasury share transactions 	199 	161 	65
End of Year 	$«37,554 	$«35,257 	$«31,528
Accumulated Other Comprehensive Income (Loss):
Beginning of Year 	$÷(8,051) 	$÷(8,374) 	$÷(8,946)
Other comprehensive income (loss) 	212 	323 	572
End of Year 	$÷(7,839) 	$÷(8,051) 	$÷(8,374)
Noncontrolling Interests in Subsidiaries:
Beginning of Year 	$÷÷÷219 	$÷÷÷222 	$÷÷÷219
Noncontrolling Interests’ share of income, net of distributions and
share repurchases 	5 	(3) 	3
End of Year 	$÷÷÷224 	$÷÷÷219 	$÷÷÷222
The accompanying notes to consolidated financial statements are an integral part of this statement.
C O N S O L I D AT E D S TAT E M E N T O F S H A R E H O L D E R S ’ I N V E S T M E N T
(in millions except shares and per share data)

-- 44 of 86 --

43
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 1 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of Business — Abbott’s principal business is the discovery,
development, manufacture and sale of a broad line of health care
products.
Basis of Consolidation — The consolidated financial statements
include the accounts of the parent company and subsidiaries, after
elimination of intercompany transactions.
Use of Estimates — The consolidated financial statements have
been prepared in accordance with generally accepted accounting
principles in the United States and necessarily include amounts
based on estimates and assumptions by management. Actual
results could differ from those amounts. Significant estimates
include amounts for sales rebates, income taxes, pension and other
post-employment benefits, valuation of intangible assets, litiga-
tion, derivative financial instruments, and inventory and accounts
receivable exposures.
Foreign Currency Translation — The statements of earnings of foreign
subsidiaries whose functional currencies are other than the U.S.
dollar are translated into U.S. dollars using average exchange rates
for the period. The net assets of foreign subsidiaries whose functional
currencies are other than the U.S. dollar are translated into U.S.
dollars using exchange rates as of the balance sheet date. The U.S.
dollar effects that arise from translating the net assets of these
subsidiaries at changing rates are recorded in the foreign currency
translation adjustment account, which is included in equity as a
component of Accumulated other comprehensive income (loss).
Transaction gains and losses are recorded on the Net foreign
exchange (gain) loss line of the Consolidated Statement of Earnings.
Revenue Recognition — Revenue from product sales is recognized
upon the transfer of control, which is generally upon shipment or
delivery, depending on the delivery terms set forth in the customer
contract. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for in
the period the related sales are recorded. Sales incentives to cus-
tomers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Revenue from the launch of a new product, from an
improved version of an existing product, or for shipments in
excess of a customer’s normal requirements are recorded when
the conditions noted above are met. In those situations, manage-
ment records a returns reserve for such revenue, if necessary. In
certain Abbott businesses, primarily within diagnostics, Abbott
participates in selling arrangements that include multiple perfor-
mance obligations (e.g., instruments, reagents, procedures, and
service agreements). The total transaction price of the contract is
allocated to each performance obligation in an amount based on
the estimated relative standalone selling prices of the promised
goods or services underlying each performance obligation.
Income Taxes — Deferred income taxes are provided for the tax
effect of differences between the tax bases of assets and liabilities
and their reported amounts in the financial statements at the
enacted statutory rate to be in effect when the taxes are paid. No
additional income taxes have been provided for any remaining
undistributed foreign earnings not subject to the transition tax
related to the U.S. Tax Cuts and Jobs Act (TCJA), or any additional
outside basis differences that exist, as these amounts continue to
be indefinitely reinvested in foreign operations. The TCJA sub-
jects taxpayers to tax on global intangible low-taxed income
(GILTI) earned by certain foreign subsidiaries. Abbott treats the
GILTI tax as a period expense and provides for the tax in the year
that the tax is incurred. Interest and penalties on income tax
obligations are included in taxes on earnings.
Earnings Per Share — Unvested restricted stock units and awards
that contain non-forfeitable rights to dividends are treated as
participating securities and are included in the computation of
earnings per share under the two-class method. Under the two-
class method, net earnings are allocated between common shares
and participating securities. Net earnings allocated to common
shares in 2023, 2022 and 2021 were $5.701 billion, $6.905 billion
and $7.042 billion, respectively.
Pension and Post-Employment Benefits — Abbott accrues for the
actuarially determined cost of pension and post-employment
benefits over the service attribution periods of the employees.
Abbott must develop long-term assumptions, the most significant
of which are the health care cost trend rates, discount rates and
the expected return on plan assets. Differences between the
expected long-term return on plan assets and the actual return are
amortized over a five-year period. Actuarial losses and gains are
amortized over the remaining service attribution periods of the
employees under the corridor method.
Fair Value Measurements — For assets and liabilities that are
measured using quoted prices in active markets, total fair value
is the published market price per unit multiplied by the number
of units held without consideration of transaction costs. Assets
and liabilities that are measured using significant other observable
inputs are valued by reference to similar assets or liabilities,
adjusted for contract restrictions and other terms specific to that
asset or liability. For these items, a significant portion of fair value
is derived by reference to quoted prices of similar assets or liabili-
ties in active markets. For all remaining assets and liabilities, fair
value is derived using a fair value model, such as a discounted cash
flow model or Black-Scholes model. Purchased intangible assets
are recorded at fair value. The fair value of significant purchased
intangible assets is based on independent appraisals. Abbott uses
a discounted cash flow model to value intangible assets. The dis-
counted cash flow model requires assumptions about the timing and
amount of future net cash flows, risk, the cost of capital, terminal
values and market participants. Intangible assets are reviewed for
impairment on a quarterly basis. Goodwill and indefinite-lived
intangible assets are tested for impairment at least annually.
Share-Based Compensation — The fair value of stock options
and restricted stock awards and units are amortized over their
requisite service period, which could be shorter than the vesting
period if an employee is retirement eligible, with a charge to
compensation expense.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. Legal fees are recorded as incurred.
Cash, Cash Equivalents and Investments — Cash equivalents
consist of bank time deposits, U.S. government securities, money
market funds and U.S. treasury bills with original maturities of
three months or less. Abbott holds certain investments with a
carrying value of $141 million that are accounted for under the
equity method of accounting. Investments held in a rabbi trust

-- 45 of 86 --

44
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
and investments in publicly traded equity securities are recorded
at fair value and changes in fair value are recorded in earnings.
Investments in equity securities that are not traded on public stock
exchanges are recorded at cost minus impairment, if any, plus or
minus changes resulting from observable price changes in orderly
transactions for identical or similar investments of the same issuer.
Trade Receivable Valuations — Accounts receivable are stated at
the net amount expected to be collected. The allowance for doubt-
ful accounts reflects the current estimate of credit losses expected
to be incurred over the life of the accounts receivable. Abbott
considers various factors in establishing, monitoring, and adjust-
ing its allowance for doubtful accounts, including the aging of the
accounts and aging trends, the historical level of charge-offs, and
specific exposures related to particular customers. Abbott also
monitors other risk factors and forward-looking information, such
as country risk, when determining credit limits for customers and
establishing adequate allowances. Accounts receivable are charged
off after all reasonable means to collect the full amount (including
litigation, where appropriate) have been exhausted.
Inventories — Inventories are stated at the lower of cost (first-in,
first-out basis) or net realizable value. Cost includes material and
conversion costs.
Property and Equipment — Depreciation and amortization are
provided on a straight-line basis over the estimated useful lives of
the assets. The following table shows estimated useful lives of
property and equipment:
Classification 	Estimated Useful Lives
Buildings 	10 to 50 years
Equipment 	2 to 20 years
Product Liability — Abbott accrues for product liability claims
when it is probable that a liability has been incurred and the
amount of the liability can be reasonably estimated based on
existing information. The liabilities are adjusted quarterly as
additional information becomes available. Product liability
losses are self-insured.
Research and Development Costs — Internal research and develop-
ment costs are expensed as incurred. Clinical trial costs incurred
by third parties are expensed as the contracted work is performed.
Where contingent milestone payments are due to third parties
under research and development arrangements, the milestone
payment obligations are expensed when the milestone results
are achieved.
Acquired In-Process and Collaborations Research and Development
(IPR&D) — The initial costs of rights to IPR&D projects obtained in
an asset acquisition are expensed as IPR&D unless the project has an
alternative future use. These costs include initial payments incurred
prior to regulatory approval in connection with research and devel-
opment collaboration agreements that provide rights to develop,
manufacture, market and/or sell pharmaceutical or medical device
products. The fair value of IPR&D projects acquired in a business
combination are capitalized and accounted for as indefinite-lived
intangible assets until completed and are then amortized over the
remaining useful life. Collaborations are not significant.
Concentration of Risk and Guarantees — Due to the nature of its
operations, Abbott is not subject to significant concentration risks
relating to customers, products or geographic locations. Product
warranties are not significant.
Abbott has no material exposures to off-balance sheet arrange-
ments; no special purpose entities; nor activities that include
non-exchange-traded contracts accounted for at fair value. Abbott
periodically acquires a business or product rights in which Abbott
agrees to pay contingent consideration based on attaining certain
thresholds or based on the occurrence of certain events.
NOTE 2 — NEW ACCOUNTING STANDARDS
RECENTLY ADOPTED ACCOUNTING STANDARDS
In September 2022, the FASB issued Accounting Standards
Update (ASU) 2022-04, Disclosure of Supplier Finance Program
Obligations, which requires an entity to report information about
its supplier finance program. Abbott adopted the standard on
January 1, 2023. The new standard did not have an impact on
Abbott’s consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes, which
among other things, eliminates certain exceptions in the current
rules regarding the approach for intraperiod tax allocations and
the methodology for calculating income taxes in an interim period,
and clarifies the accounting for transactions that result in a
step-up in the tax basis of goodwill. Abbott adopted the standard
on January 1, 2021. The new standard did not have an impact on
its consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of
required segment disclosures. The guidance is required to be
applied retrospectively to all periods presented in the financial
statements. The standard becomes effective for Abbott for full year
2024 reporting and for interim periods beginning in the first
quarter of 2025. Abbott is currently evaluating the impact of this
new standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes
(Topic 740): Improvements to Income Tax Disclosures, which
requires an entity to disclose annually additional information
related to the company’s income tax rate reconciliation and
income taxes paid during the period. The guidance should be
applied prospectively with the option to apply the standard retro-
spectively. The standard becomes effective for Abbott for full year
2025 reporting. Abbott is currently evaluating the impact of this
new standard on its consolidated financial statements.
NOTE 3 — REVENUE
Abbott’s revenues are derived primarily from the sale of a
broad line of health care products under short-term receivable
arrangements. Patent protection and licenses, technological and
performance features, and inclusion of Abbott’s products under
a contract most impact which products are sold; price controls,
competition and rebates most impact the net selling prices of
products; and foreign currency translation impacts the measure-
ment of net sales and costs. Abbott’s products are generally sold
directly to retailers, wholesalers, distributors, hospitals, health
care facilities, laboratories, physicians’ offices and government
agencies throughout the world. Abbott has four reportable seg-
ments: Established Pharmaceutical Products, Diagnostic Products,
Nutritional Products, and Medical Devices.

-- 46 of 86 --

45
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following tables provide detail by sales category:
2023 	2022 	2021
(in millions) 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total 	U.S. 	Int’l 	Total
Established Pharmaceutical Products —
Key Emerging Markets 	$÷÷÷÷— 	$÷3,807 	$÷3,807 	$÷÷÷÷— 	$÷3,766 	$÷3,766 	$÷÷÷÷— 	$÷3,565 	$÷3,565
Other 	— 	1,259 	1,259 	— 	1,146 	1,146 	— 	1,153 	1,153
Total 	— 	5,066 	5,066 	— 	4,912 	4,912 	— 	4,718 	4,718
Nutritionals —
Pediatric Nutritionals 	1,977 	1,957 	3,934 	1,562 	1,919 	3,481 	2,192 	2,106 	4,298
Adult Nutritionals 	1,436 	2,784 	4,220 	1,357 	2,621 	3,978 	1,364 	2,632 	3,996
Total 	3,413 	4,741 	8,154 	2,919 	4,540 	7,459 	3,556 	4,738 	8,294
Diagnostics —
Core Laboratory 	1,243 	3,916 	5,159 	1,137 	3,751 	4,888 	1,145 	3,983 	5,128
Molecular 	172 	402 	574 	370 	625 	995 	566 	861 	1,427
Point of Care 	396 	169 	565 	372 	153 	525 	384 	152 	536
Rapid Diagnostics 	2,518 	1,172 	3,690 	6,652 	3,409 	10,061 	4,916 	3,519 	8,435
Total 	4,329 	5,659 	9,988 	8,531 	7,938 	16,469 	7,011 	8,515 	15,526
Medical Devices —
Rhythm Management 	1,085 	1,170 	2,255 	1,029 	1,090 	2,119 	1,018 	1,180 	2,198
Electrophysiology 	1,008 	1,187 	2,195 	909 	1,018 	1,927 	778 	1,129 	1,907
Heart Failure 	888 	273 	1,161 	809 	226 	1,035 	772 	235 	1,007
Vascular 	978 	1,703 	2,681 	864 	1,619 	2,483 	915 	1,739 	2,654
Structural Heart 	883 	1,061 	1,944 	818 	894 	1,712 	730 	880 	1,610
Neuromodulation 	725 	165 	890 	619 	151 	770 	616 	165 	781
Diabetes Care 	2,129 	3,632 	5,761 	1,633 	3,123 	4,756 	1,212 	3,116 	4,328
Total 	7,696 	9,191 	16,887 	6,681 	8,121 	14,802 	6,041 	8,444 	14,485
Other 	14 	— 	14 	11 	— 	11 	34 	18 	52
Total 	$15,452 	$24,657 	$40,109 	$18,142 	$25,511 	$43,653 	$16,642 	$26,433 	$43,075
Note: The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $115 million of sales in 2022 and $118 million of sales
in 2021 were moved from Rapid Diagnostics to Heart Failure.
Products sold by the Diagnostics segment include various types
of diagnostic tests to detect the COVID-19 coronavirus. Abbott’s
COVID-19 testing-related sales totaled approximately $1.6 billion
in 2023, $8.4 billion in 2022 and $7.7 billion in 2021.
Abbott recognizes revenue from product sales upon the transfer
of control, which is generally upon shipment or delivery, depend-
ing on the delivery terms set forth in the customer contract. For
maintenance agreements that provide service beyond Abbott’s
standard warranty and other service agreements, revenue is
recognized ratably over the contract term. A time-based measure
of progress appropriately reflects the transfer of services to the
customer. Payment terms between Abbott and its customers vary
by the type of customer, country of sale, and the products or
services offered. The term between invoicing and the payment
due date is not significant.
Management exercises judgment in estimating variable consider-
ation. Provisions for discounts, rebates and sales incentives to
customers, and returns and other adjustments are provided for in
the period the related sales are recorded. Sales incentives to cus-
tomers are not material. Historical data is readily available and
reliable, and is used for estimating the amount of the reduction in
gross sales. Abbott provides rebates to government agencies, whole-
salers, group purchasing organizations and other private entities.
Rebate amounts are usually based upon the volume of purchases
using contractual or statutory prices for a product. Factors used
in the rebate calculations include the identification of which
products have been sold subject to a rebate, which customer or
government agency price terms apply, and the estimated lag time
between sale and payment of a rebate. Using historical trends,
adjusted for current changes, Abbott estimates the amount of the
rebate that will be paid, and records the liability as a reduction of
gross sales when Abbott records its sale of the product. Settlement
of the rebate generally occurs from one to six months after sale.
Abbott regularly analyzes the historical rebate trends and makes
adjustments to reserves for changes in trends and terms of rebate
programs. Historically, adjustments to prior years’ rebate accruals
have not been material to net income.
Other allowances charged against gross sales include cash dis-
counts and returns, which are not significant. Cash discounts are
known within 15 to 30 days of sale, and therefore can be reliably
estimated. Returns can be reliably estimated because Abbott’s
historical returns are low, and because sales return terms and
other sales terms have remained relatively unchanged for several
periods. Product warranties are also not significant.

-- 47 of 86 --

46
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Abbott also applies judgment in determining the timing of
revenue recognition related to contracts that include multiple
performance obligations. The total transaction price of the con-
tract is allocated to each performance obligation in an amount
based on the estimated relative standalone selling prices of the
promised goods or services underlying each performance
obligation. For goods or services for which observable standalone
selling prices are not available, Abbott uses an expected cost plus
a margin approach to estimate the standalone selling price of
each performance obligation.
REMAINING PERFORMANCE OBLIGATIONS
As of December 31, 2023, the estimated revenue expected to be
recognized in the future related to performance obligations that are
unsatisfied (or partially unsatisfied) was approximately $4.4 billion
in the Diagnostic Products segment and approximately $478 million
in the Medical Devices segment. Abbott expects to recognize reve-
nue on approximately 58 percent of these remaining performance
obligations over the next 24 months, approximately 17 percent over
the subsequent 12 months and the remainder thereafter.
These performance obligations primarily reflect the future sale
of reagents/consumables in contracts with minimum purchase
obligations, extended warranty or service obligations related
to previously sold equipment, and remote monitoring services
related to previously implanted devices. Abbott has applied the
practical expedient described in ASC 606-10-50-14 and has not
included remaining performance obligations related to contracts
with original expected durations of one year or less in the
amounts above.
ASSETS RECOGNIZED FOR COSTS TO OBTAIN A
CONTRACT WITH A CUSTOMER
Abbott has applied the practical expedient in ASC 340-40-25-4
and records as an expense the incremental costs of obtaining
contracts with customers in the period of occurrence when the
amortization period of the asset that Abbott otherwise would have
recognized is one year or less. Upfront commission fees paid to
sales personnel as a result of obtaining or renewing contracts with
customers are incremental to obtaining the contract. Abbott capi-
talizes these amounts as contract costs. Capitalized commission
fees are amortized based on the contract duration to which the
assets relate which ranges from two to ten years. The amounts as
of December 31, 2023 and 2022 were not significant.
Additionally, the cost of transmitters provided to customers that
use Abbott’s remote monitoring service with respect to certain
medical devices are capitalized as contract costs. Capitalized
transmitter costs are amortized based on the timing of the transfer
of services to which the assets relate, which typically ranges from
eight to ten years. The amounts as of December 31, 2023 and 2022
were not significant.
OTHER CONTRACT ASSETS AND LIABILITIES
Abbott discloses Trade receivables separately in the Consolidated
Balance Sheet at the net amount expected to be collected. Contract
assets primarily relate to Abbott’s conditional right to consider-
ation for work completed but not billed at the reporting date.
Contract assets at the beginning and end of the period, as well as
the changes in the balance, were not significant.
Contract liabilities primarily relate to payments received from
customers in advance of performance under the contract. Abbott’s
contract liabilities arise primarily in the Medical Devices reportable
segment when payment is received upfront for various multi-
period extended service arrangements. Changes in the contract
liabilities during the period are as follows:
(in millions)
Contract Liabilities:
Balance at December 31, 2021 	$«520
Unearned revenue from cash received during the period 	578
Revenue recognized related to contract liability balance 	(598)
Balance at December 31, 2022 	500
Unearned revenue from cash received during the period 	469
Revenue recognized related to contract liability balance 	(424)
Balance at December 31, 2023 	$«545
NOTE 4 — SUPPLEMENTAL FINANCIAL INFORMATION
Other (income) expense, net, for 2023, 2022 and 2021 includes
approximately $498 million, $406 million and $270 million of
income, respectively, related to the non-service cost components
of the net periodic benefit costs associated with the pension and
post-retirement medical plans.
The following summarizes the activity related to the allowance
for doubtful accounts:
(in millions)
Allowance for Doubtful Accounts:
Balance at December 31, 2021 	$313
Provisions/charges to income 	6
Amounts charged off and other deductions 	(57)
Balance at December 31, 2022 	262
Provisions/charges to income 	26
Amounts charged off and other deductions 	(47)
Balance at December 31, 2023 	$241
The allowance for doubtful accounts reflects the current estimate
of credit losses expected to be incurred over the life of the accounts
receivable. Abbott considers various factors in establishing,
monitoring, and adjusting its allowance for doubtful accounts,
including the aging of the accounts and aging trends, the historical
level of charge-offs, and specific exposures related to particular
customers. Abbott also monitors other risk factors and forward-
looking information, such as country risk, when determining
credit limits for customers and establishing adequate allowances.

-- 48 of 86 --

47
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The detail of various balance sheet components is as follows:
(in millions)
December 31 	2023 	2022
Long-term Investments:
Equity securities 	$555 	$558
Other 	244 	208
Total 	$799 	$766
The increase in Abbott’s long-term investments as of December 31,
2023 versus the balance as of December 31, 2022 is primarily due
to investments acquired as part of a business acquisition and other
additional investments, partially offset by the impact of equity
method investment losses.
Abbott’s equity securities as of December 31, 2023 and December 31,
2022, include $314 million and $298 million, respectively, of
investments in mutual funds that are held in a rabbi trust acquired
as part of the St. Jude Medical, Inc. (St. Jude Medical) business
acquisition. These investments, which are specifically designated
as available for the purpose of paying benefits under a deferred
compensation plan, are not available for general corporate pur-
poses and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of December 31, 2023
with a carrying value of $141 million that are accounted for under
the equity method of accounting and other equity investments
with a carrying value of $88 million that do not have a readily
determinable fair value.
(in millions)
December 31 	2023 	2022
Other Accrued Liabilities:
Accrued rebates payable to government agencies 	$÷«650 	$÷«638
Accrued other rebates (a) 	1,091 	1,087
All other 	3,681 	4,120
Total 	$5,422 	$5,845
(a) Accrued wholesaler chargeback rebates of $232 million and $234 million at December 31, 2023
and 2022, respectively, are netted in trade receivables because Abbott’s customers are invoiced
at a higher catalog price but only remit to Abbott their contract price for the products..
(in millions)
December 31 	2023 	2022
Post-employment Obligations and
Other Long-term Liabilities:
Defined benefit pension plans and post-employment
medical and dental plans for significant plans 	$1,964 	$1,784
Deferred income taxes 	568 	991
Operating lease liabilities 	949 	943
All other (b) 	3,466 	3,804
Total 	$6,947 	$7,522
(b) Includes approximately $650 million and $850 million of net unrecognized tax benefits
and $430 million and $740 million of transition tax obligation related to the TCJA in
2023 and 2022, respectively.
NOTE 5 — ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)
The components of the changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
(in millions)
Cumulative Foreign
Currency Translation
Adjustments
Net Actuarial Gains
(Losses) and Prior
Service (Costs)
and Credits
Cumulative Gains
(Losses) on Derivative
Instruments Designated
as Cash Flow Hedges 	Total
Balance at December 31, 2021 	$(5,839) 	$(2,670) 	$«135 	$(8,374)
Other comprehensive income (loss) before reclassifications 	(894) 	1,007 	199 	312
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	— 	170 	(159) 	11
Net current period other comprehensive income (loss) 	(894) 	1,177 	40 	323
Balance at December 31, 2022 	(6,733) 	(1,493) 	175 	(8,051)
Other comprehensive income (loss) before reclassifications 	212 	127 	5 	344
(Income) loss amounts reclassified from accumulated other
comprehensive income (a) 	17 	(10) 	(139) 	(132)
Net current period other comprehensive income (loss) 	229 	117 	(134) 	212
Balance at December 31, 2023 	$(6,504) 	$(1,376) 	$÷«41 	$(7,839)
(a) (Income) loss amounts reclassified from accumulated other comprehensive income related to cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost
is included as a component of net periodic benefit cost – see Note 14 for additional information.

-- 49 of 86 --

48
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 6 — BUSINESS ACQUISITIONS
On September 22, 2023, Abbott completed the acquisition of Bigfoot
Biomedical, Inc. (Bigfoot), which will further Abbott’s efforts to
develop connected solutions for making diabetes management more
personal and precise. The purchase price, the preliminary allocation
of acquired assets and liabilities, and the revenue and net income
contributed by Bigfoot since the date of acquisition are not material
to Abbott’s consolidated financial statements.
On April 27, 2023, Abbott completed the acquisition of
Cardiovascular Systems, Inc. (CSI) for $20 per common share,
which equated to a purchase price of $851 million. The transaction
was funded with cash on hand and accounted for as a business
combination. CSI’s atherectomy system, which is used in treating
peripheral and coronary artery disease, adds complementary
technologies to Abbott’s portfolio of vascular device offerings.
The preliminary allocation of the purchase price of the CSI acqui-
sition resulted in the recording of two non-deductible developed
technology intangible assets of $305 million; non-deductible
in-process research and development of $15 million, which will be
accounted for as an indefinite-lived intangible asset until regula-
tory approval or discontinuation; non-deductible goodwill of
$371 million; net deferred tax assets of approximately $46 million
and other net assets of approximately $114 million. The goodwill
is identifiable to the Medical Devices reportable segment and is
attributable to expected synergies from combining operations, as
well as intangible assets that do not qualify for separate recogni-
tion. Allocation of the purchase price of the acquisition will be
finalized when the valuation of assets and liabilities is completed.
Revenues and earnings of CSI included in Abbott’s consolidated
financial statements since the acquisition date are not material to
Abbott’s consolidated revenue and earnings. If the acquisition of
CSI had taken place as of the beginning of 2022, consolidated net
sales and earnings would not have been significantly different
from reported amounts.
In September 2021, Abbott acquired Walk Vascular, LLC (Walk
Vascular), a commercial-stage medical device company with a
minimally invasive thrombectomy system designed to remove
peripheral blood clots. Walk Vascular’s peripheral thrombectomy
system has been incorporated into Abbott’s existing endovascular
portfolio. The purchase price, the allocation of acquired assets and
liabilities, and the revenue and net income contributed by Walk
Vascular since the date of acquisition are not material to Abbott’s
consolidated financial statements.
NOTE 7 — GOODWILL AND INTANGIBLE ASSETS
The total amount of goodwill reported was $23.7 billion at
December 31, 2023 and $22.8 billion at December 31, 2022.
In 2023, recent business acquisitions increased goodwill by
approximately $576 million. Foreign currency translation adjust-
ments increased goodwill by $304 million in 2023 and decreased
goodwill by $431 million in 2022. The amount of goodwill related
to reportable segments at December 31, 2023 was $2.7 billion for
the Established Pharmaceutical Products segment, $285 million
for the Nutritional Products segment, $3.6 billion for the
Diagnostic Products segment, and $17.1 billion for the Medical
Devices segment. There were no reductions of goodwill relating
to impairments in 2023 and 2022.
The gross amount of amortizable intangible assets, primarily
product rights and technology, was $27.7 billion and $27.2 billion
as of December 31, 2023 and 2022, respectively. The gross amount
of amortizable intangible assets increased by $305 million due
to a recent business acquisition. Accumulated amortization was
$19.7 billion and $17.6 billion as of December 31, 2023 and
December 31, 2022, respectively. Foreign currency translation
adjustments increased intangible assets by $44 million in 2023
and decreased intangible assets by $150 million in 2022. The
estimated annual amortization expense for intangible assets
recorded at December 31, 2023 is approximately $1.9 billion in
2024, $1.7 billion in 2025, $1.6 billion in 2026, $1.3 billion in 2027
and $0.7 billion in 2028. Amortizable intangible assets are amor-
tized over 2 to 20 years.
Indefinite-lived intangible assets, which relate to IPR&D acquired
in a business combination, were approximately $787 million and
$807 million at December 31, 2023 and 2022, respectively. In 2023,
$100 million of impairment charges related to certain indefinite-
lived intangible assets in the Medical Devices reportable segment
were recorded on the Research and development line of the
Consolidated Statement of Earnings. Recent business acquisitions
increased IPR&D assets by $80 million. In 2022, $111 million of
impairment charges were recorded on the Research and develop-
ment line of the Consolidated Statement of Earnings related to
certain IPR&D intangible assets associated with the Medical
Devices business segment.
NOTE 8 — RESTRUCTURING PLANS
In 2023, Abbott management approved plans to restructure
various operations in order to reduce costs in its medical devices,
diagnostic, and established pharmaceutical businesses. Abbott
recorded employee related severance and other charges of approx-
imately $144 million of which approximately $56 million was
recorded in Cost of products sold, approximately $22 million
was recorded in Research and development and approximately
$66 million was recorded in Selling, general and administrative
expenses. Payments related to these actions totaled $65 million
in 2023 and the remaining liability totaled $79 million at
December 31, 2023. In addition, Abbott recognized fixed asset
impairment and inventory related charges of approximately
$31 million related to these restructuring plans.
In 2022, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
its medical devices, nutritional, diagnostic, and established
pharmaceutical businesses. Abbott recorded employee related
severance and other charges of approximately $234 million of
which approximately $59 million was recorded in Cost of products
sold, approximately $36 million was recorded in Research and
development and approximately $139 million was recorded in
Selling, general and administrative expenses. In addition, Abbott
recognized inventory related charges of approximately $23 million
and fixed assets impairment charges of approximately $4 million
related to these restructuring plans.

-- 50 of 86 --

49
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following summarizes the activity related to the 2022
restructuring actions and the status of the related accruals as
of December 31, 2023:
(in millions)
Restructuring charges in 2022 	$«234
Payments and other adjustments 	(6)
Accrued balance at December 31, 2022 	228
Payments and other adjustments 	(170)
Accrued balance at December 31, 2023 	$÷«58
In 2021, Abbott management approved a restructuring plan related
to its Diagnostic Products segment to align its manufacturing
network for COVID-19 diagnostic tests with changes in the second
quarter of 2021 in projected testing demand driven by several
factors, including significant reductions in cases in the U.S. and
other major developed countries, the accelerated rollout of
COVID-19 vaccines globally and the U.S. health authority’s updated
guidance on testing for fully vaccinated individuals. Charges under
this plan were recorded in Cost of products sold and totaled
$441 million in 2021.
The following summarizes the activity related to this restructuring
action and the status of the related accruals as of December 31, 2023:
(in millions)
Inventory-
Related
Charges
Fixed
Asset
Write-
Downs
Other
Exit
Costs 	Total
Restructuring charges
recorded in 2021 	$«248 	$«80 	$113 	$«441
Payments 	— 	— 	(90) 	(90)
Other non-cash 	(248) 	(80) 	— 	(328)
Accrued balance at
December 31, 2021 	— 	— 	23 	23
Payments and other
adjustments 	— 	— 	(10) 	(10)
Accrued balance at
December 31, 2022 	— 	— 	13 	13
Payments and other
adjustments 	— 	— 	(13) 	(13)
Accrued balance at
December 31, 2023 	$÷÷— 	$÷— 	$÷÷— 	$÷÷—
In 2021, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies
in its diagnostic, established pharmaceutical, nutritional, and
medical device businesses. Abbott recorded employee related
severance and other charges of approximately $68 million of
which approximately $16 million was recorded in Cost of products
sold, approximately $4 million was recorded in Research and
development and approximately $48 million was recorded in
Selling, general and administrative expenses. Restructuring activi-
ties under the 2021 plans have been completed and there are no
remaining liabilities under these plans as of December 31, 2023.
NOTE 9 — INCENTIVE STOCK PROGRAM
The 2017 Incentive Stock Program authorizes the granting of
nonqualified stock options, restricted stock awards, restricted
stock units, performance awards, foreign benefits and other share-
based awards. Stock options and restricted stock awards and units
comprise the majority of benefits that have been granted and are
currently outstanding under this program and a prior program.
In 2023, Abbott granted 2,027,255 stock options, 474,369 restricted
stock awards and 4,981,231 restricted stock units under this program.
Under Abbott’s stock incentive programs, the purchase price of
shares under option must be at least equal to the fair market value
of the common stock on the date of grant, and the maximum term
of an option is 10 years. Options generally vest equally over three
years. Restricted stock awards generally vest over three years, with
no more than one-third of the award vesting in any one year upon
Abbott reaching a minimum return on equity target. Restricted
stock units vest over three years and upon vesting, the recipient
receives one share of Abbott stock for each vested restricted stock
unit. The aggregate fair market value of options and restricted stock
awards and units is recognized as expense over the requisite service
period, which may be shorter than the vesting period if an employee
is retirement eligible. Forfeitures are estimated at the time of grant.
Restricted stock awards and settlement of vested restricted stock
units are issued out of treasury shares. Abbott generally issues new
shares for exercises of stock options. As a policy, Abbott does not
purchase its shares relating to its share-based programs.
In April 2017, Abbott’s shareholders authorized the 2017 Incentive
Stock Program under which a maximum of 170 million shares
were available for issuance. At December 31, 2023, approximately
74 million shares remained available for future issuance.
The following table summarizes stock option activity for the year ended December 31, 2023 and the outstanding stock options as of
December 31, 2023.
(intrinsic values in millions) 	Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Life (Years)
Aggregate
Intrinsic Value
Outstanding at December 31, 2022 	28,288,046 	$÷70.64 	5.3 	$1,167
Granted 	2,027,255 	106.03
Exercised 	(1,664,222) 	44.71
Lapsed 	(82,004) 	122.08
Outstanding at December 31, 2023 	28,569,075 	$÷74.52 	4.8 	$1,073
Exercisable at December 31, 2023 	23,921,284 	$÷66.90 	4.1 	$1,064

-- 51 of 86 --

50
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes restricted stock awards and units
activity for the year ended December 31, 2023.
Share Units
Weighted
Average
Grant-Date
Fair Value
Outstanding at December 31, 2022 	10,400,328 	$114.59
Granted 	5,455,600 	106.11
Vested 	(5,069,639) 	109.81
Forfeited 	(508,003) 	113.48
Outstanding at December 31, 2023 	10,278,286 	$112.51
The fair market value of restricted stock awards and units vested
in 2023, 2022 and 2021 was $536 million, $639 million and
$809 million, respectively.
The total intrinsic value of options exercised in 2023, 2022 and
2021 was $102 million, $85 million and $393 million, respectively.
The total unrecognized compensation cost related to all share-
based compensation plans at December 31, 2023 amounted to
approximately $450 million, which is expected to be recognized
over the next three years.
Total non-cash stock compensation expense charged against income
in 2023, 2022 and 2021 for share-based plans totaled approximately
$644 million, $685 million and $640 million, respectively, and the
tax benefit recognized was approximately $144 million, $170 million
and $267 million, respectively. Stock compensation cost capitalized
as part of inventory is not significant.
The table below summarizes the fair value of an option granted
in 2023, 2022 and 2021 and the assumptions included in the Black-
Scholes option-pricing model used to estimate the fair value:
2023 	2022 	2021
Fair value 	$26.87 	$25.26 	$24.17
Risk-free interest rate 	4.0% 	1.9% 	0.8%
Average life of options (years) 	6.0 	6.0 	6.0
Volatility 	24.4% 	23.8% 	23.8%
Dividend yield 	1.9% 	1.6% 	1.5%
The risk-free interest rate is based on the rates available at the
time of the grant for zero-coupon U.S. government issues with a
remaining term equal to the option’s expected life. The average life
of an option is based on both historical and projected exercise and
lapsing data. Expected volatility is based on implied volatilities
from traded options on Abbott’s stock and historical volatility of
Abbott’s stock over the expected life of the option. Dividend yield
is based on the option’s exercise price and annual dividend rate
at the time of grant.
NOTE 10 — DEBT AND LINES OF CREDIT
The following is a summary of long-term debt at December 31:
(in millions) 	2023 	2022
0.875% Notes, due 2023 	$÷÷÷÷— 	$÷1,215
3.40% Notes, due 2023 	— 	1,050
5-year term loan due 2024 	419 	446
0.10% Notes, due 2024 	655 	629
2.95% Notes, due 2025 	1,000 	1,000
3.875% Notes, due 2025 	500 	500
1.50% Notes, due 2026 	1,266 	1,215
3.75% Notes, due 2026 	1,700 	1,700
0.375% Notes, due 2027 	655 	629
1.15% Notes, due 2028 	650 	650
1.40% Notes, due 2030 	650 	650
4.75% Notes, due 2036 	1,650 	1,650
6.15% Notes, due 2037 	547 	547
6.00% Notes, due 2039 	515 	515
5.30% Notes, due 2040 	694 	694
4.75% Notes, due 2043 	700 	700
4.90% Notes, due 2046 	3,250 	3,250
Unamortized debt issuance costs 	(56) 	(71)
Other, including fair value adjustments
relating to interest rate hedge contracts
designated as fair value hedges 	(116) 	(196)
Total carrying amount of long-term debt 	14,679 	16,773
Less: Current portion 	1,080 	2,251
Total long-term portion 	$13,599 	$14,522
On November 30, 2023, Abbott repaid the $1.05 billion
outstanding principal amount of its 3.40% Notes upon maturity.
On September 27, 2023, Abbott repaid the €1.14 billion outstanding
principal amount of its 0.875% Notes upon maturity. The repay-
ment equated to approximately $1.2 billion. In September 2023,
Abbott repaid approximately $197 million of debt assumed as
part of a recent business acquisition. On March 15, 2022, Abbott
repaid the $750 million outstanding principal amount of its 2.55%
Notes upon maturity.
In December 2021, Abbott repaid a short-term facility for
approximately $195 million. After the repayment, Abbott has no
short-term borrowings.
Abbott has readily available financial resources, including
unused lines of credit that support commercial paper borrowing
arrangements and provide Abbott with the ability to borrow
up to $5 billion on an unsecured basis. The lines of credit as of
December 31, 2023 were a part of a Five Year Credit Agreement
that Abbott entered into on November 12, 2020. On January 29,
2024, Abbott terminated the 2020 Agreement and entered into a
new Five Year Credit Agreement (Revolving Credit Agreement).

-- 52 of 86 --

51
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
There were no outstanding borrowings under the 2020 Agreement
at the time of its termination. Any borrowings under the Revolving
Credit Agreement will mature and be payable on January 29, 2029
and will bear interest, at Abbott’s option, based on either a base
rate or Secured Overnight Financing Rate (SOFR) rate, plus an
applicable margin based on Abbott’s credit ratings.
Principal payments required on long-term debt outstanding at
December 31, 2023 are $1.1 billion in 2024, $1.5 billion in 2025,
$3.0 billion in 2026, $656 million in 2027, $651 million in 2028 and
$8.0 billion in 2029 and thereafter.
At December 31, 2023, Abbott’s long-term debt rating was AA- by
S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott
expects to maintain an investment grade rating.
NOTE 11 — LEASES
LEASES WHERE ABBOTT IS THE LESSEE
Abbott has entered into operating leases as the lessee for office
space, manufacturing facilities, R&D laboratories, warehouses,
vehicles and equipment. Finance leases are not significant.
Abbott’s operating leases generally have remaining lease terms
of 1 to 10 years. Some leases include options to extend beyond the
original lease term, generally up to 10 years and some include
options to terminate early. These options have been included in
the determination of the lease liability when it is reasonably
certain that the option will be exercised.
For all of its asset classes, Abbott elected the practical expedient
allowed under FASB ASC No. 842, “Leases” to account for each
lease component (e.g., the right to use office space) and the
associated non-lease components (e.g., maintenance services)
as a single lease component. Abbott also elected the short-term
lease accounting policy for all asset classes; therefore, Abbott is
not recognizing a lease liability or right of use (ROU) asset for
any lease that, at the commencement date, has a lease term of
12 months or less and does not include an option to purchase the
underlying asset that Abbott is reasonably certain to exercise.
As Abbott’s leases typically do not provide an implicit rate,
the interest rate used to determine the present value of the pay-
ments under each lease typically reflects Abbott’s incremental
borrowing rate based on information available at the lease
commencement date.
The following table provides information related to Abbott’s
operating leases:
(in millions, except weighted averages) 	2023 	2022 	2021
Operating lease cost (a) 	$356 	$355 	$359
Cash paid for amounts included in the
measurement of operating lease liabilities 	276 	274 	287
ROU assets arising from entering into new
operating lease obligations 	253 	263 	343
Weighted average remaining lease term at
December 31 (in years) 	7 	8 	8
Weighted average discount rate at December 31 	3.4% 	2.9% 	2.7%
(a) Includes short-term lease expense and variable lease costs, which were immaterial in the
years ended December 31, 2023, 2022 and 2021.
Future minimum lease payments under non-cancellable operating
leases as of December 31, 2023 were as follows:
(in millions)
2024 	$÷«278
2025 	246
2026 	206
2027 	146
2028 	110
Thereafter 	376
Total future minimum lease payments – undiscounted 	1,362
Less: imputed interest 	(168)
Present value of lease liabilities 	$1,194
The following table summarizes the amounts and location of
operating lease ROU assets and lease liabilities:
(in millions)
December 31 	2023 	2022 	Balance Sheet Caption
Operating Lease –
ROU Asset
$1,122 	$1,116 	Deferred income taxes
and other assets
Operating Lease Liability:
Current 	$÷«245 	$÷«230 	Other accrued liabilities
Non-current 	949 	943 	Post-employment
obligations and other
long-term liabilities
Total Liability 	$1,194 	$1,173
LEASES WHERE ABBOTT IS THE LESSOR
Certain assets, primarily diagnostics instruments, are leased
to customers under contractual arrangements that typically
include an operating or sales-type lease as well as performance
obligations for reagents and other consumables. Sales-type leases
are not significant. Contract terms vary by customer and may
include options to terminate the contract or options to extend the
contract. Where instruments are provided under operating lease
arrangements, some portion or the entire lease revenue may be
variable and subject to subsequent non-lease component (e.g.,
reagent) sales. The allocation of revenue between the lease and
non-lease components is based on standalone selling prices.
Operating lease revenue represented less than 3 percent of
Abbott’s total net sales in the years ended December 31, 2023,
2022 and 2021.
Assets related to operating leases are reported within Net property
and equipment on the Consolidated Balance Sheet. The original
cost and the net book value of such assets were $3.9 billion and
$1.8 billion, respectively, as of December 31, 2023 and $3.6 billion
and $1.6 billion, respectively, as of December 31, 2022.

-- 53 of 86 --

52
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
NOTE 12 — FINANCIAL INSTRUMENTS, DERIVATIVES AND
FAIR VALUE MEASURES
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates primarily for anticipated intercompany
purchases by those subsidiaries whose functional currencies are
not the U.S. dollar. These contracts, with gross notional amounts
totaling $7.3 billion at December 31, 2023, and $7.7 billion at
December 31, 2022, are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign exchange
rates and are recorded at fair value. Accumulated gains and losses
as of December 31, 2023 will be included in Cost of products sold
at the time the products are sold, generally through the next
twelve to eighteen months.
Abbott enters into foreign currency forward exchange contracts
to manage currency exposures for foreign currency denominated
third-party trade payables and receivables, and for intercompany
loans and trade accounts payable where the receivable or payable
is denominated in a currency other than the functional currency
of the entity. For intercompany loans, the contracts require Abbott
to sell or buy foreign currencies, primarily European currencies,
in exchange for primarily U.S. dollars and European currencies.
For intercompany and trade payables and receivables, the
currency exposures are primarily the U.S. dollar and European
currencies. At December 31, 2023 and 2022, Abbott held gross
notional amounts of $13.8 billion and $12.0 billion, respectively, of
such foreign currency forward exchange contracts.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $419 million and $446 million as of December 31,
2023 and December 31, 2022, respectively, as a hedge of the net
investment in certain foreign subsidiaries. The change in the
value of the debt, which is due to changes in foreign exchange
rates, is recorded in Accumulated other comprehensive income
(loss), net of tax.
Abbott is a party to interest rate hedge contracts to manage its
exposure to changes in the fair value of fixed-rate debt. These
contracts are designated as fair value hedges of the variability of
the fair value of fixed-rate debt due to changes in the long-term
benchmark interest rates. The effect of the hedge is to change a
fixed-rate interest obligation to a variable rate for that portion
of the debt. Abbott records the contracts at fair value and adjusts
the carrying amount of the fixed-rate debt by an offsetting amount.
Abbott had interest rate contracts totaling approximately
$2.2 billion at December 31, 2023 and $2.9 billion in 2022. The
decrease from 2022 was due to the maturity of $700 million of
interest rate hedge contracts in 2023 in conjunction with long-
term debt that also matured in 2023.
The following table summarizes the amounts and location of certain derivative financial instruments as of December 31:
(in millions)
Fair Value—Assets 	Fair Value—Liabilities
2023 	2022 	Balance Sheet Caption 	2023 	2022 	Balance Sheet Caption
Interest rate swaps designated as fair value hedges:
Non-current 	$÷«— 	$— 	Deferred income taxes
and other assets
$÷95 	$136 	Post-employment
obligations and other
long-term liabilities
Current 	— 	— 	Other prepaid expenses
and receivables
— 	20 	Other accrued liabilities
Foreign currency forward exchange contracts:
Hedging instruments 	88 	304 	Other prepaid expenses
and receivables
134 	96 	Other accrued liabilities
Others not designated as hedges 	81 	108 	Other prepaid expenses
and receivables
97 	130 	Other accrued liabilities
Debt designated as a hedge of net investment in a
foreign subsidiary
— 	— 	n/a 	419 	446 	Current portion
of long-term debt
(Long-term debt in 2022)
$169 	$412 	$745 	$828

-- 54 of 86 --

53
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt
designated as a hedge of net investment in a foreign subsidiary and certain other derivative financial instruments, as well as the amounts
and location of income (expense) and gain (loss) reclassified into income.
(in millions)
Gain (loss) Recognized in Other
Comprehensive Income (loss)
Income (expense) and Gain (loss)
Reclassified into Income
Income Statement Caption	2023 	2022 	2021 	2023 	2022 	2021
Foreign currency forward exchange contracts
designated as cash flow hedges
$(22) 	$281 	$164 	$187 	$234 	$(252) 	Cost of products sold
Debt designated as a hedge of net investment in a
foreign subsidiary
27 	75 	56 	n/a 	n/a 	n/a 	n/a
Interest rate swaps designated as fair value hedges 	n/a 	n/a 	n/a 	61 	(243) 	(123) 	Interest expense
A loss of $44 million and gains of $70 million and $19 million were
recognized in 2023, 2022 and 2021, respectively, related to foreign
currency forward exchange contracts not designated as hedges.
These amounts are reported in the Consolidated Statement of
Earnings on the Net foreign exchange (gain) loss line.
The interest rate swaps are designated as fair value hedges of
the variability of the fair value of fixed-rate debt due to changes
in the long-term benchmark interest rates. The hedged debt is
marked to market, offsetting the effect of marking the interest
rate swaps to market.
The carrying values and fair values of certain financial instruments
as of December 31 are shown in the table below. The carrying values
of all other financial instruments approximate their estimated fair
values. The counterparties to financial instruments consist of select
major international financial institutions. Abbott does not expect
any losses from nonperformance by these counterparties.
(in millions)
2023 	2022
Carrying Value 	Fair Value 	Carrying Value 	Fair Value
Long-term Investment Securities:
Equity securities 	$÷÷÷555 	$÷÷÷555 	$÷÷÷558 	$÷÷÷558
Other 	244 	244 	208 	208
Total long-term debt 	(14,679) 	(14,769) 	(16,773) 	(16,313)
Foreign Currency Forward Exchange Contracts:
Receivable position 	169 	169 	412 	412
(Payable) position 	(231) 	(231) 	(226) 	(226)
Interest Rate Hedge Contracts:
(Payable) position 	(95) 	(95) 	(156) 	(156)
The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

-- 55 of 86 --

54
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted Prices in
Active Markets
Significant Other
Observable
Inputs
Significant
Unobservable
Inputs
December 31, 2023:
Equity securities 	$÷«326 	$326 	$÷÷÷— 	$÷«—
Foreign currency forward exchange contracts 	169 	— 	169 	—
Total Assets 	$÷«495 	$326 	$÷«169 	$÷«—
Fair value of hedged long-term debt 	$2,052 	$÷«— 	$2,052 	$÷«—
Interest rate swap derivative financial instruments 	95 	— 	95 	—
Foreign currency forward exchange contracts 	231 	— 	231 	—
Contingent consideration related to business combinations 	112 	— 	— 	112
Total Liabilities 	$2,490 	$÷«— 	$2,378 	$112
December 31, 2022:
Equity securities 	$÷«307 	$307 	$÷÷÷— 	$÷«—
Foreign currency forward exchange contracts 	412 	— 	412 	—
Total Assets 	$÷«719 	$307 	$÷«412 	$÷«—
Fair value of hedged long-term debt 	$2,691 	$÷«— 	$2,691 	$÷«—
Interest rate swap derivative financial instruments 	156 	— 	156 	—
Foreign currency forward exchange contracts 	226 	— 	226 	—
Contingent consideration related to business combinations 	130 	— 	— 	130
Total Liabilities 	$3,203 	$÷«— 	$3,073 	$130
The fair value of foreign currency forward exchange contracts is
determined using a market approach, which utilizes values for
comparable derivative instruments. The fair value of the debt was
determined based on the face value of the debt adjusted for the fair
value of the interest rate swaps, which is based on a discounted
cash flow analysis using significant other observable inputs.
Contingent consideration relates to businesses acquired by
Abbott. The fair value of the contingent consideration was deter-
mined based on independent appraisals at the time of acquisition,
adjusted for the time value of money and other changes in fair
value. The decrease in the amount of contingent consideration
from December 31, 2022 reflects the impact of projected timeline
changes for events that will trigger payment of contingent consid-
eration, partially offset by additional contingent consideration
assumed in a business acquisition in 2023. The maximum amount
for certain contingent consideration is not determinable as it is
based on a percent of certain sales. Excluding such contingent
consideration, the maximum amount that may be due under the
other contingent consideration arrangements was estimated at
December 31, 2023 to be approximately $190 million, which is
dependent upon attaining certain sales thresholds or upon the
occurrence of certain events, such as regulatory approvals.
NOTE 13 — LITIGATION AND ENVIRONMENTAL MATTERS
Abbott has been identified as a potentially responsible party for
investigation and cleanup costs at a number of locations in the
United States and Puerto Rico under federal and state remediation
laws and is investigating potential contamination at a number of
company-owned locations. Abbott has recorded an estimated
cleanup cost for each site for which management believes Abbott
has a probable loss exposure. No individual site cleanup exposure
is expected to exceed $4 million, and the aggregate cleanup
exposure is not expected to exceed $10 million.
Abbott is involved in various claims and legal proceedings, and
Abbott estimates the range of possible loss for its legal proceedings
and environmental exposures to be from approximately $30 million
to $45 million. The recorded accrual balance at December 31, 2023
for these proceedings and exposures was approximately $40 million.
This accrual represents management’s best estimate of probable
loss, as defined by FASB ASC No. 450, “Contingencies.” Within the
next year, legal proceedings may occur that may result in a change
in the estimated loss accrued by Abbott. While it is not feasible to
predict the outcome of all such proceedings and exposures with
certainty, management believes that their ultimate disposition
should not have a material adverse effect on Abbott’s financial
position, cash flows, or results of operations.

-- 56 of 86 --

55
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The $458 million of defined benefit plan losses and $35 million
of medical and dental plan losses in 2023 that increased the pro-
jected benefit obligations primarily reflect the year-over-year
decline in the discount rates used to measure the obligations.
The $3.6 billion of defined benefit plan gains and $437 million of
medical and dental plan gains in 2022 that decreased the projected
benefit obligations primarily reflect the year-over-year increase
in the discount rates used to measure the obligations. The pro-
jected benefit obligations for non-U.S. defined benefit plans were
$2.6 billion and $2.2 billion at December 31, 2023 and 2022,
respectively. The accumulated benefit obligations for all defined
benefit plans were $9.2 billion and $8.4 billion at December 31,
2023 and 2022, respectively.
NOTE 14 — POST-EMPLOYMENT BENEFITS
Retirement plans consist of defined benefit, defined contribution and medical and dental plans. Information for Abbott’s major defined
benefit plans and post-employment medical and dental benefit plans is as follows:
(in millions)
Defined Benefit Plans 	Medical and Dental Plans
2023 	2022 	2023 	2022
Projected benefit obligations, January 1 	$÷9,167 	$12,773 	$1,126 	$1,566
Service cost — benefits earned during the year 	230 	374 	38 	50
Interest cost on projected benefit obligations 	455 	300 	59 	36
(Gains) losses, primarily changes in discount rates, plan design changes, law changes
and differences between actual and estimated health care costs 	458 	(3,645) 	35 	(437)
Benefits paid 	(377) 	(368) 	(77) 	(70)
Other, including foreign currency translation 	97 	(267) 	— 	(19)
Projected benefit obligations, December 31 	$10,030 	$÷9,167 	$1,181 	$1,126
Plan assets at fair value, January 1 	$11,373 	$13,468 	$÷«302 	$÷«370
Actual return (loss) on plan assets 	1,611 	(1,856) 	26 	(33)
Company contributions 	349 	413 	37 	35
Benefits paid 	(377) 	(368) 	(77) 	(70)
Other, including foreign currency translation 	129 	(284) 	— 	—
Plan assets at fair value, December 31 	$13,085 	$11,373 	$÷«288 	$÷«302
Projected benefit obligations less (greater) than plan assets, December 31 	$÷3,055 	$÷2,206 	$÷(893) 	$÷(824)
Long-term assets 	$÷4,164 	$÷3,200 	$÷÷÷— 	$÷÷÷—
Short-term liabilities 	(36) 	(32) 	(2) 	(2)
Long-term liabilities 	(1,073) 	(962) 	(891) 	(822)
Net asset (liability) 	$÷3,055 	$÷2,206 	$÷(893) 	$÷(824)
Amounts Recognized in Accumulated Other Comprehensive Income (loss):
Actuarial losses, net 	$÷1,751 	$÷1,960 	$÷÷«62 	$«÷÷27
Prior service costs (credits) 	6 	(6) 	(22) 	(33)
Total 	$÷1,757 	$÷1,954 	$÷÷«40 	$÷÷÷(6)
For plans where the projected benefit obligations exceeded plan
assets at December 31, 2023 and 2022, the projected benefit
obligations and the aggregate plan assets were as follows:
(in millions) 	2023 	2022
Projected benefit obligation 	$1,314 	$1,270
Fair value of plan assets 	205 	276
For plans where the accumulated benefit obligations exceeded
plan assets at December 31, 2023 and 2022, the aggregate accumu-
lated benefit obligations, the projected benefit obligations and the
aggregate plan assets were as follows:
(in millions) 	2023 	2022
Accumulated benefit obligation 	$1,175 	$1,044
Projected benefit obligation 	1,248 	1,134
Fair value of plan assets 	144 	141

-- 57 of 86 --

56
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The components of the net periodic benefit cost were as follows:
(in millions)
Defined Benefit Plans 	Medical and Dental Plans
2023 	2022 	2021 	2023 	2022 	2021
Service cost — benefits earned during the year 	$«230 	$«374 	$«391 	$«38 	$÷50 	$«56
Interest cost on projected benefit obligations 	455 	300 	248 	59 	36 	33
Expected return on plans’ assets 	(971) 	(931) 	(843) 	(23) 	(30) 	(27)
Amortization of actuarial losses (gains) 	11 	231 	317 	(2) 	11 	29
Amortization of prior service costs (credits) 	1 	1 	1 	(13) 	(24) 	(28)
Total net cost (income) 	$(274) 	$÷(25) 	$«114 	$«59 	$«43 	$«63
In addition, approximately $15 million of income was recognized in
2023 related to the curtailment of a non-U.S. defined benefit plan.
Other comprehensive income (loss) for each respective year
includes the amortization of actuarial losses and prior service
costs (credits) as noted in the previous table. Other comprehensive
income (loss) for each respective year also includes: net actuarial
gains of $182 million for defined benefit plans and a loss of
$33 million for medical and dental plans in 2023; net actuarial
gains of $858 million for defined benefit plans and a gain of
$374 million for medical and dental plans in 2022, and net actuarial
gains of $1.14 billion for defined benefit plans and a gain of
$45 million for medical and dental plans in 2021. The net actuarial
gains in 2023 related to defined benefit plans are primarily due to
the favorable impact of actual asset returns in excess of expected
returns, partially offset by the year-over-year decrease in discount
rates. The net actuarial losses in 2023 related to medical and
dental plans are primarily due to the year-over-year decrease in
discount rates. The net actuarial gains in 2022 were primarily due
to the year-over-year increase in discount rates, partially offset by
the impact of 2022 actual asset returns being less than expected
returns. The net actuarial gains in 2021 are primarily due to the
favorable impact of actual 2021 asset returns in excess of expected
returns and the year-over-year increase in discount rates.
The weighted average assumptions used to determine benefit
obligations for defined benefit plans and medical and dental plans
are as follows:
2023 	2022 	2021
Discount rate 	4.8% 	5.0% 	2.7%
Expected aggregate average
long-term change in compensation 	4.6% 	4.5% 	4.3%
The weighted average assumptions used to determine the net
cost for defined benefit plans and medical and dental plans are
as follows:
2023 	2022 	2021
Discount rate 	5.0% 	2.7% 	2.3%
Expected return on plan assets 	7.6% 	7.5% 	7.5%
Expected aggregate average long-
term change in compensation 	4.5% 	4.4% 	4.3%
The assumed health care cost trend rates for medical and dental
plans at December 31 were as follows:
2023 	2022 	2021
Health care cost trend rate
assumed for the next year 	8% 	7% 	7%
Rate that the cost trend rate
gradually declines to 	5% 	5% 	5%
Year that rate reaches the
assumed ultimate rate 	2029 	2027 	2026
The discount rates used to measure liabilities were determined
based on high-quality fixed income securities that match the
duration of the expected retiree benefits. The health care cost
trend rates represent Abbott’s expected annual rates of change in
the cost of health care benefits and are forward projections of
health care costs as of the measurement date.

-- 58 of 86 --

57
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the bases used to measure the defined benefit and medical and dental plan assets at fair value:
(in millions)
Outstanding
Balances
Basis of Fair Value Measurement
Quoted
Prices in
Active Markets
Significant
Other Observable
Inputs
Significant
Unobservable
Inputs
Measured
at NAV ( j)
December 31, 2023
Equities:
U.S. large cap (a) 	$÷3,425 	$2,305 	$÷÷÷— 	$— 	$1,120
U.S. mid and small cap (b) 	814 	807 	— 	1 	6
International (c) 	2,725 	493 	— 	— 	2,232
Fixed income securities:
U.S. government securities (d) 	391 	5 	371 	— 	15
Corporate debt instruments (e) 	1,519 	125 	1,055 	— 	339
Non-U.S. government securities (f ) 	586 	36 	3 	— 	547
Other (g) 	863 	322 	106 	— 	435
Absolute return funds (h) 	1,669 	270 	— 	— 	1,399
Cash and Cash Equivalents 	276 	16 	— 	— 	260
Other (i) 	1,105 	5 	— 	— 	1,100
$13,373 	$4,384 	$1,535 	$«1 	$7,453
December 31, 2022
Equities:
U.S. large cap (a) 	$÷2,866 	$1,840 	$÷÷÷— 	$— 	$1,026
U.S. mid and small cap (b) 	693 	684 	— 	1 	8
International (c) 	2,401 	454 	— 	— 	1,947
Fixed income securities:
U.S. government securities (d) 	362 	5 	341 	— 	16
Corporate debt instruments (e) 	1,318 	123 	890 	— 	305
Non-U.S. government securities (f ) 	419 	16 	— 	— 	403
Other (g) 	775 	297 	75 	— 	403
Absolute return funds (h) 	1,678 	304 	— 	— 	1,374
Cash and Cash Equivalents 	154 	20 	— 	— 	134
Other (i) 	1,009 	7 	— 	— 	1,002
$11,675 	$3,750 	$1,306 	$«1 	$6,618
(a) A mix of index funds and actively managed equity accounts that are benchmarked to various large cap indices.
(b) A mix of index funds and actively managed equity accounts that are benchmarked to various mid and small cap indices.
(c) A mix of index funds and actively managed pooled investment funds that are benchmarked to various non-U.S. equity indices in both developed and emerging markets.
(d) A mix of index funds and actively managed accounts that are benchmarked to various U.S. government bond indices.
(e) A mix of index funds and actively managed accounts that are benchmarked to various corporate bond indices.
(f ) Primarily United Kingdom, Canada, Japan and Eurozone government bonds.
(g) Primarily asset backed securities, bank loans, interest rate swap positions and diversified fixed income vehicles benchmarked to SOFR, Sterling Overnight Interbank Average (SONIA)
or EURIBOR.
(h) Primarily hedge funds and funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including,
but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed upon benchmark with specific return and volatility targets.
(i) Primarily investments in private funds, such as private equity, private credit, private real estate and private energy funds.
( j) Investments measured at fair value using the net asset value (NAV) practical expedient have not been classified in the fair value hierarchy. The fair value amounts presented in this table are
intended to permit reconciliation of the fair value hierarchy to the amounts presented in the consolidated balance sheet.

-- 59 of 86 --

58
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
Equities that are valued using quoted prices are valued at the
published market prices. Equities in a common collective trust or
a registered investment company are valued at the NAV provided
by the fund administrator. The NAV is based on the value of the
underlying assets owned by the fund minus its liabilities. For
approximately half of these funds, investments may be redeemed
once per week or month, with a required 2 to 30 day notice period.
For the remaining funds, daily redemption of an investment is
allowed. Fixed income securities that are valued using significant
other observable inputs are valued at prices obtained from inde-
pendent financial service industry recognized vendors. Abbott
did not have any unfunded commitments related to fixed income
funds at December 31, 2023 and 2022. Fixed income securities in
a common collective trust or a registered investment company
are valued at the NAV provided by the fund administrator. For
the majority of these funds, investments may be redeemed either
weekly or monthly, with a required 2 to 60 day notice period.
For the remaining funds, investments may be generally
redeemed daily.
Absolute return funds are valued at the NAV provided by the
fund administrator. All private funds are valued at the NAV pro-
vided by the fund on a one-quarter lag adjusted for known cash
flows and significant events through the reporting date. Abbott
did not have any unfunded commitments related to absolute
return funds at December 31, 2023 and 2022. Investments in these
funds may be generally redeemed monthly or quarterly with
required notice periods ranging from 45 to 90 days. For approxi-
mately $280 million and $250 million of the absolute return funds,
redemptions are subject to a 33 percent gate and a 25 percent
gate, respectively, and $80 million is subject to a lock until 2025.
Investments in the private funds cannot be redeemed but the
funds will make distributions through liquidation. The estimate
of the liquidation period for each fund ranges from 2024 to 2033.
Abbott’s unfunded commitment in these funds was $555 million
and $569 million as of December 31, 2023 and 2022, respectively.
The investment mix of equity securities, fixed income and other
asset allocation strategies is based upon achieving a desired return,
as well as balancing higher return, more volatile equity securities
with lower return, less volatile fixed income securities. Investment
allocations are made across a range of markets, industry sectors,
capitalization sizes, and in the case of fixed income securities,
maturities and credit quality. The plans do not directly hold any
securities of Abbott. There are no known significant concentrations
of risk in the plans’ assets. Abbott’s medical and dental plans’ assets
are invested in a similar mix as the pension plan assets. The actual
asset allocation percentages at year end are consistent with the
company’s targeted asset allocation percentages.
The plans’ expected return on assets, as shown above, is based
on management’s expectations of long-term average rates of
return to be achieved by the underlying investment portfolios.
In establishing this assumption, management considers historical
and expected returns for the asset classes in which the plans are
invested, as well as current economic and capital market conditions.
Abbott funds its domestic pension plans according to U.S. Internal
Revenue Service (IRS) funding limitations. International pension
plans are funded according to similar regulations. Abbott funded
$349 million in 2023 and $413 million in 2022 to defined pension
plans. Abbott expects to contribute approximately $350 million to
its pension plans in 2024.
Total benefit payments expected to be paid to participants, which
includes payments funded from company assets, as well as paid
from the plans, are as follows:
(in millions)
Defined
Benefit Plans
Medical and
Dental Plans
2024 	$÷«395 	$÷65
2025 	414 	67
2026 	434 	70
2027 	457 	73
2028 	479 	77
2029 to 2033 	2,757 	425
The Abbott Stock Retirement Plan is the principal defined contri-
bution plan. Abbott’s contributions to this plan were $199 million
in 2023, $190 million in 2022 and $181 million in 2021.
NOTE 15 — TAXES ON EARNINGS
Taxes on earnings reflect the annual effective rates, including
charges for interest and penalties. Deferred income taxes reflect
the tax consequences on future years of differences between the
tax bases of assets and liabilities and their financial reporting
amounts.
Taxes on earnings include approximately $22 million, $43 million
and $145 million in excess tax benefits associated with share-
based compensation in 2023, 2022 and 2021, respectively. As a
result of the resolution of various tax positions related to prior
years, taxes on earnings in 2023, 2022 and 2021 also include
approximately $80 million and $20 million of net tax expense and
$55 million of net tax benefits, respectively.
The TCJA includes a one-time transition tax that is based on
Abbott’s total post-1986 earnings and profits (E&P) that were previ-
ously deferred from U.S. income taxes. The tax computation also
requires the determination of the amount of post-1986 E&P consid-
ered held in cash and other specified assets. As of December 31,
2023, the remaining balance of Abbott’s transition tax obligation
related to the TCJA is approximately $598 million, which will be
paid over the next three years as allowed by the TCJA.
Undistributed foreign earnings remain indefinitely reinvested in
foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed foreign
earnings not subject to the transition tax and additional outside
basis difference in its foreign entities is not practicable.
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the IRS for the 2019 Federal tax year in
the amount of $417 million. The primary adjustments proposed
in the SNOD relate to the reallocation of income between Abbott’s
U.S. entities and its foreign affiliates. Abbott believes that the
income reallocation adjustments proposed in the SNOD are
without merit, in part because certain adjustments contradict
methods that were agreed to with the IRS in prior audit periods.

-- 60 of 86 --

59
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The SNOD also contains other proposed adjustments that Abbott
believes are erroneous and unsupported. Abbott filed a petition
with the U.S. Tax Court contesting the SNOD in December of 2023.
Abbott’s 2017 and 2018 Federal tax years are also currently under
examination by the IRS with respect to income reallocation issues
similar to those included in the 2019 Federal tax year. Abbott
intends to vigorously defend its filing positions through ongoing
discussions with the IRS, the IRS independent appeals process
and/or through litigation as necessary.
Abbott reserves for uncertain tax positions related to unresolved
matters with the IRS and other taxing authorities. Abbott contin-
ues to believe that its reserves for uncertain tax positions are
appropriate.
There are numerous other income tax jurisdictions for which
tax returns are not yet settled, none of which Abbott expects to
be individually significant. Reserves for interest and penalties
are not significant.
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised international
tax system. Pillar 1 proposes to reallocate taxing rights among the
jurisdictions in which in-scope multinational corporations operate.
Abbott is continuing to analyze the Pillar 1 proposal. Pillar 2
proposes to assess a 15 percent minimum tax on the earnings of
in-scope multinational corporations on a country-by-country
basis. Numerous countries have enacted legislation to adopt the
Pillar 2 model rules with a subset of the rules becoming effective
January 1, 2024, and the remaining rules becoming effective
January 1, 2025, or in later periods. Abbott is also continuing to
analyze the Pillar 2 model rules. Implementation of the OECD
proposal may have a material impact on Abbott’s Consolidated
Financial Statements in the future.
Earnings before taxes, and the related provisions for taxes on
earnings, were as follows:
(in millions) 	2023 	2022 	2021
Earnings Before Taxes:
Domestic 	$1,192 	$3,732 	$3,264
Foreign 	5,472 	4,574 	4,947
Total 	$6,664 	$8,306 	$8,211
(in millions) 	2023 	2022 	2021
Taxes on Earnings:
Current:
Domestic 	$÷«528 	$1,309 	$÷«859
Foreign 	874 	723 	790
Total current 	1,402 	2,032 	1,649
Deferred:
Domestic 	(382) 	(610) 	(355)
Foreign 	(79) 	(49) 	(154)
Total deferred 	(461) 	(659) 	(509)
Total 	$÷«941 	$1,373 	$1,140
Differences between the effective income tax rate and the U.S.
statutory tax rate were as follows:
2023 	2022 	2021
Statutory tax rate on earnings 	21.0% 	21.0% 	21.0%
Impact of foreign operations 	(3.6)÷« 	(2.5)÷« 	(3.9)÷«
Foreign-derived intangible income
benefit 	(2.2)÷« 	(2.0)÷« 	(1.1)÷«
Domestic impairment loss 	—÷÷ 	—÷÷« 	(0.1)÷«
Excess tax benefits related to stock
compensation 	(0.3)÷« 	(0.5)÷« 	(1.7)÷«
Research tax credit 	(1.1)÷« 	(0.9)÷« 	(0.6)÷«
Resolution of certain tax positions
pertaining to prior years 	1.2÷« 	0.2÷« 	(0.7)÷«
Intercompany restructurings and
integration 	(1.4)÷« 	—÷÷ 	0.1÷«
State taxes, net of federal benefit 	0.5÷« 	0.7÷« 	0.4÷«
All other, net 	—÷« 	0.5÷« 	0.5÷«
Effective tax rate on earnings 	14.1% 	16.5% 	13.9%
Impact of foreign operations is primarily derived from operations
in Puerto Rico, Switzerland, Ireland, the Netherlands, Costa Rica,
Singapore, Malta and Malaysia.
The tax effect of the differences that give rise to deferred tax
assets and liabilities were as follows:
(in millions) 	2023 	2022
Deferred tax assets:
Compensation and employee benefits 	$÷÷÷«89 	$÷÷230
Trade receivable reserves 	221 	227
Research and development costs 	568 	319
Inventory reserves 	198 	187
Lease liabilities 	272 	263
Deferred intercompany profit 	283 	260
NOLs, reserves not currently deductible,
credit carryforwards and other 	9,922 	2,402
Total deferred tax assets before valuation
allowance 	11,553 	3,888
Valuation allowance 	(8,690) 	(1,169)
Total deferred tax assets 	2,863 	2,719
Deferred tax liabilities:
Depreciation 	(414) 	(376)
Right of Use lease assets 	(258) 	(252)
Other, primarily the excess of book basis over
tax basis of intangible assets 	(1,777) 	(2,038)
Total deferred tax liabilities 	(2,449) 	(2,666)
Total net deferred tax assets (liabilities) 	$÷÷«414 	$÷÷÷53
Abbott has incurred losses in a foreign jurisdiction where realiza-
tion of the future economic benefit was, in previous reporting
periods, considered so remote that the benefit was not recognized
as a deferred tax asset. In 2023, Abbott concluded that the future
economic benefit of the incurred losses is no longer remote and
therefore, a deferred tax asset was recognized. Abbott also con-
cluded that it is not more likely than not that the tax benefit
associated with the deferred tax asset will be realized; therefore,
an offsetting valuation allowance was recognized.

-- 61 of 86 --

60
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
The following table summarizes the gross amounts of unrecognized
tax benefits without regard to reduction in tax liabilities or addi-
tions to deferred tax assets and liabilities if such unrecognized tax
benefits were settled:
(in millions) 	2023 	2022
January 1 	$2,036 	$1,908
Increase due to current year tax positions 	225 	154
Increase due to prior year tax positions 	1,338 	108
Decrease due to prior year tax positions 	(89) 	(115)
Settlements 	(144) 	3
Lapse of statute 	(43) 	(22)
December 31 	$3,323 	$2,036
Abbott’s unrecognized tax benefits table includes amounts related
to tax positions for which a deferred tax asset has not been recog-
nized because the recognition of the future benefit is not expected.
In 2023, Abbott’s unrecognized tax benefits increased by $1.3 billion
to $3.32 billion, which includes $2.06 billion attributable to tax
positions that, if recognized, would result in a deferred tax asset
and a related valuation allowance.
The total amount of unrecognized tax benefits that, if recognized,
would impact the effective tax rate is approximately $1.22 billion.
Abbott believes that it is reasonably possible that the recorded
amount of gross unrecognized tax benefits may decrease between
$70 million and $1.48 billion, including cash adjustments, within
the next twelve months as a result of concluding various domestic
and international tax matters.
NOTE 16 — SEGMENT AND GEOGRAPHIC AREA INFORMATION
Abbott’s principal business is the discovery, development, manu-
facture and sale of a broad line of health care products. Abbott’s
products are generally sold directly to retailers, wholesalers,
hospitals, health care facilities, laboratories, physicians’ offices
and government agencies throughout the world.
Abbott’s reportable segments are as follows:
Established Pharmaceutical Products—International sales of a
broad line of branded generic pharmaceutical products.
Nutritional Products—Worldwide sales of a broad line of adult
and pediatric nutritional products.
Diagnostic Products—Worldwide sales of diagnostic systems
and tests for blood banks, hospitals, commercial laboratories
and alternate-care testing sites. For segment reporting purposes,
the Core Laboratory Diagnostics, Rapid Diagnostics, Molecular
Diagnostics and Point of Care Diagnostics businesses are aggre-
gated and reported as the Diagnostic Products segment.
Medical Devices—Worldwide sales of rhythm management,
electrophysiology, heart failure, vascular, structural heart, neuro-
modulation and diabetes care products. For segment reporting
purposes, the Cardiac Rhythm Management, Electrophysiology,
Heart Failure, Vascular, Structural Heart, Neuromodulation and
Diabetes Care divisions are aggregated and reported as the
Medical Devices segment.
Abbott’s underlying accounting records are maintained on a
legal entity basis for government and public reporting require-
ments. Segment disclosures are on a performance basis consistent
with internal management reporting. The cost of some corporate
functions and the cost of certain employee benefits are charged
to segments at predetermined rates that approximate cost.
Remaining costs, if any, are not allocated to segments. In addition,
intangible asset amortization is not allocated to operating
segments, and intangible assets and goodwill are not included
in the measure of each segment’s assets.
The following segment information has been prepared in
accordance with the internal accounting policies of Abbott, as
described above, and are not presented in accordance with
generally accepted accounting principles applied to the
consolidated financial statements.
(in millions)
Net Sales to External
Customers (a) 	Operating Earnings (a)
2023 	2022 	2021 	2023 	2022 	2021
Established
Pharmaceutical
Products 	$÷5,066 $÷4,912 $÷4,718 	$÷1,206 $÷1,049 $÷÷«889
Nutritional
Products 	8,154 	7,459 	8,294 	1,333 	706 	1,763
Diagnostic
Products (b) 	9,988 	16,469 	15,526 	2,433 	6,640 	6,237
Medical Devices (b) 	16,887 	14,802 	14,485 	5,306 	4,436 	4,533
Total Reportable
Segments 	40,095 	43,642 	43,023 	$10,278 $12,831 $13,422
Other 	14 	11 	52
Total 	$40,109 $43,653 $43,075
(a) In 2023 and 2022, foreign exchange unfavorably impacted net sales and operating
earnings. In 2021, foreign exchange favorably impacted net sales and unfavorably
impacted operating earnings.
(b) 2022 and 2021 Sales and Operating Earnings for the Diagnostic Products and Medical
Devices reportable segments have been updated to reflect the internal transfer of the
Acelis Connected Health business from Diagnostic Products to Medical Devices on
January 1, 2023.
(in millions) 	2023 	2022 	2021
Total Reportable Segment
Operating Earnings 	$10,278 	$12,831 	$13,422
Corporate functions and
benefit plan costs 	(308) 	(509) 	(801)
Net interest expense 	(252) 	(375) 	(490)
Share-based compensation 	(644) 	(685) 	(640)
Amortization of intangible assets 	(1,966) 	(2,013) 	(2,047)
Other, net (c) 	(444) 	(943) 	(1,233)
Earnings before Taxes 	$÷6,664 	$÷8,306 	$÷8,211
(c) Other, net includes costs directly related to integrating acquired businesses and restructur-
ing charges in 2023, 2022, and 2021. Charges and expenses for restructuring actions and
other cost reduction initiatives were approximately $122 million in 2023, $265 million in
2022, and $375 million in 2021. Other, net in 2023 also includes charges of $100 million
related to indefinite-lived intangible asset impairments, partially offset by income arising
from fair value changes in contingent consideration related to previous business acquisi-
tions. Other, net in 2022 also includes $176 million of charges related to a voluntary
recall within the Nutritional products segment and $111 million of charges related to the
impairment of IPR&D intangible assets. Other, net in 2021 also includes costs related
to certain litigation.

-- 62 of 86 --

61
A B B O T T 2 0 2 3 A N N U A L R E P O R T
N O T E S T O C O N S O L I D AT E D F I N A N C I A L S TAT E M E N T S
(in millions)
Depreciation
Additions to
Property and Equipment (d) 	Total Assets
2023 	2022 	2021 	2023 	2022 	2021 	2023 	2022 	2021
Established Pharmaceuticals 	$÷«104 	$÷÷«97 	$÷÷«94 	$÷«185 	$÷«175 	$÷«169 	$÷3,118 	$÷2,883 	$÷s2,789
Nutritionals 	155 	155 	151 	457 	251 	174 	4,270 	3,625 	3,425
Diagnostics 	499 	494 	760 	750 	832 	980 	7,767 	7,985 	7,699
Medical Devices 	315 	311 	285 	604 	335 	348 	9,029 	7,844 	7,261
Total Reportable Segments 	1,073 	1,057 	1,290 	1,996 	1,593 	1,671 	$24,184 	$22,337 	$21,174
Other 	204 	197 	201 	213 	182 	201
Total 	$1,277 	$1,254 	$1,491 	$2,209 	$1,775 	$1,872
(in millions) 	2023 	2022
Total Reportable Segment Assets 	$24,184 	$22,337
Cash and investments 	8,078 	10,936
Goodwill and intangible assets 	32,494 	33,253
All other (e) 	8,458 	7,912
Total Assets 	$73,214 	$74,438
(d) Amounts exclude property, plant and equipment acquired through business acquisitions.
(e) All other includes the long-term assets associated with the defined benefit plans of $4.16 billion in 2023 and $3.20 billion in 2022.
(in millions)
Net Sales to External Customers (f )
2023 	2022 	2021
United States 	$15,452 	$18,142 	$16,642
Germany 	2,345 	2,340 	2,572
China 	2,253 	2,133 	2,392
India 	1,750 	1,649 	1,561
Switzerland 	1,638 	1,336 	1,313
Japan 	1,513 	1,932 	1,695
Netherlands 	1,074 	1,111 	1,174
All Other Countries 	14,084 	15,010 	15,726
Consolidated 	$40,109 	$43,653 	$43,075
(f ) Sales by country are based on the country that sold the product.
Long-lived assets on a geographic basis primarily include property
and equipment. It excludes goodwill, intangible assets, deferred
tax assets, and financial instruments. At December 31, 2023 and
2022, long-lived assets totaled $16.2 billion and $14.2 billion,
respectively, and in the United States such assets totaled
$8.9 billion and $7.7 billion, respectively. Long-lived asset balances
associated with other countries were not material on an individual
country basis in either of the two years.

-- 63 of 86 --

62
A B B O T T 2 0 2 3 A N N U A L R E P O R T
M A N A G E M E N T R E P O R T O N I N T E R N A L
C O N T R O L O V E R F I N A N C I A L R E P O R T I N G
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
The management of Abbott Laboratories is responsible for estab-
lishing and maintaining adequate internal control over financial
reporting. Abbott’s internal control system was designed to pro-
vide reasonable assurance to the company’s management and
board of directors regarding the preparation and fair presentation
of published financial statements.
All internal control systems, no matter how well designed, have
inherent limitations. Therefore, even those systems determined to
be effective can provide only reasonable assurance with respect to
financial statement preparation and presentation.
Abbott’s management assessed the effectiveness of the company’s
internal control over financial reporting as of December 31, 2023.
In making this assessment, it used the criteria set forth in Internal
Control — Integrated Framework (2013) issued by the Committee
of Sponsoring Organizations of the Treadway Commission. Based
on our assessment, we believe that, as of December 31, 2023, the
company’s internal control over financial reporting was effective
based on those criteria.
Abbott’s independent registered public accounting firm has issued
an audit report on their assessment of the effectiveness of the
company’s internal control over financial reporting. This report
appears on page 64.
Robert B. Ford
Chairman of the Board and Chief Executive Officer
Philip P. Boudreau
Senior Vice President, Finance and Chief Financial Officer
John A. McCoy, Jr.
Vice President, Finance and Controller
February 16, 2024
To the Shareholders and the Board of Directors of Abbott Laboratories
OPINION ON THE FINANCIAL STATEMENTS
We have audited the accompanying consolidated balance sheets
of Abbott Laboratories and subsidiaries (the Company) as of
December 31, 2023 and 2022, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2023, and the related notes (collectively referred
to as the “consolidated financial statements”). In our opinion, the
consolidated financial statements present fairly, in all material
respects, the financial position of the Company at December 31,
2023 and 2022, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 2023,
in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the Company’s internal control over financial reporting
as of December 31, 2023, based on criteria established in Internal
Control-Integrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (2013
framework), and our report dated February 16, 2024 expressed
an unqualified opinion thereon.
BASIS FOR OPINION
These financial statements are the responsibility of the Company’s
management. Our responsibility is to express an opinion on the
Company’s financial statements based on our audits. We are a
public accounting firm registered with the PCAOB and are required
to be independent with respect to the Company in accordance with
the U.S. federal securities laws and the applicable rules and regula-
tions of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the
PCAOB. Those standards require that we plan and perform the
audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to
error or fraud. Our audits included performing procedures to
assess the risks of material misstatement of the financial state-
ments, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining,
on a test basis, evidence regarding the amounts and disclosures in
the financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reason-
able basis for our opinion.

-- 64 of 86 --

63
A B B O T T 2 0 2 3 A N N U A L R E P O R T
CRITICAL AUDIT MATTER
The critical audit matter communicated below is a matter arising
from the current period audit of the financial statements that was
communicated or required to be communicated to the audit com-
mittee and that: (1) relates to accounts or disclosures that are
material to the financial statements and (2) involved our especially
challenging, subjective or complex judgments. The communication
of the critical audit matter does not alter in any way our opinion on
the consolidated financial statements, taken as a whole, and we are
not, by communicating the critical audit matter below, providing a
separate opinion on the critical audit matter or on the accounts or
disclosures to which it relates.
Income taxes – Unrecognized tax benefits
Description of the Matter
As described in Note 15 to the consolidated financial statements,
unrecognized tax benefits were approximately $3.3 billion at
December 31, 2023. Unrecognized tax benefits are assessed by
management quarterly for identification and measurement, or
more frequently if there are any indicators suggesting a change
in unrecognized tax benefits. Assessing tax positions involves
judgment including interpreting tax laws of multiple jurisdictions
and assumptions relevant to the measurement of an unrecognized
tax benefit, including the estimated amount of tax liability that
may be incurred should the tax position not be sustained upon
inspection by a tax authority. These judgments and assumptions
can significantly affect unrecognized tax benefits.
How We Addressed the Matter in our Audit
We obtained an understanding, evaluated the design and tested
the operating effectiveness of controls over the Company’s identi-
fication and measurement of unrecognized tax benefits, as well
as its process for the assessment of events that may indicate a
change in unrecognized tax benefits is warranted. For example,
we tested controls over management’s review of the completeness
of identified unrecognized tax benefits, as well as controls over
management’s review of significant assumptions used within the
measurement of unrecognized tax benefits.
With the support of our tax professionals, among other audit
procedures performed, we evaluated the reasonableness of man-
agement’s judgment with respect to the interpretation of tax laws
of multiple jurisdictions by reading and evaluating management’s
documentation, including relevant accounting policies, and by
considering how tax law, including statutes, regulations, and
case law, affected management’s judgments. We tested the com-
pleteness of management’s assessment of the identification of
unrecognized tax benefits and possible outcomes related to it
including evaluation of technical merits of the unrecognized tax
benefits. We also tested the appropriateness and consistency of
management’s methods and significant assumptions associated
with the measurement of unrecognized tax benefits, including
assessing the estimated amount of tax liability that may be incurred
should the tax position not be sustained upon inspection by a tax
authority.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2013.
Chicago, Illinois
February 16, 2024

-- 65 of 86 --

64
A B B O T T 2 0 2 3 A N N U A L R E P O R T
DEFINITION AND LIMITATIONS OF INTERNAL CONTROL
OVER FINANCIAL REPORTING
A company’s internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial
reporting includes those policies and procedures that (1) pertain
to the maintenance of records that, in reasonable detail, accurately
and fairly reflect the transactions and dispositions of the assets of
the company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management
and directors of the company; and (3) provide reasonable assur-
ance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could
have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Also, projec-
tions of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or
procedures may deteriorate.
/s/ Ernst & Young LLP
Chicago, Illinois
February 16, 2024
R E P O R T O F I N D E P E N D E N T R E G I S T E R E D
P U B L I C A C C O U N T I N G F I R M
To the Shareholders and the Board of Directors of Abbott Laboratories
OPINION ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
We have audited Abbott Laboratories and subsidiaries’ internal
control over financial reporting as of December 31, 2023, based
on criteria established in Internal Control—Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission (2013 framework) (the COSO criteria). In
our opinion, Abbott Laboratories and subsidiaries (the Company)
maintained, in all material respects, effective internal control over
financial reporting as of December 31, 2023, based on the COSO
criteria.
We also have audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States)
(PCAOB), the consolidated balance sheets of the Company as of
December 31, 2023 and 2022, the related consolidated statements
of earnings, comprehensive income, shareholders’ investment
and cash flows for each of the three years in the period ended
December 31, 2023, and the related notes and our report dated
February 16, 2024 expressed an unqualified opinion thereon.
BASIS FOR OPINION
The Company’s management is responsible for maintaining
effective internal control over financial reporting and for its
assessment of the effectiveness of internal control over financial
reporting included in the accompanying Management Report on
Internal Control Over Financial Reporting. Our responsibility is to
express an opinion on the Company’s internal control over finan-
cial reporting based on our audit. We are a public accounting firm
registered with the PCAOB and are required to be independent
with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of
the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether effective
internal control over financial reporting was maintained in all
material respects.
Our audit included obtaining an understanding of internal con-
trol over financial reporting, assessing the risk that a material
weakness exists, testing and evaluating the design and operating
effectiveness of internal control based on the assessed risk, and
performing such other procedures as we considered necessary
in the circumstances. We believe that our audit provides a reason-
able basis for our opinion.

-- 66 of 86 --

65
A B B O T T 2 0 2 3 A N N U A L R E P O R T
F I N A N C I A L I N S T R U M E N T S A N D R I S K M A N A G E M E N T
MARKET PRICE SENSITIVE INVESTMENTS
The fair value of equity securities held by Abbott with a readily
determinable fair value was approximately $12 million and
$9 million as of December 31, 2023 and 2022, respectively. These
equity securities are subject to potential changes in fair value.
A hypothetical 20 percent decrease in the share prices of these
investments would decrease their fair value at December 31, 2023
by approximately $2 million. Changes in the fair value of these
securities are recorded in earnings. The fair value of investments
in mutual funds that are held in a rabbi trust for the purpose of
paying benefits under a deferred compensation plan was approxi-
mately $314 million and $298 million as of December 31, 2023 and
2022, respectively. Changes in the fair value of these investments,
as well as an offsetting change in the benefit obligation, are
recorded in earnings.
NON-PUBLICLY TRADED EQUIT Y SECURITIES
Abbott holds equity securities that are not traded on public
stock exchanges. The carrying value of these investments was
$88 million and $83 million as of December 31, 2023 and 2022,
respectively. No individual investment is recorded at a value in
excess of $20 million. Abbott measures these investments at cost
minus impairment, if any, plus or minus changes resulting from
observable price changes in orderly transactions for the identical
or a similar investment of the same issuer.
INTEREST RATE SENSITIVE FINANCIAL INSTRUMENTS
At December 31, 2023 and 2022, Abbott had interest rate hedge
contracts with notional values totaling $2.2 billion and $2.9 billion,
respectively, to manage its exposure to changes in the fair value of
debt. The effect of these hedges is to change the fixed interest rate
to a variable rate for the portion of the debt that is hedged. Abbott
does not use derivative financial instruments, such as interest
rate swaps, to manage its exposure to changes in interest rates
for its investment securities. The fair value of long-term debt at
December 31, 2023 and 2022 amounted to $14.8 billion and
$16.3 billion, respectively (average interest rates of 3.6% and 3.5%
as of December 31, 2023 and 2022, respectively) with maturities
through 2046. At December 31, 2023 and 2022, the fair value of
current and long-term investment securities amounted to approxi-
mately $1.2 billion and $1.1 billion, respectively. A hypothetical
100-basis point change in the interest rates would not have a
material effect on cash flows, income or fair values.
FOREIGN CURRENCY SENSITIVE FINANCIAL INSTRUMENTS
Certain Abbott foreign subsidiaries enter into foreign currency
forward exchange contracts to manage exposures to changes in
foreign exchange rates for anticipated intercompany purchases
by those subsidiaries whose functional currencies are not the U.S.
dollar. These contracts are designated as cash flow hedges of the
variability of the cash flows due to changes in foreign currency
exchange rates and are marked-to-market with the resulting gains
or losses reflected in Accumulated other comprehensive income
(loss). Gains or losses will be included in Cost of products sold
at the time the products are sold, generally within the next twelve
to eighteen months. At December 31, 2023 and 2022, Abbott held
$7.3 billion and $7.7 billion of notional values, respectively, of
such contracts. Contracts held at December 31, 2023 will mature
in 2024 or 2025 depending on the contract. Contracts held at
December 31, 2022 matured in 2023 or will mature in 2024
depending upon the contract.
Abbott enters into foreign currency forward exchange contracts
to manage its exposure to foreign currency denominated inter-
company loans and trade payables and third-party trade payables
and receivables. The contracts are marked-to-market, and result-
ing gains or losses are reflected in income and are generally offset
by losses or gains on the foreign currency exposure being managed.
At December 31, 2023 and 2022, Abbott held $13.8 billion and
$12.0 billion of notional values, respectively, of such contracts,
which mature within 13 months.
Abbott has designated a yen-denominated, 5-year term loan of
approximately $419 million and $446 million as of December 31,
2023 and December 31, 2022, respectively, as a hedge of the net
investment in certain foreign subsidiaries. The change in the
value of the debt, which is due to changes in foreign exchange
rates, is recorded in Accumulated other comprehensive income
(loss), net of tax.
The following table reflects the total foreign currency forward exchange contracts outstanding at December 31, 2023 and 2022:
(dollars in millions)
2023 	2022
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Contract
Amount
Weighted
Average
Exchange
Rate
Fair and
Carrying
Value
Receivable/
(Payable)
Primarily U.S. dollars to be exchanged for
the following currencies:
Euro 	$÷9,221 	1.0865 	$(35) 	$÷7,656 	1.0664 	$÷92
Chinese Yuan 	2,115 	7.0785 	3 	2,264 	6.8825 	12
Japanese Yen 	1,635 	138.2288 	24 	1,797 	133.0344 	(7)
All other currencies 	8,189 	n/a 	(54) 	8,029 	n/a 	89
Total 	$21,160 	$(62) 	$19,746 	$186

-- 67 of 86 --

F I N A N C I A L R E V I E W
66
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Abbott’s revenues are derived primarily from the sale of a broad
line of health care products, which include medical devices,
diagnostic testing products, nutritional products and branded
generic pharmaceuticals. These products are sold under short-
term receivable arrangements. Patent protection and licenses,
technological and performance features, and inclusion of Abbott’s
products under a contract most impact which products are sold;
price controls, competition and rebates most impact the net selling
prices of products; and the measurement of net sales and costs is
impacted by foreign currency translation. Sales in international
markets comprise 61 percent of consolidated net sales.
Over the period from 2020 through 2023, the coronavirus
(COVID-19) pandemic affected Abbott’s diversified health care
businesses in various ways. Abbott’s Diagnostics segment experi-
enced the most significant change in sales from 2020 to 2023
as a result of the COVID-19 pandemic. (The Diagnostics segment
includes the Rapid Diagnostics, Core Laboratory Diagnostics,
Molecular Diagnostics and Point of Care Diagnostics businesses.)
After mobilizing its teams across multiple fronts in 2020 and 2021,
Abbott developed and launched multiple types of new diagnostic
tests to detect COVID-19. Tests were launched in the U.S. pursuant
to Emergency Use Authorizations (EUA) and in countries outside
of the U.S. pursuant to CE Marks.
During the pandemic, COVID-19 testing-related sales grew to
17.8 percent and 19.2 percent of Abbott’s sales in 2021 and 2022,
respectively. Abbott’s COVID-19 testing-related sales totaled
approximately $7.7 billion in 2021 and $8.4 billion in 2022, led by
sales related to Abbott’s BinaxNOW, Panbio and ID NOW rapid
testing platforms. Demand for COVID-19 tests was volatile during
the pandemic as the number of COVID-19 cases, especially in the
U.S., fluctuated during this period.
In 2023, the pandemic shifted to an endemic state and the U.S.
federal public health emergency expired, resulting in significantly
lower demand for COVID-19 tests. In 2023, Abbott’s COVID-19
testing-related sales totaled approximately $1.6 billion, of which
$730 million occurred in the first quarter of 2023. Demand for
COVID-19 tests is expected to continue to be unpredictable in
2024.
With respect to other products sold by the Diagnostics segment,
demand for routine diagnostic testing generally fluctuated
throughout the pandemic with changes in the number of
COVID-19 cases in various geographic regions. Across Abbott’s
cardiovascular and neuromodulation businesses, procedure
volumes were negatively impacted during the pandemic by
surges of COVID-19 in various geographies as well as intermittent
COVID-19 lockdown restrictions and healthcare staffing chal-
lenges. Despite such challenges, overall volume trends improved
in several cardiovascular businesses and in routine diagnostic
testing in 2022 and that growth continued in 2023. While Abbott’s
branded generic pharmaceuticals business was also negatively
affected by the pandemic in 2020 as COVID-19 spread across
emerging market countries, volumes recovered and grew over
the 2021 to 2023 period. Abbott’s nutritional and diabetes care
businesses were the least affected by the pandemic.
While Abbott’s total sales over the last three years were most
significantly affected by the impacts of the COVID-19 pandemic,
sales over this period also reflect the introduction of new products
across various businesses, as well as higher sales of various
existing products. Sales in emerging markets, which represent
approximately 38 percent of total company sales, increased
5.4 percent in 2023 and 5.6 percent in 2022, excluding the impact
of foreign exchange. (Emerging markets include all countries,
except the United States, Japan, Canada, Australia, New Zealand
and Western European countries.)
In U.S. Pediatric Nutritionals, Abbott initiated a voluntary recall
in February 2022 of certain infant powder formula products
manufactured at its facility in Sturgis, Michigan and stopped
production at the facility. On May 16, 2022, Abbott entered into a
consent decree with the U.S. Food and Drug Administration (FDA)
on the steps necessary to resume production and maintain the
Sturgis facility and operations. On July 1, 2022, Abbott restarted
partial production at the facility beginning with its specialty for-
mula EleCare® and metabolic formulas. Subsequently, Abbott
restarted Similac® production. The consent decree does not affect
any other Abbott plants or operations.
In 2022, Abbott took various actions to mitigate the impact of
the recall on the supply of formula in the U.S. The 2022 actions
included the shipment of infant formula powder into the U.S. from
Abbott’s FDA-registered facility in Ireland; prioritization of infant
formula production at its Columbus, Ohio facility; conversion of
other liquid manufacturing lines into manufacturing Similac
liquid ready-to-feed product; increased production of powder
infant formula at its Casa Grande, Arizona manufacturing site;
and importation of product from its facility in Spain as permitted
by the FDA.
In 2023, as Abbott’s production of infant formula increased in
the U.S., Abbott made progress toward recovering market share
in this business. In the fourth quarter of 2023, Abbott returned to
having the market-leading position in the U.S., as measured on
a volume basis.
Over the last three years, Abbott’s operating margin as a percent-
age of sales decreased from 19.6 percent in 2021 to 19.2 percent in
2022 and 16.2 percent in 2023. The decrease in 2023 from 2021
reflects the unfavorable effects of lower COVID-19 testing-related
sales, foreign exchange, and higher costs for various manufactur-
ing inputs. The decrease in 2022 from 2021 reflects the impact of
the voluntary infant product recall and manufacturing stoppage in
U.S. Pediatric Nutritionals and the impact of inflation and supply
chain challenges on various manufacturing inputs and transporta-
tion costs across Abbott’s businesses. In both 2023 and 2022, these
unfavorable effects were partially offset by the favorable impact
of margin improvement initiatives.
While Abbott experienced availability issues with some services
and materials used in its products over the last three years, Abbott
was able to manage the various supply chain challenges without
significant supply disruption or shortage for services, raw materials
and supplies. While Abbott experienced inflationary pressures
on various raw materials, packaging materials and transportation
costs over the last three years, the impact of such cost increases
was partially mitigated by price increases in certain businesses
and the impact of continued gross margin improvement initiatives.

-- 68 of 86 --

F I N A N C I A L R E V I E W
67
A B B O T T 2 0 2 3 A N N U A L R E P O R T
With respect to the performance of each reportable segment
over the last three years, sales in the Medical Devices segment,
excluding the impact of foreign exchange, increased 15.1 percent
in 2023 and 8.1 percent in 2022. The sales increases in 2023 and
2022 were driven by growth in Diabetes Care, Electrophysiology,
Heart Failure, and Structural Heart. The 2023 increase was also
driven by growth in Neuromodulation sales.
In 2023, operating earnings for the Medical Devices segment
increased 19.6 percent. The operating margin profile for the
Medical Devices segment decreased from 31.3 percent in 2021
to 30.0 percent in 2022 and then increased to 31.4 percent in
2023. The decrease in 2022 from 2021 reflects various factors,
including the impacts of inflationary pressures and supply chain
challenges related to various manufacturing inputs and processes.
The increase in 2023 from 2022 reflects the impact of higher
sales volumes across the Medical Devices businesses.
In 2023, key product approvals in the Medical Devices
segment included:
• FDA clearance for Navitor, Abbott’s second-generation
transcatheter aortic valve implantation system to treat people
with severe aortic stenosis who are at high or extreme risk
for open-heart surgery,
• FDA clearance of Abbott’s Freestyle Libre continuous glucose
monitoring system for integration with automated insulin
delivery systems,
• FDA approval of Abbott’s Epic® Max stented tissue valve to
treat people with aortic regurgitation or stenosis,
• FDA approval of Abbott’s TactiFlex® Ablation Catheter, Sensor
Enabled™, the world’s first ablation catheter with a flexible
electrode tip and contact force sensing technology to treat
patients with atrial fibrillation,
• FDA approval of Abbott’s AVEIR™ dual-chamber leadless
pacemaker system, the world’s first dual chamber leadless
pacing system that treats people with abnormal or slow heart
rhythms, and
• CE Mark for Abbott’s AVEIR single-chamber leadless
pacemaker.
In Abbott’s Diagnostics segment, sales decreased 38.2 percent in
2023 and increased 10.4 percent in 2022, excluding the impact of
foreign exchange. As was discussed above, the 2023 sales decrease
was driven by lower demand for Abbott’s COVID-19 tests, partially
offset by higher routine diagnostics testing in the core laboratory
business. The 2022 sales growth was driven by demand for
Abbott’s portfolio of rapid diagnostics tests for COVID-19 and
higher routine diagnostics testing in the core laboratory business,
partially offset by lower demand for Abbott’s laboratory-based
tests for COVID-19 in the molecular diagnostics business.
In 2023, operating earnings for the Diagnostics segment decreased
63.4 percent. The operating margin profile decreased from
40.2 percent in 2021 to 24.4 percent in 2023 primarily due to lower
demand for Abbott’s COVID-19 tests.
Abbott has regulatory approvals in the U.S., Europe, China, and
other markets for the “Alinity c” and “Alinity i” instruments and
has continued to build out its test menu for clinical chemistry
and immunoassay diagnostics. Abbott has obtained regulatory
approval for the “Alinity h” system for hematology in the U.S.,
Europe, Japan and other regions. Abbott has also obtained
regulatory approvals in the U.S., Europe and other markets for
the “Alinity s” (blood screening) and “Alinity m” (molecular)
instruments and several testing assays. In the fourth quarter of
2023, Abbott received FDA approval of its new laboratory automa-
tion system, GLP systems Track™, to help laboratories optimize
the performance and safety of diagnostics testing.
In Abbott’s Nutritional Products segment, total pediatric nutrition
sales, excluding the impact of foreign exchange, increased
14.8 percent in 2023, which includes market share recovery in
the U.S. infant formula business following the voluntary recall of
certain products in the prior year. In 2022, pediatric nutrition
sales decreased 16.6 percent as a result of the voluntary recall and
manufacturing stoppage discussed above, as well as challenging
market dynamics in China. In December 2022, Abbott initiated
steps to exit its pediatric nutrition business in China. Excluding
the impact of foreign exchange, total adult nutrition sales
increased 8.8 percent in 2023 and 4.8 percent in 2022, led by the
continued growth of Abbott’s Ensure® and Glucerna® products
across several countries.
In 2023, operating earnings for the Nutritional Products segment
increased 88.9 percent compared to 2022. Operating margins for
this segment decreased from 21.3 percent in 2021 to 9.5 percent in
2022 and then increased to 16.4 percent in 2023. The decrease in
2022 was driven by the impact of the voluntary infant product
recall and manufacturing stoppage as well as higher manufactur-
ing and distribution costs, including commodity prices, partially
offset by the impact of gross margin improvement initiatives. The
increase in 2023 reflects the favorable effects of higher sales and a
continued focus on gross margin improvement initiatives, partially
offset by higher commodity and other costs.
The Established Pharmaceutical Products segment focuses on
the sale of its products in emerging markets. Excluding the impact
of foreign exchange, Established Pharmaceutical sales increased
10.9 percent in 2023 and 10.6 percent in 2022. The sales increases
in 2023 and 2022 reflect higher sales in several geographies
including India, Vietnam, and Brazil. In 2023, operating earnings
for the Established Pharmaceutical Products segment increased
15.0 percent. Operating margins increased from 18.8 percent in
2021 to 23.8 percent in 2023 primarily due to the impact of gross
margin improvement initiatives and higher sales, partially offset
by inflation on various product inputs.
With respect to Abbott’s financial position, at December 31, 2023
and 2022, Abbott’s cash and cash equivalents and short-term
investments total approximately $7.3 billion and $10.2 billion,
respectively. Abbott’s long-term debt totals $14.7 billion and
$16.8 billion at December 31, 2023 and 2022, respectively.

-- 69 of 86 --

F I N A N C I A L R E V I E W
68
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Abbott declared dividends of $2.08 per share in 2023 and $1.92 per
share in 2022, an increase of 8.3 percent. Dividends paid totaled
$3.556 billion compared to $3.309 billion in 2022. The year-over-
year change in the amount of dividends paid reflects the increase in
the dividend rate. In December 2023, Abbott increased the compa-
ny’s quarterly dividend by 7.8 percent to $0.55 per share from
$0.51 per share, effective with the dividend paid in February 2024.
In December 2022, Abbott increased the company’s quarterly
dividend by 8.5 percent to $0.51 per share from $0.47 per share,
effective with the dividend paid in February 2023.
On September 22, 2023, Abbott completed the acquisition of
Bigfoot Biomedical, Inc. (Bigfoot), which will further Abbott’s
efforts to develop connected solutions for making diabetes man-
agement more personal and precise. On April 27, 2023, Abbott
completed the acquisition of Cardiovascular Systems, Inc. (CSI).
CSI’s atherectomy system, which is used in treating peripheral
and coronary artery disease, adds complementary technologies
to Abbott’s portfolio of vascular device offerings.
In 2024, Abbott will focus on continuing to invest in product
development areas that provide the opportunity for strong sus-
tainable growth over the next several years. In its diagnostics
business, Abbott’s focus will include driving sales growth from
its Alinity suite of diagnostics instruments and its portfolio of
rapid diagnostic testing systems. In the medical devices business,
Abbott will focus on growing recently launched new products and
expanding its market position across the various businesses. In
its nutritional business, Abbott will continue to focus on driving
growth globally and further enhancing its portfolio with the
introduction of science-based products and line extensions. In
the established pharmaceuticals business, Abbott will continue
to focus on growing its business with the depth and breadth of
its portfolio in emerging markets.
CRITICAL ACCOUNTING POLICIES
Sales Rebates — In 2023, 49 percent of Abbott’s consolidated gross
revenues were subject to various forms of rebates and allowances
that Abbott recorded as reductions of revenues at the time of sale.
Most of these rebates and allowances in 2023 are in the Nutritional
Products and Diabetes Care businesses. Abbott provides rebates to
state agencies that administer the Special Supplemental Nutrition
Program for Women, Infants, and Children (WIC), wholesalers,
group purchasing organizations, and other government agencies
and private entities. Rebate amounts are usually based upon the
volume of purchases using contractual or statutory prices for a
product. Factors used in the rebate calculations include the identi-
fication of which products have been sold subject to a rebate,
which customer or government agency price terms apply, and the
estimated lag time between sale and payment of a rebate. Using
historical trends, adjusted for current changes, Abbott estimates
the amount of the rebate that will be paid, and records the liability
as a reduction of gross sales when Abbott records its sale of the
product. Settlement of the rebate generally occurs from one to six
months after sale. Abbott regularly analyzes the historical rebate
trends and makes adjustments to reserves for changes in trends and
terms of rebate programs. Rebates and chargebacks charged against
gross sales in 2023, 2022, and 2021 amounted to approximately
$3.9 billion per year, or 17.4 percent, 17.6 percent, and 17.5 percent
of gross sales, respectively, based on gross sales of approximately
$22.7 billion, $22.4 billion, and $22.3 billion, respectively, subject
to rebate. A one-percentage point increase in the percentage of
rebates to related gross sales would decrease net sales by approxi-
mately $227 million in 2023. Abbott considers a one-percentage
point increase to be a reasonably likely increase in the percentage
of rebates to related gross sales. Other allowances charged against
gross sales were approximately $263 million, $280 million, and
$268 million for cash discounts in 2023, 2022, and 2021, respec-
tively, and $169 million, $379 million, and $211 million for returns
in 2023, 2022, and 2021, respectively. Cash discounts are known
within 15 to 30 days of sale, and therefore can be reliably estimated.
Returns can be reliably estimated because Abbott’s historical
returns are low, and because sales returns terms and other sales
terms have remained relatively unchanged for several periods.
Management analyzes the adequacy of ending rebate accrual
balances each quarter. In the domestic nutritional business,
management uses both internal and external data available to
estimate the accruals. In the WIC business, estimates are required
for the amount of WIC sales within each state where Abbott holds
the WIC contract. The state where the sale is made, which is the
determining factor for the applicable rebated price, is reliably
determinable. Rebated prices are based on contractually obligated
agreements generally lasting a period of two to four years. Except
for a change in contract price or a transition period before or after
a change in the supplier for the WIC business in a state, accruals
are based on historical redemption rates and data from the U.S.
Department of Agriculture (USDA) and the states submitting
rebate claims. The USDA, which administers the WIC program,
has been making its data available for many years. Management
also estimates the states’ processing lag time based on sales and
claims data. Management has access to several large customers’
inventory management data, which allows management to make
reliable estimates of inventory in the retail distribution channel.
At December 31, 2023, Abbott had WIC business in 40 states.
Historically, adjustments to prior years’ rebate accruals have
not been material to net earnings. Abbott employs various tech-
niques to verify the accuracy of claims submitted to it, and where
possible, works with the organizations submitting claims to gain
insight into changes that might affect the rebate amounts. For
government agency programs, the calculation of a rebate involves
interpretations of relevant regulations, which are subject to
challenge or change in interpretation.

-- 70 of 86 --

F I N A N C I A L R E V I E W
69
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Income Taxes — Abbott operates in numerous countries where
its income tax returns are subject to audits and adjustments.
Because Abbott operates globally, the nature of the audit items is
often very complex, and the objectives of the government auditors
can result in a tax on the same income in more than one country.
Abbott employs internal and external tax professionals to mini-
mize audit adjustment amounts where possible. In accordance
with the accounting rules relating to the measurement of tax
contingencies, in order to recognize an uncertain tax benefit, the
taxpayer must be more likely than not of sustaining the position,
and the measurement of the benefit is calculated as the largest
amount that is more than 50 percent likely to be realized upon
resolution of the benefit. Application of these rules requires a
significant amount of judgment. In the U.S., Abbott’s federal income
tax returns through 2016 were settled as of December 31, 2023.
Undistributed foreign earnings remain indefinitely reinvested in
foreign operations. Determining the amount of unrecognized
deferred tax liability related to any remaining undistributed
foreign earnings not subject to the transition tax and additional
outside basis difference in its foreign entities is not practicable.
Pension and Post-Employment Benefits — Abbott offers pension
benefits and post-employment health care to many of its employ-
ees. Abbott engages outside actuaries to assist in the determination
of the obligations and costs under these programs. Abbott must
develop long-term assumptions, the most significant of which are
the health care cost trend rates, discount rates and the expected
return on plan assets. The discount rates used to measure liabili-
ties were determined based on high-quality fixed income
securities that match the duration of the expected retiree benefits.
The health care cost trend rates represent Abbott’s expected
annual rates of change in the cost of health care benefits and are
a forward projection of health care costs as of the measurement
date. A difference between the assumed rates and the actual rates,
which will not be known for years, can be significant in relation to
the obligations and the annual cost recorded for these programs.
The net actuarial gains for these plans in 2023 reflect the impact
of actual asset returns during the year in excess of expected
returns, partially offset by the impact of lower discount rates on
the measurement of plan liabilities. At December 31, 2023, pretax
net actuarial losses and prior service costs and (credits)
recognized in Accumulated other comprehensive income (loss)
were net losses of $1.8 billion for Abbott’s defined benefit plans
and net losses of $40 million for Abbott’s medical and dental
plans. Actuarial losses and gains are amortized over the remaining
service attribution periods of the employees under the corridor
method, in accordance with the rules for accounting for post-
employment benefits. Differences between the expected long-term
return on plan assets and the actual annual return are amortized
over a five-year period.
Valuation of Intangible Assets — Abbott has acquired and contin-
ues to acquire significant intangible assets that Abbott records
at fair value at the acquisition date. Transactions involving the
purchase or sale of intangible assets occur with some frequency
between companies in the health care field and valuations are
usually based on a discounted cash flow analysis. The discounted
cash flow model requires assumptions about the timing and
amount of future net cash flows, risk, cost of capital, terminal
values and market participants. Each of these factors can signifi-
cantly affect the value of the intangible asset. Abbott engages
independent valuation experts who review Abbott’s critical
assumptions and calculations for acquisitions of significant
intangibles. Abbott reviews definite-lived intangible assets for
impairment each quarter. An undiscounted net cash flows
approach is used to test for impairment. If the undiscounted cash
flows of an intangible asset are less than the carrying value of an
intangible asset, the intangible asset is written down to its fair
value, which is usually the discounted cash flow amount. Where
cash flows cannot be identified for an individual asset, the review
is applied at the lowest group level for which cash flows are identi-
fiable. Goodwill and indefinite-lived intangible assets, which relate
to in-process research and development acquired in a business
combination, are reviewed for impairment annually or when an
event that could result in an impairment occurs. At December 31,
2023, goodwill amounted to $23.7 billion and net intangibles
amounted to $8.8 billion. Amortization expense for intangible
assets amounted to $2.0 billion per year in 2023, 2022 and 2021.
There was no reduction of goodwill relating to impairments in
2023, 2022, and 2021.
Litigation — Abbott accounts for litigation losses in accordance
with Financial Accounting Standards Board (FASB) Accounting
Standards Codification (ASC) No. 450, “Contingencies.” Under
ASC No. 450, loss contingency provisions are recorded for proba-
ble losses at management’s best estimate of a loss, or when a best
estimate cannot be made, a minimum loss contingency amount is
recorded. These estimates are often initially developed substan-
tially earlier than the ultimate loss is known, and the estimates are
refined each accounting period as additional information becomes
known. Accordingly, Abbott is often initially unable to develop a
best estimate of loss, and therefore the minimum amount, which
could be zero, is recorded. As information becomes known, either
the minimum loss amount is increased, resulting in additional
loss provisions, or a best estimate can be made, also resulting in
additional loss provisions. Occasionally, a best estimate amount is
changed to a lower amount when events result in an expectation
of a more favorable outcome than previously expected. Abbott
estimates the range of possible loss to be from approximately
$30 million to $45 million for its legal proceedings and environ-
mental exposures. Accruals of approximately $40 million have
been recorded at December 31, 2023 for these proceedings and
exposures. These accruals represent management’s best estimate
of probable loss, as defined by FASB ASC No. 450, “Contingencies.”

-- 71 of 86 --

F I N A N C I A L R E V I E W
70
A B B O T T 2 0 2 3 A N N U A L R E P O R T
RESULTS OF OPERATIONS
SALES
The following table details the components of sales growth by
reportable segment for the last two years:
Total %
Change
Components of % Change
Price 	Volume 	Exchange
Total Net Sales
2023 vs. 2022 	(8.1) 	2.6 	(8.7) 	(2.0)
2022 vs. 2021 	1.3 	(0.3) 	6.7 	(5.1)
Total U.S.
2023 vs. 2022 	(14.8) 	1.1 	(15.9) 	—
2022 vs. 2021 	9.0 	(0.6) 	9.6 	—
Total International
2023 vs. 2022 	(3.3) 	3.7 	(3.5) 	(3.5)
2022 vs. 2021 	(3.5) 	— 	4.7 	(8.2)
Established Pharmaceutical Products Segment
2023 vs. 2022 	3.1 	6.0 	4.9 	(7.8)
2022 vs. 2021 	4.1 	3.7 	6.9 	(6.5)
Nutritional Products Segment
2023 vs. 2022 	9.3 	11.4 	0.2 	(2.3)
2022 vs. 2021 	(10.1) 	7.4 	(13.6) 	(3.9)
Diagnostic Products Segment
2023 vs. 2022 	(39.4) 	(0.9) 	(37.3) 	(1.2)
2022 vs. 2021 	6.0 	(5.5) 	15.9 	(4.4)
Medical Devices Segment
2023 vs. 2022 	14.1 	1.0 	14.1 	(1.0)
2022 vs. 2021 	2.2 	(0.2) 	8.3 	(5.9)
The decrease in total net sales in 2023 reflects the decline in
demand for Abbott’s rapid diagnostic tests to detect COVID-19,
partially offset by higher sales in the Medical Devices, Established
Pharmaceutical Products and Nutritional Products segments.
Abbott’s COVID-19 testing-related sales totaled approximately
$1.6 billion in 2023, $8.4 billion in 2022 and $7.7 billion in 2021.
Excluding the impact of COVID-19 testing-related sales, Abbott’s
total net sales increased 9.2 percent in 2023. Excluding the impacts
of COVID-19 testing-related sales and foreign exchange, Abbott’s
total net sales increased 11.7 percent. Abbott’s net sales in 2023
were unfavorably impacted by changes in foreign exchange rates
as the relatively stronger U.S. dollar decreased total international
sales by 3.5 percent and total sales by 2.0 percent.
The increase in total net sales in 2022 reflects growth in demand for
Abbott’s rapid diagnostic tests to detect COVID-19 as well as growth
in the Established Pharmaceutical Products and Medical Devices
segments, partially offset by lower Nutritional Products sales.
Excluding the impact of COVID-19 testing-related sales, Abbott’s
total net sales decreased 0.3 percent in 2022. Excluding the
impacts of COVID-19 testing-related sales and foreign exchange,
Abbott’s 2022 total net sales increased 5.1 percent. Abbott’s net
sales in 2022 were unfavorably impacted by changes in foreign
exchange rates as the relatively stronger U.S. dollar decreased total
international sales by 8.2 percent and total sales by 5.1 percent.
The price declines related to the Diagnostic Products segment in
2023 and 2022 primarily reflect lower pricing for COVID-19 tests.
The table below provides detail by sales category for the years
ended December 31. Percent changes are versus the prior year and
are based on unrounded numbers.
(dollars in millions) 	2023 	2022
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals —
Key Emerging
Markets 	$3,807 	$3,766 	1.1% 	(9.2)«% 	10.3%
Other 	1,259 	1,146 	9.8÷« 	(3.0)÷÷ 	12.8÷«
Nutritionals —
International
Pediatric
Nutritionals 	1,957 	1,919 	2.0÷« 	(3.2)÷÷ 	5.2÷«
U.S. Pediatric
Nutritionals 	1,977 	1,562 	26.6÷« 	—÷÷ 	26.6÷«
International Adult
Nutritionals 	2,784 	2,621 	6.2÷« 	(4.2)÷÷ 	10.4÷«
U.S. Adult
Nutritionals 	1,436 	1,357 	5.8÷« 	—÷÷ 	5.8÷«
Diagnostics —
Core Laboratory 	5,159 	4,888 	5.5÷« 	(2.9)÷÷ 	8.4÷«
Molecular 	574 	995 	(42.3)÷« 	(0.7)÷÷ 	(41.6)÷«
Point of Care 	565 	525 	7.5÷« 	(0.2)÷÷ 	7.7÷«
Rapid Diagnostics 	3,690 	10,061 	(63.3)÷« 	(0.4)÷÷ 	(62.9)÷«
Medical Devices —
Rhythm
Management 	2,255 	2,119 	6.5÷« 	(1.0)÷÷ 	7.5÷«
Electrophysiology 	2,195 	1,927 	13.9÷« 	(2.0)÷÷ 	15.9÷«
Heart Failure 	1,161 	1,035 	12.1÷« 	0.1÷÷ 	12.0÷«
Vascular 	2,681 	2,483 	8.0÷« 	(1.3)÷÷ 	9.3÷«
Structural Heart 	1,944 	1,712 	13.6÷« 	(0.7)÷÷ 	14.3÷«
Neuromodulation 	890 	770 	15.5÷« 	(0.9)÷÷ 	16.4÷«
Diabetes Care 	5,761 	4,756 	21.1÷« 	(0.8)÷÷ 	21.9÷«

-- 72 of 86 --

F I N A N C I A L R E V I E W
71
A B B O T T 2 0 2 3 A N N U A L R E P O R T
(dollars in millions) 	2022 	2021
Total
Change
Impact of
Exchange
Total
Change
Excl.
Exchange
Total Established
Pharmaceuticals —
Key Emerging
Markets 	$÷3,766 	$3,565 	5.6% 	(6.5)«% 	12.1%
Other 	1,146 	1,153 	(0.6)÷« 	(6.7)÷÷ 	6.1÷«
Nutritionals —
International
Pediatric
Nutritionals 	1,919 	2,106 	(8.9)÷« 	(5.0)÷÷ 	(3.9)÷«
U.S. Pediatric
Nutritionals 	1,562 	2,192 	(28.7)÷« 	—÷÷ 	(28.7)÷«
International Adult
Nutritionals 	2,621 	2,632 	(0.4) ÷« 	(8.0)÷÷ 	7.6÷«
U.S. Adult
Nutritionals 	1,357 	1,364 	(0.5)÷« 	—÷÷ 	(0.5)÷«
Diagnostics —
Core Laboratory 	4,888 	5,128 	(4.7)÷« 	(6.6)÷÷ 	1.9÷«
Molecular 	995 	1,427 	(30.3)÷« 	(2.9)÷÷ 	(27.4)÷«
Point of Care 	525 	536 	(2.1)÷« 	(1.5)÷÷ 	(0.6)÷«
Rapid Diagnostics 	10,061 	8,435 	19.3÷« 	(3.5)÷÷ 	22.8÷«
Medical Devices —
Rhythm
Management 	2,119 	2,198 	(3.6)÷« 	(5.1)÷÷ 	1.5÷«
Electrophysiology 	1,927 	1,907 	1.1÷« 	(6.2)÷÷ 	7.3÷«
Heart Failure 	1,035 	1,007 	2.8÷« 	(2.1)÷÷ 	4.9÷«
Vascular 	2,483 	2,654 	(6.4)÷« 	(5.4)÷÷ 	(1.0)÷«
Structural Heart 	1,712 	1,610 	6.3÷« 	(6.7)÷÷ 	13.0÷«
Neuromodulation 	770 	781 	(1.4)÷« 	(2.3)÷÷ 	0.9÷«
Diabetes Care 	4,756 	4,328 	9.9÷« 	(7.5)÷÷ 	17.4÷«
Notes:
The Acelis Connected Health business was internally transferred from Diagnostic Products to
Medical Devices on January 1, 2023. As a result, $115 million of sales in 2022 and $118 million
of sales in 2021 were moved from Diagnostic Products to Medical Devices.
In order to compute results excluding the impact of exchange rates, current year U.S. dollar
sales are multiplied or divided, as appropriate, by the current year average foreign exchange
rates and then those amounts are multiplied or divided, as appropriate, by the prior year
average foreign exchange rates.
Total Established Pharmaceutical Products sales increased
10.9 percent in 2023 and 10.6 percent in 2022, excluding the
unfavorable impact of foreign exchange. Excluding the effect of
foreign exchange, sales in Key Emerging Markets for Established
Pharmaceutical Products increased 10.3 percent in 2023 and
12.1 percent in 2022, led by growth in several countries and across
several therapeutic areas, including cardiometabolic, central
nervous system/pain management and respiratory. Other
Emerging Markets, excluding the effect of foreign exchange,
increased by 12.8 percent in 2023 and 6.1 percent in 2022.
Excluding the impact of foreign exchange, total Nutritional
Products sales increased 11.6 percent in 2023 compared to a
6.2 percent decrease in 2022. In U.S. Pediatric Nutritional sales,
the 26.6 percent increase in 2023 reflects progress in recovering
market share in 2023 following the voluntary recall of certain
infant formula products in the first quarter of 2022, as well as
the unfavorable 2022 impact of the recall, partially offset by a
decrease in 2023 Pedialyte® sales. In 2022, U.S. Pediatric
Nutritional sales decreased 28.7 percent as a result of the volun-
tary recall and production stoppage of certain infant powder
formula products, partially offset by increased demand for
Abbott’s Pedialyte products.
Excluding the effect of foreign exchange, the 5.2 percent increase
in International Pediatric Nutritional sales in 2023 reflects higher
sales in Latin America and Canada, partially offset by the impact
of exiting the pediatric nutrition business in China. In 2022, the
3.9 percent decrease in International Pediatric Nutritional sales,
excluding the effect of foreign exchange, reflects the impact of
the challenging market dynamics in the infant category in China,
partially offset by higher sales volumes in several countries in
Southeast Asia and Latin America.
In 2023 and 2022, U.S. Adult Nutritional sales increased
5.8 percent and decreased 0.5 percent, respectively. The growth
in 2023 was led by higher Ensure® and Glucerna® product sales.
In 2022, the growth of the Ensure brand was offset by lower sales
of other products and the impact of temporarily utilizing liquid
manufacturing capacity to manufacture infant formula. In 2023
and 2022, International Adult Nutritionals sales, excluding the
effect of foreign exchange, increased 10.4 percent and 7.6 percent,
respectively, led by growth of Ensure® and Glucerna® products
in various countries.
Excluding the effect of foreign exchange, Diagnostics segment
sales decreased 38.2 percent in 2023 and increased 10.4 percent
in 2022, driven by changes in demand for COVID-19 tests. Rapid
Diagnostics sales decreased 62.9 percent in 2023 and increased
22.8 percent in 2022, excluding the effect of foreign exchange. The
decrease in 2023 reflects lower demand for COVID-19 tests across
Abbott’s rapid testing platforms. Rapid Diagnostics COVID-19
testing-related sales were $1.5 billion in 2023, $7.9 billion in 2022
and $6.6 billion in 2021.
In 2023, Rapid Diagnostics sales were virtually unchanged,
excluding COVID-19 testing-related sales. Rapid Diagnostics sales
increased 1.3 percent, excluding the impact of foreign exchange
and COVID-19 testing-related sales. Growth in various Rapid
Diagnostics products was partially offset by the unfavorable effects
of an early 2022 flu season and a later start of the 2023 flu season.
In 2022, Rapid Diagnostics sales increased 17.0 percent, excluding
COVID-19 testing-related sales, and 20.5 percent, excluding the
impact of foreign exchange and COVID-19 testing-related sales.
These increases reflect higher sales of ID NOW tests for flu,
strep, and respiratory syncytial virus (RSV), as well as growth
in various other Rapid Diagnostics products.

-- 73 of 86 --

F I N A N C I A L R E V I E W
72
A B B O T T 2 0 2 3 A N N U A L R E P O R T
In Core Laboratory Diagnostics, sales increased 8.4 percent in
2023 and 1.9 percent in 2022, excluding the effect of foreign
exchange. The increases in 2023 and 2022 were due to higher
year-over-year volume of routine diagnostic testing performed
in hospitals and other laboratories, partially offset by lower test
sales for the detection of COVID-19 IgG and IgM antibodies.
Core Laboratory Diagnostics COVID-19 testing-related sales on
Abbott’s ARCHITECT and Alinity i platforms were $20 million in
2023, $62 million in 2022, and $204 million in 2021. Excluding
COVID-19 testing-related sales, Core Laboratory Diagnostics sales
increased 6.5 percent in 2023 and decreased 2.0 percent in 2022.
Excluding the impact of foreign exchange and COVID-19 testing-
related sales, Core Laboratory Diagnostics sales increased
9.4 percent in 2023 and 4.8 percent in 2022.
In Molecular Diagnostics, sales decreased 41.6 percent in 2023
and 27.4 percent in 2022, excluding the effect of foreign exchange.
In both years the decreases were driven by lower demand for
laboratory-based molecular tests for COVID-19. Molecular
Diagnostics COVID-19 testing-related sales were $43 million in
2023, $411 million in 2022 and $891 million in 2021. In 2023,
Molecular Diagnostics sales decreased 9.2 percent, excluding
COVID-19 testing-related sales, and decreased 8.1 percent, exclud-
ing the impact of foreign exchange and COVID-19 testing-related
sales. 2023 sales were impacted by lower demand for respiratory
testing compared to significantly higher-than-usual demand in
2022. In 2022, Molecular Diagnostics sales increased 9.0 percent,
excluding COVID-19 testing-related sales, and 13.8 percent,
excluding the impact of foreign exchange and COVID-19 testing-
related sales.
Excluding the effect of foreign exchange, total Medical Devices
sales grew 15.1 percent in 2023 and 8.0 percent in 2022, led by
double-digit growth in 2023 in Diabetes Care, Structural Heart,
Heart Failure, Neuromodulation and Electrophysiology. Higher
Diabetes Care sales were driven by continued growth of FreeStyle
Libre®, Abbott’s continuous glucose monitoring system, in the
U.S. and internationally. FreeStyle Libre sales totaled $5.3 billion
in 2023, which reflected a 25.5 percent increase, excluding the
effect of foreign exchange, over 2022 when FreeStyle Libre sales
totaled $4.3 billion.
In 2022, while procedure volumes across Abbott’s cardiovascular
and neuromodulation businesses were negatively impacted by
surges of COVID-19 in various geographies, as well as intermittent
COVID-19 lockdown restrictions in China and healthcare staffing
challenges throughout the year, overall volumes improved from
2021 levels.
In 2023, the 15.9 percent increase in Electrophysiology sales,
excluding the effect of foreign exchange, primarily reflects higher
procedure volumes in the U.S., China, and various European
countries. In 2022, Electrophysiology sales increased 7.3 percent,
excluding the effect of foreign exchange, due to an increase in
procedure volumes and the continued roll-out of Abbott’s EnSite
X® EP System with EnSite Omnipolar Technology (OT), a new
cardiac mapping platform available in the U.S., Japan and
across Europe.
In Neuromodulation, the 16.4 percent increase in 2023 sales,
excluding the effect of foreign exchange, was driven by the recent
launch of the Eterna® rechargeable spinal cord stimulation system
for the treatment of chronic pain along with market growth
compared to the prior year.
In Structural Heart, excluding the effect of foreign exchange, the
14.3 percent and 13.0 percent sales increases in 2023 and 2022,
respectively, reflect continued growth of the MitraClip® product
as well as various other products, including Amplatzer® Amulet®
Left Atrial Appendage Occluder, Navitor®, and TriClip®.
In Vascular, the 9.3 percent increase in 2023 sales, excluding the
impact of foreign exchange, reflects the acquisition of CSI on April
27, 2023, as well as double-digit growth in endovascular sales. In
2022, Vascular sales decreased 1.0 percent, excluding the impact of
foreign exchange, as higher endovascular sales were offset by the
negative effect of lower average selling prices globally on tradi-
tional drug eluting stents (DES) and other coronary products and
a lower recovery of percutaneous coronary intervention (PCI)
procedures which impacted the coronary business.
Abbott’s operations in Russia and Ukraine represent approxi-
mately 2 percent of Abbott’s total revenues and net assets, and to
date the financial impact of Russia’s invasion of Ukraine has not
been material to Abbott’s operations or financial condition. Future
implications are difficult to predict, but at present Abbott does not
anticipate that the Russia-Ukraine conflict will have a material
impact on its operations or financial condition. A more detailed
discussion of the risks associated with the Russia-Ukraine conflict
is contained in Item 1A. Risk Factors.
The expiration of licenses and patent protection can affect the
future revenues and operating income of Abbott. There are no
significant patent or license expirations in the next three years
that are expected to materially affect Abbott.
OPERATING EARNINGS
Gross profit margins were 50.3 percent of net sales in 2023,
51.5 percent of net sales in 2022, and 52.2 percent of net sales
in 2021. The decrease in 2023 reflects the unfavorable effects
of lower sales of COVID-19 tests, foreign exchange, and higher
costs for various manufacturing inputs, partially offset by the
nonrecurrence of the negative impact in 2022 of the voluntary
product recall in the Nutritional business and the impact in 2023
of gross margin improvement initiatives. In 2022, the decrease
reflected the impact of the voluntary infant product recall and
Sturgis manufacturing stoppage, as well as the prioritization of
infant formula sales related to the WIC Program in the Nutritional
business. The decrease also reflected higher manufacturing and
supply chain costs across Abbott’s businesses, including inflation,
commodities and distribution expenses.
Research and development (R&D) expenses were $2.7 billion in
2023, $2.9 billion in 2022, and $2.7 billion in 2021. The decrease in
R&D expense in 2023 was primarily driven by lower restructuring
charges, lower impairment charges related to in-process R&D
assets acquired in previous business combinations, and other cost
reductions. The increase in 2022 versus 2021 primarily reflected
higher spending on various projects to advance products in devel-
opment, as well as a charge related to the impairment of certain
in-process R&D intangible assets, partially offset by the favorable
impact of foreign exchange.

-- 74 of 86 --

F I N A N C I A L R E V I E W
73
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Selling, general and administrative (SG&A) expenses were
$10.9 billion in 2023, $11.2 billion in 2022 and $11.3 billion in
2021. The 2023 decrease reflects the favorable impact of foreign
exchange and lower restructuring charges in 2023 as well as
the non-recurrence of 2022 expenses related to the voluntary
product recall in the Nutritional segment. SG&A expenses were
virtually unchanged in 2022 compared to 2021 as higher selling
and marketing spending to drive growth was offset by the
favorable impact of foreign exchange.
RESTRUCTURINGS
In 2023, Abbott management approved plans to restructure
various operations in order to reduce costs in its medical devices,
diagnostic, and established pharmaceutical businesses. Abbott
recorded employee related severance and other charges of approx-
imately $144 million of which approximately $56 million was
recorded in Cost of products sold, approximately $22 million
was recorded in Research and development and approximately
$66 million was recorded in Selling, general and administrative
expenses. In addition, Abbott recognized fixed assets impairment
and inventory related charges of approximately $31 million
related to these restructuring plans.
In 2022, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in
its medical devices, nutritional, diagnostic, and established
pharmaceutical businesses. Abbott recorded employee related
severance and other charges of approximately $234 million of
which approximately $59 million was recorded in Cost of products
sold, approximately $36 million was recorded in Research and
development and approximately $139 million was recorded in
Selling, general and administrative expenses. In addition, Abbott
recognized inventory related charges of approximately $23 million
and fixed assets impairment charges of approximately $4 million
related to these restructuring plans.
In 2021, Abbott management approved a restructuring plan
related to its Diagnostic Products segment to align its manufac-
turing network for COVID-19 diagnostic tests with changes in
the second quarter of 2021 in projected testing demand driven
by several factors, including significant reductions in cases in the
U.S. and other major developed countries, the accelerated rollout
of COVID-19 vaccines globally and the U.S. health authority’s
updated guidance on testing for fully vaccinated individuals.
Charges under this plan were recorded in Cost of products sold
and totaled $441 million in 2021.
In 2021, Abbott management approved plans to streamline
operations in order to reduce costs and improve efficiencies in its
diagnostic, established pharmaceutical, nutritional, and medical
device businesses. Abbott recorded employee related severance
and other charges of approximately $68 million of which
approximately $16 million was recorded in Cost of products
sold, approximately $4 million was recorded in Research and
development and approximately $48 million was recorded in
Selling, general and administrative expenses.
INTEREST EXPENSE AND INTEREST (INCOME)
Interest expense, net decreased from $375 million in 2022 to
$252 million in 2023. The decrease was due to the favorable impact
of higher interest rates on interest income, partially offset by the
negative impact of interest rate hedge contracts related to certain
fixed-rate debt. Interest expense, net decreased $115 million in
2022 due to the impact of higher interest rates and cash and short-
term investment balances on interest income and the repayment of
debt in the first quarter of 2022, partially offset by the impact of
interest rate hedge contracts related to certain fixed-rate debt.
OTHER (INCOME) EXPENSE, NET
Other income, net increased from $277 million of income in 2021
and $321 million of income in 2022 to $479 million of income in
2023. Other income, net includes income of approximately
$498 million, $406 million, and $270 million in 2023, 2022, and
2021, respectively, related to the non-service cost components
of the net periodic benefit costs associated with the pension and
post-retirement medical plans. Other income, net also includes
equity investment impairments that totaled approximately
$39 million in 2023 and $45 million in 2022; in 2023 income from
a $42 million reduction in the fair value of contingent consider-
ation related to previous business acquisitions; and a gain on the
sale of an equity method investment in 2021.
TAXES ON EARNINGS
Taxes on earnings include approximately $22 million, $43 million
and $145 million in excess tax benefits associated with share-based
compensation in 2023, 2022 and 2021, respectively. As a result of
the resolution of various tax positions related to prior years, taxes
on earnings in 2023, 2022 and 2021 also include approximately
$80 million and $20 million of net tax expense and $55 million of
net tax benefits, respectively.
Exclusive of these discrete items, tax expense was favorably
impacted by lower tax rates and tax exemptions on foreign income
primarily derived from operations in Puerto Rico, Switzerland,
Ireland, the Netherlands, Costa Rica, Singapore, Malta and
Malaysia. Abbott benefits from a combination of favorable
statutory tax rules, tax rulings, grants, and exemptions in these
tax jurisdictions.
The 2017 U.S. Tax Cuts and Jobs Act (TCJA) includes a one-time
transition tax that is based on Abbott’s total post-1986 earnings
and profits (E&P) that were previously deferred from U.S. income
taxes. The tax computation also requires the determination of
the amount of post-1986 E&P considered held in cash and other
specified assets. As of December 31, 2023, the remaining balance
of Abbott’s transition tax obligation related to the TCJA is approx-
imately $598 million, which will be paid over the next three
years as allowed by the TCJA. Undistributed foreign earnings
remain indefinitely reinvested in foreign operations. Determining
the amount of unrecognized deferred tax liability related to any
remaining undistributed foreign earnings not subject to the transi-
tion tax and additional outside basis difference in its foreign
entities is not practicable.

-- 75 of 86 --

F I N A N C I A L R E V I E W
74
A B B O T T 2 0 2 3 A N N U A L R E P O R T
In the U.S., Abbott’s federal income tax returns through 2016 are
settled. In September 2023, Abbott received a Statutory Notice of
Deficiency (SNOD) from the U.S. Internal Revenue Service (IRS)
for the 2019 Federal tax year in the amount of $417 million. The
primary adjustments proposed in the SNOD relate to the realloca-
tion of income between Abbott’s U.S. entities and its foreign
affiliates. Abbott believes that the income reallocation adjustments
proposed in the SNOD are without merit, in part because certain
adjustments contradict methods that were agreed to with the IRS
in prior audit periods. The SNOD also contains other proposed
adjustments that Abbott believes are erroneous and unsupported.
Abbott filed a petition with the U.S. Tax Court contesting the
SNOD in December of 2023.
Abbott’s 2017 and 2018 Federal tax years are also currently under
examination by the IRS with respect to income reallocation issues
similar to those included in the 2019 Federal tax year. Abbott
intends to vigorously defend its filing positions through ongoing
discussions with the IRS, the IRS independent appeals process
and/or through litigation as necessary.
Abbott reserves for uncertain tax positions related to unresolved
matters with the IRS and other taxing authorities. Abbott contin-
ues to believe that its reserves for uncertain tax positions are
appropriate.
There are numerous other income tax jurisdictions for which
tax returns are not yet settled, none of which Abbott expects to
be individually significant. Reserves for interest and penalties
are not significant.
The Organization for Economic Cooperation & Development
(OECD) has proposed a two-pillared plan for a revised interna-
tional tax system. Pillar 1 proposes to reallocate taxing rights
among the jurisdictions in which in-scope multinational corpora-
tions operate. Abbott is continuing to analyze the Pillar 1 proposal.
Pillar 2 proposes to assess a 15% minimum tax on the earnings of
in-scope multinational corporations on a country-by-country
basis. Numerous countries have enacted legislation to adopt the
Pillar 2 model rules with a subset of the rules becoming effective
January 1, 2024, and the remaining rules becoming effective
January 1, 2025, or in later periods. Abbott is also continuing to
analyze the Pillar 2 model rules. Implementation of the OECD
proposal may have a material impact on Abbott’s Consolidated
Financial Statements in the future.
See Note 15 to the consolidated financial statements for a
full reconciliation of the effective tax rate to the U.S. federal
statutory rate.
RESEARCH AND DEVELOPMENT PROGRAMS
Abbott currently has numerous pharmaceutical, medical devices,
diagnostic and nutritional products in development.
RESEARCH AND DEVELOPMENT PROCESS
In the Established Pharmaceuticals segment, the development
process focuses on the geographic expansion and continuous
improvement of the segment’s existing products to provide bene-
fits to patients and customers. As Established Pharmaceuticals
does not actively pursue primary research, development usually
begins with work on existing products or after the acquisition
of an advanced stage licensing opportunity.
Depending upon the product, the phases of development
may include:
• Drug product development.
• Phase I bioequivalence studies to compare a future Established
Pharmaceutical’s brand with an already marketed compound
with the same active pharmaceutical ingredient (API).
• Phase II studies to test the efficacy of benefits in a small group
of patients.
• Phase III studies to broaden the testing to a wider population
that reflects the actual medical use.
• Phase IV and other post-marketing studies to obtain new
clinical use data on existing products within approved indications.
The specific requirements (e.g., scope of clinical trials) for
obtaining regulatory approval vary across different countries and
geographic regions. The process may range from one year for a
bioequivalence study project to six or more years for complex
formulations, new indications, or geographic expansion in specific
countries, such as China.
In the Diagnostics segment, the phases of the research and
development process include:
• Discovery which focuses on identification of a product that
will address a specific therapeutic area, platform, or unmet
clinical need.
• Concept/Feasibility during which the materials and
manufacturing processes are evaluated, testing may include
product characterization and analysis is performed to
confirm clinical utility.
• Development during which extensive testing is performed
to demonstrate that the product meets specified design
requirements and that the design specifications conform
to user needs and intended uses.
The regulatory requirements for diagnostic products vary across
different countries and geographic regions. In the U.S., the FDA
classifies diagnostic products into classes (I, II, or III) and the
classification determines the regulatory process for approval.
While the Diagnostics segment has products in all three classes,
the vast majority of its products are categorized as Class I or
Class II. Submission of a separate regulatory filing is not required
for Class I products. Class II products typically require pre-market
notification to the FDA through a regulatory filing known as a
510(k) submission. Most Class III products are subject to the
FDA’s Premarket Approval (PMA) requirements. Other Class III
products, such as those used to screen blood, require the submis-
sion and approval of a Biological License Application (BLA).
In the European Union (EU), diagnostic products are also
categorized into different categories and the regulatory process,
which had been governed by the European In Vitro Diagnostic
Medical Device Directive, depends upon the category, with certain
product categories requiring review and approval by an indepen-
dent company, known as a Notified Body, before the manufacturer
can affix a CE mark to the product to declare conformity to the
Directive. Other products only require a self-certification process.
In 2017, the EU adopted the new In Vitro Diagnostic Regulation
(IVDR) which replaced the existing directive in the EU for in vitro

-- 76 of 86 --

F I N A N C I A L R E V I E W
75
A B B O T T 2 0 2 3 A N N U A L R E P O R T
diagnostic products and imposed additional premarket and post-
market regulatory requirements on manufacturers of such
products. In December 2021, the IVDR was amended to extend
the regulation’s previous two-year transition period by a range
of one to three years, with the transition period extending to
May 2027 for certain classes of diagnostic devices. However, the
amendment did not delay the date of application of the IVDR
itself which took effect on May 26, 2022.
In the Medical Devices segment, the research and development
process begins with research on a specific technology that is
evaluated for feasibility and commercial viability. If the research
program passes that hurdle, it moves forward into development.
The development process includes evaluation, selection and
qualification of a product design, completion of applicable clinical
trials to test the product’s safety and efficacy, and validation of
the manufacturing process to demonstrate its repeatability and
ability to consistently meet pre-determined specifications.
Similar to the diagnostic products discussed above, in the U.S.,
medical devices are classified as Class I, II, or III. Most of Abbott’s
medical device products are classified as Class II devices that
follow the 510(k) regulatory process or Class III devices that are
subject to the PMA process.
In the EU, medical devices are also categorized into different
classes and the regulatory process, which had been governed
by the European Medical Device Directive and the Active
Implantable Medical Device Directive, varies by class. In the
second quarter of 2017, the EU adopted the new Medical Devices
Regulation (MDR) which replaced the existing directives in the
EU for medical devices and imposes additional premarket and
post-market regulatory requirements on manufacturers of such
products. The MDR applies to manufacturers as of May 26, 2021
with extended transition periods lasting as long as December 31,
2028 depending on the risk classification of the device in the
regulation. Each product must bear a CE mark to show compli-
ance with the MDR.
Some products require submission of a design dossier to the
appropriate regulatory authority for review and approval prior
to CE marking of the device. For other products, the company is
required to prepare a technical file which includes testing results
and clinical evaluations but can self-certify its ability to apply the
CE mark to the product. Outside the U.S. and the EU, the regula-
tory requirements vary across different countries and regions.
After approval and commercial launch of some medical devices,
post-market trials may be conducted either due to a conditional
requirement of the regulatory market approval or with the
objective of proving product superiority.
In the Nutritional segment, the research and development
process generally focuses on identifying and developing ingredi-
ents and products that address the nutritional needs of particular
populations (e.g., infants and adults) or patients (e.g., people with
diabetes). Depending upon the country and/or region, if claims
regarding a product’s efficacy will be made, clinical studies
typically must be conducted.
In the U.S., the FDA requires that it be notified of proposed new
formulations and formulation or packaging changes related to
infant formula products. Prior to the launch of an infant formula
or product packaging change, the company is required to obtain
the FDA’s confirmation that it has no objections to the proposed
product or packaging. For other nutritional products, notification
or pre-approval from the FDA is not required unless the product
includes a new food additive. In some countries, regulatory
approval may be required for certain nutritional products,
including infant formula and medical nutritional products.
AREAS OF FOCUS
In 2024 and beyond, Abbott expects to focus on the
following areas:
Established Pharmaceuticals — Abbott focuses on building
country-specific portfolios made up of high-quality medicines
that meet the needs of people in emerging markets. Over the next
several years, Abbott plans to expand its product portfolio in key
therapeutic areas and biosimilars with the aim of addressing the
health needs of more people in emerging markets and being
among the first to launch new off-patent and differentiated medi-
cines. In addition, Abbott continues to expand existing brands into
new markets, implement product enhancements that provide
value to patients and acquire strategic products and technology
through licensing activities. Abbott is also actively working on
the further development of several key brands such as Creon™,
Duphaston™, Femoston™ and Influvac™. Depending on the
product, the activities focus on development of new data, markets,
formulations, delivery systems, or indications.
Medical Devices — Abbott’s research and development programs
focus on:
• Cardiac Rhythm Management – Development of next-generation
rhythm management technologies, including advanced commu-
nication capabilities and leadless pacing therapies.
• Heart Failure – Continued enhancements to Abbott’s mechani-
cal circulatory support and pulmonary artery pressure systems,
including enhanced clinical performance and usability.
• Electrophysiology – Development of next-generation
technologies in the areas of ablation, diagnostic, mapping,
and visualization and recording.
• Vascular – Development of next-generation technologies for
use in coronary and peripheral vascular procedures.
• Structural Heart – Development of transcatheter and surgical
devices for the repair and replacement of heart valves, and
occlusion therapies for congenital heart defects and stroke-risk
reduction.
• Neuromodulation – Development of clinical evidence and next-
generation technologies leveraging digital health to support
improved patient clinical outcomes, physician engagement, and
expanded indications in the treatment of chronic pain, move-
ment disorders and other indications.
• Diabetes Care – Develop enhancements and additional
indications for the FreeStyle Libre platform of continuous
glucose monitoring products to help patients improve their
ability to manage diabetes and for use beyond diabetes.

-- 77 of 86 --

F I N A N C I A L R E V I E W
76
A B B O T T 2 0 2 3 A N N U A L R E P O R T
Nutritionals — Abbott is focusing its research and development
spend on platforms that span the pediatric and adult nutrition
areas: gastrointestinal/immunity health, brain health, mobility
and metabolism, and user experience platforms. Numerous new
products that build on advances in these platforms are currently
under development, including clinical outcome testing, and are
expected to be launched over the coming years.
Core Laboratory Diagnostics — Abbott continues to commercialize
its next-generation blood and plasma screening, immunoassay,
clinical chemistry and hematology systems, along with assays,
including a focus on unmet medical needs, in various areas includ-
ing infectious disease, cardiac care, metabolics, oncology, and
neurologic assays as well as informatics solutions to help optimize
diagnostics laboratory performance and automation solutions to
increase efficiency in laboratories.
Molecular Diagnostics — Several new molecular in vitro diagnostic
(IVD) tests are in various stages of development and launch.
Rapid Diagnostics — Abbott’s research and development programs
focus on the development of diagnostic products for infectious
disease, cardiometabolic disease and toxicology.
In addition, the Diagnostics segment is pursuing the FDA’s
customary regulatory process for various COVID-19 tests for
which EUAs were obtained.
Given the diversity of Abbott’s business, its intention to remain a
broad-based health care company and the numerous sources for
potential future growth, no individual project is expected to be
material to cash flows or results of operations over the next five
years. Factors considered included research and development
expenses projected to be incurred for the project over the next year
relative to Abbott’s total research and development expenses, as
well as qualitative factors, such as marketplace perceptions
and impact of a new product on Abbott’s overall market position.
There were no delays in Abbott’s 2023 research and development
activities that are expected to have a material impact on operations.
While the aggregate cost to complete the numerous projects
currently in development is expected to be material, the total
cost to complete will depend upon Abbott’s ability to successfully
finish each project, the rate at which each project advances, and
the ultimate timing for completion. Given the potential for signifi-
cant delays and the risk of failure inherent in the development
of medical device, diagnostic and pharmaceutical products and
technologies, it is not possible to accurately estimate the total
cost to complete all projects currently in development. Abbott
plans to manage its portfolio of projects to achieve research and
development spending that will be competitive in each of the
businesses in which it participates, and such spending is targeted
at approximately 7 percent of total Abbott sales in 2024. Abbott
does not regularly accumulate or make management decisions
based on the total expenses incurred for a particular development
phase in a given period.
GOODWILL
At December 31, 2023, goodwill recorded as a result of business
combinations totaled $23.7 billion. Goodwill is reviewed for
impairment annually in the third quarter or when an event that
could result in an impairment occurs, using a quantitative assess-
ment to determine whether it is more likely than not that the fair
value of any reporting unit is less than its carrying amount. The
income and market approaches are used to calculate the fair value
of each reporting unit. The results of the last impairment test
indicated that the fair value of each reporting unit was substan-
tially in excess of its carrying value.
FINANCIAL CONDITION
CASH FLOW
Net cash from operating activities amounted to $7.3 billion,
$9.6 billion, and $10.5 billion in 2023, 2022, and 2021, respectively.
The decrease in Net cash from operating activities in 2023 as
compared to 2022 is primarily due to the decline in operating
earnings and increased payments related to accounts payable
and accrued liabilities, partially offset by lower expenditures for
inventory and lower cash payments for income taxes due to lower
earnings. The decrease in Net cash from operating activities in
2022 as compared to 2021 was primarily due to the unfavorable
cash flow impact of an increased investment in working capital,
partially offset by reduced expenditures related to restructuring
actions and lower cash payments for income taxes.
A substantial portion of Abbott’s cash and cash equivalents at
December 31, 2023, is held by Abbott affiliates outside of the U.S.
If these funds were needed for operations in the U.S., Abbott does
not expect to incur significant additional income taxes in the
future to repatriate these funds.
Abbott funded $349 million in 2023, $413 million in 2022, and
$418 million in 2021 to defined benefit pension plans. Abbott
expects pension funding of approximately $350 million in 2024
for its pension plans. Abbott expects annual cash flow from oper-
ating activities to continue to exceed Abbott’s capital expenditures
and cash dividends.
DEBT AND CAPITAL
At December 31, 2023, Abbott’s long-term debt rating was AA- by
S&P Global Ratings and Aa3 by Moody’s Investors Service. Abbott
expects to maintain an investment grade rating.
Abbott has readily available financial resources, including unused
lines of credit that support commercial paper borrowing arrange-
ments and provide Abbott with the ability to borrow up to
$5 billion on an unsecured basis. The lines of credit as of
December 31, 2023 were a part of a Five Year Credit Agreement
that Abbott entered into on November 12, 2020. On January 29,
2024, Abbott terminated the 2020 Agreement and entered into a
new Five Year Credit Agreement (Revolving Credit Agreement).

-- 78 of 86 --

F I N A N C I A L R E V I E W
77
A B B O T T 2 0 2 3 A N N U A L R E P O R T
There were no outstanding borrowings under the 2020 Agreement
at the time of its termination. Any borrowings under the Revolving
Credit Agreement will mature and be payable on January 29, 2029
and will bear interest, at Abbott’s option, based on either a base
rate or Secured Overnight Financing Rate (SOFR) rate, plus an
applicable margin based on Abbott’s credit ratings.
As of December 31, 2023, Abbott’s total debt outstanding was
$14.7 billion, of which approximately $1.1 billion will mature in
2024. Abbott expects to repay the $655 million of notes maturing
in 2024 through the use of cash on hand and to refinance the
$419 million term loan in 2024.
On November 30, 2023, Abbott repaid the $1.05 billion outstanding
principal amount of its 3.40% Notes upon maturity. On September
27, 2023, Abbott repaid the €1.14 billion outstanding principal
amount of its 0.875% Notes upon maturity. The euro debt repay-
ment equated to approximately $1.2 billion. In September 2023,
Abbott repaid approximately $197 million of debt assumed as part
of a recent business acquisition. On March 15, 2022, Abbott repaid
the $750 million outstanding principal amount of its 2.55% Notes
upon maturity.
In 2021, Abbott repaid approximately $195 million on a short-term
facility upon maturity. After the repayment, Abbott has no short-
term debt.
In October 2019, the board of directors authorized the repurchase
of up to $3 billion of Abbott’s common shares from time to time.
This authorization was in addition to the unused portion of a
previous share repurchase program that was authorized in 2014.
In 2021, Abbott repurchased 16.6 million of its common shares for
$2.016 billion, which fully utilized the authorization remaining
under the 2014 share repurchase program and a portion of the
2019 authorization. In December 2021, the board of directors
authorized the repurchase of up to $5 billion of Abbott’s common
shares from time to time. This authorization was in addition to the
$1.081 billion portion of the share repurchase program authorized
in 2019 that was unused as of December 31, 2021. In 2022, Abbott
repurchased 32.3 million of its common shares for $3.65 billion
which fully utilized the authorization remaining under the 2019
share repurchase program and a portion of the 2021 authorization.
In 2023, Abbott repurchased approximately 9.8 million of its
common shares for $1.025 billion. As of December 31, 2023,
$1.41 billion remains available for repurchase under the 2021
repurchase program.
Abbott declared dividends of $2.08 per share in 2023 compared to
$1.92 per share in 2022, an increase of 8.3 percent. Dividends paid
were $3.556 billion in 2023 compared to $3.309 billion in 2022.
The year-over-year change in dividends paid reflects the impact of
the increase in the dividend rate.
WORKING CAPITAL
Working capital was $8.8 billion at December 31, 2023 and
$9.7 billion at December 31, 2022. The decrease was due largely to
a decrease in cash and cash equivalents, partially offset by the
repayment of debt due in 2023. The decrease in cash and cash
equivalents from $9.9 billion at December 31, 2022 to $6.9 billion
at December 31, 2023 primarily reflects the payment of dividends,
the repayment of debt, capital expenditures, share repurchases,
and the cost of business acquisitions, partially offset by the cash
generated from operations.
Abbott monitors the credit worthiness of customers and estab-
lishes an allowance that reflects the current estimate of credit
losses expected to be incurred over the life of the financial asset.
Abbott considers various factors in establishing, monitoring, and
adjusting its allowance for doubtful accounts, including the aging
of the accounts and aging trends, the historical level of charge-
offs, and specific exposures related to particular customers. Abbott
also monitors other risk factors and forward-looking information,
such as country risk, when determining credit limits for customers
and establishing adequate allowances.
CAPITAL EXPENDITURES
Capital expenditures of $2.2 billion in 2023, $1.8 billion in 2022,
and $1.9 billion in 2021 were principally for upgrading and
expanding manufacturing and research and development facilities
and equipment in various segments, investments in information
technology, and laboratory instruments placed with customers.
CONTRACTUAL OBLIGATIONS
Abbott believes that its available cash and cash equivalents along
with its ability to generate operating cash flow and continued
access to debt markets are sufficient to fund existing and planned
cash requirements. Abbott’s material cash requirements include
the following contractual obligations:
Debt — Principal payments required on long-term debt outstand-
ing at December 31, 2023 are $1.1 billion in 2024, $1.5 billion in
2025, $3.0 billion in 2026, $656 million in 2027, $651 million in
2028 and $8.0 billion in 2029 and thereafter. Interest payments
required on long-term debt outstanding at December 31, 2023 are
projected to be $526 million in 2024, $508 million in 2025,
$474 million in 2026, $391 million in 2027, $385 million in 2028
and $5.0 billion in 2029 and thereafter.
Operating leases — As of December 31, 2023, estimated contractual
obligations for operating lease payments were $1.362 billion, with
$278 million due within 12 months.
In addition, Abbott enters into purchase commitments in the
normal course of business to meet operational and capital expen-
diture requirements. The majority of outstanding purchase
commitments generally do not extend past one year.

-- 79 of 86 --

F I N A N C I A L R E V I E W
78
A B B O T T 2 0 2 3 A N N U A L R E P O R T
CONTINGENT OBLIGATIONS
Abbott periodically acquires a business or product rights in which
Abbott agrees to pay contingent consideration based on attaining
certain thresholds or based on the occurrence of certain events.
BUSINESS ACQUISITIONS
On September 22, 2023, Abbott completed the acquisition of
Bigfoot, which will further Abbott’s efforts to develop connected
solutions for making diabetes management more personal and
precise. The purchase price, the preliminary allocation of acquired
assets and liabilities, and the revenue and net income contributed
by Bigfoot since the date of acquisition are not material to Abbott’s
consolidated financial statements.
On April 27, 2023, Abbott completed the acquisition of CSI for
$20 per common share, which equated to a purchase price of
$851 million. The transaction was funded with cash on hand
and accounted for as a business combination. CSI’s atherectomy
system, which is used in treating peripheral and coronary artery
disease, adds complementary technologies to Abbott’s portfolio
of vascular device offerings.
The preliminary allocation of the purchase price of the CSI acqui-
sition resulted in the recording of two non-deductible developed
technology intangible assets of $305 million; non-deductible
in-process research and development of $15 million, which will be
accounted for as an indefinite-lived intangible asset until regula-
tory approval or discontinuation; non-deductible goodwill of
$371 million; net deferred tax assets of approximately $46 million
and other net assets of approximately $114 million. The goodwill
is identifiable to the Medical Devices reportable segment and is
attributable to expected synergies from combining operations, as
well as intangible assets that do not qualify for separate recogni-
tion. Allocation of the purchase price of the acquisition will be
finalized when the valuation of assets and liabilities is completed.
Revenues and earnings of CSI included in Abbott’s consolidated
financial statements since the acquisition date are not material to
Abbott’s consolidated revenue and earnings. If the acquisition of
CSI had taken place as of the beginning of 2022, consolidated net
sales and earnings would not have been significantly different
from reported amounts.
In September 2021, Abbott acquired Walk Vascular, LLC (Walk
Vascular), a commercial-stage medical device company with a
minimally invasive thrombectomy system designed to remove
peripheral blood clots. Walk Vascular’s peripheral thrombectomy
system has been incorporated into Abbott’s existing endovascular
portfolio. The purchase price, the allocation of acquired assets
and liabilities, and the revenue and net income contributed by
Walk Vascular since the date of acquisition are not material to
Abbott’s consolidated financial statements.
LEGISLATIVE ISSUES
Abbott’s primary markets are highly competitive and subject to
substantial government regulations throughout the world. Abbott
expects debate to continue over the availability, method of deliv-
ery, and payment for health care products and services. It is not
possible to predict the extent to which Abbott or the health care
industry in general might be adversely affected by these factors
in the future. A more complete discussion of these factors is
contained in Item 1, Business, and Item 1A, Risk Factors.
RECENTLY ISSUED ACCOUNTING STANDARDS
RECENTLY ADOPTED ACCOUNTING STANDARDS
In September 2022, the FASB issued Accounting Standards
Update 2022-04, Disclosure of Supplier Finance Program
Obligations, which requires an entity to report information about
its supplier finance program. Abbott adopted the standard on
January 1, 2023. The new standard did not have an impact on
Abbott’s consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes
(Topic 740): Simplifying the Accounting for Income Taxes, which
among other things, eliminates certain exceptions in the current
rules regarding the approach for intraperiod tax allocations and
the methodology for calculating income taxes in an interim period,
and clarifies the accounting for transactions that result in a
step-up in the tax basis of goodwill. Abbott adopted the standard
on January 1, 2021. The new standard did not have an impact on
its consolidated financial statements.
RECENT ACCOUNTING STANDARDS NOT YET ADOPTED
In November 2023, the FASB issued ASU 2023-07, Segment
Reporting (Topic 280): Improvements to Reportable Segment
Disclosures, which expands the breadth and frequency of required
segment disclosures. The guidance is required to be applied
retrospectively to all periods presented in the financial statements.
The standard becomes effective for Abbott for full year 2024
reporting and for interim periods beginning in the first quarter
of 2025. Abbott is currently evaluating the impact of this new
standard on its consolidated financial statements.
In December 2023, the FASB issued ASU 2023-09, Income Taxes
(Topic 740): Improvements to Income Tax Disclosures, which
requires an entity to disclose annually additional information
related to the company’s income tax rate reconciliation and
income taxes paid during the period. The guidance should be
applied prospectively with the option to apply the standard
retrospectively. The standard becomes effective for Abbott for full
year 2025 reporting. Abbott is currently evaluating the impact of
this new standard on its consolidated financial statements.
PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 —
A CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
Under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, Abbott cautions investors that any
forward-looking statements or projections made by Abbott,
including those made in this document, are subject to risks and
uncertainties that may cause actual results to differ materially
from those projected. Economic, competitive, governmental,
technological and other factors that may affect Abbott’s operations
are discussed in Item 1A, Risk Factors.

-- 80 of 86 --

F I N A N C I A L R E V I E W
79
A B B O T T 2 0 2 3 A N N U A L R E P O R T
P E R F O R M A N C E G R A P H
Assuming $100 invested on December 31, 2018 with dividends reinvested.
Abbott Laboratories
S&P 500 Index
S&P 500 Health Care
2019	2018 	2020 	2021 	2022 	2023
$0
$50
$150
$100
$200
$250 	This graph compares the change
in Abbott’s cumulative total shareholder
return on its common shares with the
Standard & Poor’s 500 Index and the
Standard & Poor’s 500 Health Care Index.

-- 81 of 86 --

80
A B B O T T 2 0 2 3 A N N U A L R E P O R T
S U M M A R Y O F S E L E C T E D F I N A N C I A L D ATA
(Dollars in millions except per share data)
Year Ended December 31 	2023 	2022 	2021 	2020 	2019
Summary of Operations:
Net Sales 	$ 	40,109 	43,653 	43,075 	34,608 	31,904
Cost of products sold 	$ 	19,941 	21,155 	20,584 	17,135 	15,167
Research & development 	$ 	2,741 	2,888 	2,742 	2,420 	2,440
Selling, general, and administrative 	$ 	10,949 	11,248 	11,324 	9,696 	9,765
Operating earnings 	$ 	6,478 	8,362 	8,425 	5,357 	4,532
Interest expense 	$ 	637 	558 	533 	546 	670
Interest income 	$ 	(385) 	(183) 	(43) 	(46) 	(94)
Other (income) expense, net (a) 	$ 	(438) 	(319) 	(276) 	(111) 	(121)
Earnings before taxes 	$ 	6,664 	8,306 	8,211 	4,968 	4,077
Taxes on earnings from continuing operations 	$ 	941 	1,373 	1,140 	497 	390
Earnings from continuing operations 	$ 	5,723 	6,933 	7,071 	4,471 	3,687
Net earnings 	$ 	5,723 	6,933 	7,071 	4,495 	3,687
Basic earnings per common share from continuing operations 	$ 	3.28 	3.94 	3.97 	2.51 	2.07
Basic earnings per common share 	$ 	3.28 	3.94 	3.97 	2.52 	2.07
Diluted earnings per common share from continuing operations 	$ 	3.26 	3.91 	3.94 	2.49 	2.06
Diluted earnings per common share 	$ 	3.26 	3.91 	3.94 	2.50 	2.06
Financial Positions:
Working capital 	$ 	8,829 	9,735 	11,134 	8,534 	4,804
Long-term investment securities 	$ 	799 	766 	816 	821 	883
Net property & equipment 	$ 	10,154 	9,162 	8,959 	9,029 	8,038
Total assets 	$ 	73,214 	74,438 	75,196 	72,548 	67,887
Long-term debt, including current portion 	$ 	14,679 	16,773 	18,050 	18,534 	17,938
Shareholders’ investment 	$ 	38,827 	36,905 	36,024 	33,003 	31,301
Book value per share 	$ 	22.39 	21.24 	20.42 	18.63 	17.76
Other Statistics:
Gross profit margin 	% 	50.3 	51.5 	52.2 	50.5 	52.5
Research and development to net sales 	% 	6.8 	6.6 	6.4 	7.0 	7.6
Net cash from operating activities 	$ 	7,261 	9,581 	10,533 	7,901 	6,136
Capital expenditures 	$ 	2,202 	1,777 	1,885 	2,177 	1,638
Cash dividends declared per common share 	$ 	2.08 	1.92 	1.82 	1.53 	1.32
Common shares outstanding (in thousands) 	1,734,076 	1,737,795 	1,764,082 	1,771,230 	1,762,503
Number of common shareholders 	32,449 	34,019 	35,926 	37,450 	38,990
Market price per share – high 	$ 	115.83 	139.83 	142.60 	115.14 	89.24
Market price per share – low 	$ 	89.67 	93.25 	105.36 	61.61 	65.50
Market price per share – close 	$ 	110.07 	109.79 	140.74 	109.49 	86.80
a) These amounts include debt extinguishment costs and net foreign exchange (gain) loss.

-- 82 of 86 --

81	*Denotes executive officer
D I R EC TO R S
Robert J. Alpern, M.D.
Ensign Professor of Medicine
and Physiology and Professor
of Internal Medicine and
Cellular and Molecular
Physiology, and Former Dean
of Yale School of Medicine
Claire Babineaux-Fontenot
Chief Executive Officer,
Feeding America
Sally E. Blount, Ph.D.
President and Chief
Executive Officer, Catholic
Charities of the Archdiocese
of Chicago and
Michael L. Nemmers
Professor of Strategy and
Former Dean of the
J.L. Kellogg Graduate School
of Management at
Northwestern University
Robert B. Ford
Chairman of the Board and
Chief Executive Officer,
Abbott Laboratories
Paola Gonzalez
Vice President, Global FP&A,
The Clorox Company
Michelle A. Kumbier
President, Turf &
Consumer Products,
Briggs & Stratton, LLC
Darren W. McDew
Retired General, United
States Air Force, and
Former Commander of U.S.
Transportation Command
Nancy McKinstry
Chief Executive Officer
and Chairman of the
Executive Board,
Wolters Kluwer N.V.
Michael G. O’Grady
Chairman and
Chief Executive Officer,
Northern Trust Corporation
Michael F. Roman
Chairman of the Board,
President and
Chief Executive Officer,
3M Company
Daniel J. Starks
Retired Chairman, President
and Chief Executive Officer,
St. Jude Medical, Inc.
John G. Stratton
Executive Chairman,
Frontier Communications
Parent, Inc.
S E N I O R M A N AG E M E N T
Robert B. Ford*
Chairman of the Board and
Chief Executive Officer
Hubert L. Allen*
Executive Vice President,
General Counsel and
Secretary
Lisa D. Earnhardt*
Executive Vice President
and Group President,
Medical Devices
Robert E. Funck, Jr.*
Executive Vice President,
Finance
Joseph Manning
Executive Vice President,
Nutritional Products
Mary K. Moreland*
Executive Vice President,
Human Resources
Louis H. Morrone*
Executive Vice President,
Core Diagnostics
Daniel Salvadori*
Executive Vice President and
Group President, Established
Pharmaceuticals
and Nutritional Products
Andrea Wainer*
Executive Vice President,
Rapid and Molecular
Diagnostics
Jared L. Watkin
Executive Vice President,
Diabetes Care
Philip B. Boudreau*
Senior Vice President,
Finance and
Chief Financial Officer
Christopher J. Calamari
Senior Vice President,
U.S. Nutrition
Sabina A. Ewing
Senior Vice President,
Business and Technology
Services and Chief
Information Officer
J. Scott House
Senior Vice President,
Quality Assurance,
Regulatory and Engineering
Services
Sammy Karam
Senior Vice President,
Established Pharmaceuticals,
Emerging Markets
Scott M. Leinenweber
Senior Vice President,
Licensing, Acquisitions
and Ventures
Sandra Lesenfants
Senior Vice President,
Structural Heart
Fernando Mateus
Senior Vice President,
International Nutrition
Christopher J. Scoggins
Senior Vice President,
Commercial Operations and
Marketing, Diabetes Care
Julie L. Tyler
Senior Vice President,
Abbott Vascular
Alejandro D. Wellisch
Senior Vice President,
Established Pharmaceuticals,
Latin America
Randel W. Woodgrift
Senior Vice President,
Cardiac Rhythm
Management
Uri Yaron
Senior Vice President,
Electrophysiology
CO R P O R AT E V I C E PR E S I D E N T S
Venu Ambati
Vice President, Established
Pharmaceuticals, India
Elizabeth M. Balthrop
Vice President,
Transfusion Medicine
Erica L. Battaglia
Vice President, Chief Ethics
and Compliance Officer
Keith Boettiger
Vice President,
Heart Failure
Badia Boudaiffa
Vice President,
North America
Commercial Operations,
Diabetes Care
Melissa D. Brotz
Vice President,
Public Affairs and
Corporate Marketing
Fanny Chen
Vice President,
Core Diagnostics, China
Keith Cienkus
Vice President.
Molecular Diagnostics
Michael A. Comilla
Vice President, Investor
Relations
Elizabeth C. Cushman
Vice President,
Specialty Legal
Alison E. Davies
Vice President, Treasurer
Thomas C. Evers
Vice President,
Government Affairs
John S. Frels
Vice President,
Research and Development,
Immunoassay/Clinical
Chemistry
Damian P. Halloran
Vice President,
Infectious Disease,
Rapid Diagnostics
Gene Huang, Ph.D.
Vice President,
Chief Economist
Gary C. Johnson
Vice President, Clinical,
Regulatory and Health
Economics Outcomes
Research, Cardiovascular
and Neuromodulation
Robert R. Kunkler
Vice President,
Toxicology, Cardiometabolic
and Consumer Products
and Services
Brian Lehman
Vice President,
Commercial Operations,
Electrophysiology
Pedro Malha
Vice President,
Neuromodulation
John A. McCoy Jr.*
Vice President,
Finance and Controller
Jana Mihaylova
Vice President,
Nutrition, Asia Pacific
John M. Murphy
Vice President,
Nutrition Supply Chain
Joseph L. Novak
Vice President, Taxes
Michaela Pardubicka-Jenkins
Vice President, Pediatric
Nutrition
Ansgar Resch
Vice President, International
Commercial Operations,
Diabetes Care
Ric A. Schneider
Vice President,
Chief Procurement Officer
Eric Shroff
Vice President,
Abbott Point of Care
Thomas R. Stanis
Vice President,
Core Laboratory
Diagnostics, International
Commercial Operations
Frank Weitekamper
Vice President,
Abbott Transition
Organization
James R. Wenner
Vice President,
Internal Audit
Monica J. Wilkins
Vice President,
Regulatory and Quality
D I R E C T O R S A N D C O R P O R AT E O F F I C E R S
A B B O T T 2 0 2 3 A N N U A L R E P O R T

-- 83 of 86 --

82
1) Data on file, Abbott Diabetes
Care. Data based on the
number of users worldwide
for the FreeStyle Libre system
compared to the number of
users for other leading personal
use, sensor-based glucose
monitoring systems.
2) Based on a comparison of
list prices of FreeStyle Libre
14 day, FreeStyle Libre 2 and
FreeStyle Libre 3 systems versus
competitors’ CGM systems.
The actual cost to patients may
or may not be lower than other
CGM systems, depending on the
amount covered by insurance,
if any. Abbott provides this
information as a courtesy.
It is subject to change and
interpretation. The customer
is ultimately responsible for
determining the appropriate
codes, coverage, and payment
policies for individual patients.
Abbott does not guarantee
third-party coverage or
payment for our products or
reimburse customers for claims
that are denied by third-party
payers.
3) Data on file, Abbott
Diabetes Care.
4) Among patient-applied
sensors. Data on file, Abbott
Diabetes Care.
5) Canadian real-world analysis
of flash glucose monitoring and
glycemic control; Lori Berard,
Laura Brandner.
Improving HbA1c control in
people with Type 1 or Type 2
diabetes using flash glucose
monitoring: a retrospective
observational analysis in two
German centers; Gerhard
Klausmann, Ludger Rose,
Alexander Seibold.
Gerci B, Roussel R, Riveline
JP, et al. Important decrease
in hospitalizations for acute
diabetes events following
FreeStyle Libre® system
initiation in people with type
2 diabetes on basal insulin
therapy in France. Presented at
EADV, 20-22 September 2022,
Stockholm, Sweden.
6) The FreeStyle LibreLink app
is only compatible with certain
mobile devices and operating
systems. Please check our
website for more information
about device compatibility
before using the app. Use of the
FreeStyle LibreLink app requires
registration with LibreView.
7) The LibreView data
management software is
intended for use by both
patients and healthcare
professionals to assist people
with diabetes and their
healthcare professionals in the
review, analysis and evaluation
of historical glucose meter data
to support effective diabetes
management. The LibreView
software is not intended to
provide treatment decisions or
to be used as a substitute for
professional healthcare advice.
Abbott trademarks and
products in-licensed by Abbott
are shown in italics in the text
of this report.
© 2024 Abbott Laboratories
Some statements in this annual
report may be forward-looking
statements for purposes of the
Private Securities Litigation
Reform Act of 1995. Abbott
cautions that these forward-
looking statements are subject
to risks and uncertainties, that
may cause actual results to
differ materially from those
indicated in the forward-
looking statements.
Economic, competitive,
governmental, technological
and other factors that may
affect Abbott’s operations are
discussed in Item 1A, “Risk
Factors,” in our Securities and
Exchange Commission 2023
Form 10-K and are incorporated
by reference. We undertake no
obligation to release publicly
any revisions to forward-
looking statements as the
result of subsequent events
or developments, except as
required by law.
The Abbott 2023 Annual Report
cover and text is printed on
recycled paper that contains a
minimum of 10% post-consumer
fiber and the financial pages on
30% post-consumer fiber.
A B B O T T 2 0 2 3 A N N U A L R E P O R T
S H A R E H O L D E R A N D C O R P O R AT E I N F O R M AT I O N
S H A R E S L I S T I N G
The ticker symbol for Abbott’s common
shares is ABT. The principal market for
Abbott’s common shares is the New York
Stock Exchange. Shares are also listed on
the Chicago Stock Exchange and traded on
various regional and electronic exchanges.
Outside the United States, Abbott’s shares
are listed on the Swiss Stock Exchange.
Q UA R T E R LY D I V I D E N D DAT E S
Dividends are expected to be declared,
recorded, and paid on the following
schedule in 2024, pending approval by the
Board of Directors:
Quarter 	Declared Recorded Paid
First 	2/16 	4/15 	5/15
Second 	6/14 	7/15 	8/15
Third 	9/19 	10/15 	11/15
Fourth 	12/13 	1/15/25 	2/14/25
TA X INFORM ATION FOR SHAREHOLDERS
Abbott is an Illinois High Impact
Business (HIB) through June 2043 and is
located in a U.S. federal Foreign Trade
Sub-Zone (Sub-Zone 22F). Dividends may
be eligible for a subtraction from base
income for Illinois income-tax purposes.
If you have any questions, please contact
your tax advisor.
D I V I D E N D R E I N V E S TM E N T PL A N
The Abbott Dividend Reinvestment
Plan offers registered shareholders
an opportunity to purchase additional
shares, commission-free, through
automatic dividend reinvestment and/or
optional cash investments. Interested
persons may contact the transfer agent, or
call Abbott’s Investor Newsline, as listed in
the right-hand column.
D I V I D E N D D I R EC T D E P O S IT
Shareholders may have quarterly dividends
deposited directly into a checking or savings
account at any financial institution that
participates in the Automated Clearing
House system. For more information, please
contact the transfer agent, listed at right.
D I R EC T R EG I S T R AT I O N S Y S T E M
In August 2008, Abbott implemented a
Direct Registration System (DRS) for all
registered shareholder transactions.
Shareholders will be sent a statement in
lieu of a physical stock certificate for
Abbott Laboratories common shares.
Please contact the transfer agent with
any questions.
A N N UA L M E E T I N G
The Annual Meeting of Shareholders will
be held virtually at 9 a.m. Central Time on
Friday, April 26, 2024. Questions regarding
the Annual Meeting may be directed to
the Corporate Secretary. A copy of Abbott’s
2023 Form 10-K Annual Report, as filed
with the U.S. Securities and Exchange
Commission, is available on Abbott’s Web
site at www.abbott.com or by calling the
Investor Newsline (above, right).
C EO A N D CFO C E R T I FI C AT I O N S
In 2023, Abbott’s chief executive officer
(CEO) provided to the New York Stock
Exchange the annual CEO certification
regarding Abbott’s compliance with the
New York Stock Exchange’s corporate-
governance listing standards. In addition,
Abbott’s CEO and chief financial officer
(CFO) filed with the U.S. Securities and
Exchange Commission all required
certifications regarding the quality of
Abbott’s public disclosures in its fiscal
2023 reports.
I N V E S TO R N E WS L I N E
224-667-7300
I N V E S TO R R E L AT I O N S
Dept. 362, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
S H A R E H O L D E R S E RV I C E S ,
T R A N S FE R AG E N T A N D R EG I S T R A R
Computershare
P.O. Box 43078
Providence, RI 02940-3078
888-332-2268 (U.S. or Canada)
781-575-3910 (outside U.S. or Canada)
www.computershare.com
CO R P O R AT E S EC R E TA RY
Dept. 364, AP6D2
Abbott
100 Abbott Park Road
Abbott Park, IL 60064-6400 U.S.
224-667-6100
WE B S IT E
www.abbott.com
A B B OT T O N L I N E A N N UA L R E P O R T
www.abbott.com/annualreport
G LO B A L S U S TA I N A B I L IT Y R E P O R T
www.abbott.com/sustainability
S H A R E H O L D E R I N FO RM AT I O N
Shareholders with questions about their
accounts may contact the transfer agent,
listed above.
Individuals who would like to receive
additional information, or have questions
regarding Abbott’s business activities, may
call the Investor Newsline at the number
listed above, write Abbott Investor Relations
at the address above, or visit Abbott’s website,
www.abbott.com.
NOTES

-- 84 of 86 --



-- 85 of 86 --



-- 86 of 86 --